US9410208B2 - Marker and reagent for detection of human IL-17-producing helper T cells, and method for detection of human IL-17-producing helper T cells - Google Patents
Marker and reagent for detection of human IL-17-producing helper T cells, and method for detection of human IL-17-producing helper T cells Download PDFInfo
- Publication number
- US9410208B2 US9410208B2 US13/868,638 US201313868638A US9410208B2 US 9410208 B2 US9410208 B2 US 9410208B2 US 201313868638 A US201313868638 A US 201313868638A US 9410208 B2 US9410208 B2 US 9410208B2
- Authority
- US
- United States
- Prior art keywords
- cells
- protein
- human
- detecting
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 210000002443 helper t lymphocyte Anatomy 0.000 title claims abstract description 20
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 title claims abstract description 13
- 239000003550 marker Substances 0.000 title abstract description 54
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 8
- 238000001514 detection method Methods 0.000 title description 16
- 210000004027 cell Anatomy 0.000 claims description 182
- 108090000623 proteins and genes Proteins 0.000 claims description 182
- 102000004169 proteins and genes Human genes 0.000 claims description 56
- 102000013691 Interleukin-17 Human genes 0.000 claims description 28
- 108050003558 Interleukin-17 Proteins 0.000 claims description 28
- 102100031292 Prepronociceptin Human genes 0.000 claims description 24
- 102100041027 Procollagen C-endopeptidase enhancer 2 Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical group 0.000 claims description 23
- 101000779382 Homo sapiens A-kinase anchor protein 12 Proteins 0.000 claims description 20
- 101001072737 Homo sapiens Post-GPI attachment to proteins factor 4 Proteins 0.000 claims description 20
- 102100036590 Post-GPI attachment to proteins factor 4 Human genes 0.000 claims description 20
- 102100033824 A-kinase anchor protein 12 Human genes 0.000 claims description 19
- 102100035475 Blood vessel epicardial substance Human genes 0.000 claims description 19
- 101710174254 Blood vessel epicardial substance Proteins 0.000 claims description 19
- 102100026204 Class E basic helix-loop-helix protein 22 Human genes 0.000 claims description 19
- 102100028821 Fibronectin type III domain-containing protein 9 Human genes 0.000 claims description 19
- 101001059629 Homo sapiens Fibronectin type III domain-containing protein 9 Proteins 0.000 claims description 19
- 101001094649 Homo sapiens Popeye domain-containing protein 3 Proteins 0.000 claims description 19
- 101000854873 Homo sapiens V-type proton ATPase 116 kDa subunit a 4 Proteins 0.000 claims description 19
- -1 LOC401097 Proteins 0.000 claims description 19
- 102100035477 Popeye domain-containing protein 3 Human genes 0.000 claims description 19
- 102100031980 Single-minded homolog 1 Human genes 0.000 claims description 19
- 102100038853 Uroplakin-1b Human genes 0.000 claims description 19
- 102100020737 V-type proton ATPase 116 kDa subunit a 4 Human genes 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 19
- 102100020756 D(2) dopamine receptor Human genes 0.000 claims description 18
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 claims description 18
- 101000768465 Homo sapiens Protein unc-13 homolog C Proteins 0.000 claims description 18
- 102100027900 Protein unc-13 homolog C Human genes 0.000 claims description 18
- 238000002372 labelling Methods 0.000 claims description 17
- 102100029758 Cadherin-4 Human genes 0.000 claims description 16
- 101000794580 Homo sapiens Cadherin-4 Proteins 0.000 claims description 16
- 101001072729 Homo sapiens PiggyBac transposable element-derived protein 5 Proteins 0.000 claims description 16
- 101000729626 Homo sapiens Probable phospholipid-transporting ATPase IIA Proteins 0.000 claims description 16
- 101000707284 Homo sapiens Protein Shroom2 Proteins 0.000 claims description 16
- 102100036593 PiggyBac transposable element-derived protein 5 Human genes 0.000 claims description 16
- 102100031600 Probable phospholipid-transporting ATPase IIA Human genes 0.000 claims description 16
- 102100025764 Transmembrane protein 163 Human genes 0.000 claims description 16
- 108091007507 ADAM12 Proteins 0.000 claims description 15
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 claims description 15
- 101000645402 Homo sapiens Transmembrane protein 163 Proteins 0.000 claims description 15
- 101001053754 Homo sapiens Type II iodothyronine deiodinase Proteins 0.000 claims description 15
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 102100024060 Type II iodothyronine deiodinase Human genes 0.000 claims description 15
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 claims description 15
- 101000666331 Homo sapiens Teneurin-4 Proteins 0.000 claims description 14
- 102000005031 SLC6A15 Human genes 0.000 claims description 14
- 108060007754 SLC6A15 Proteins 0.000 claims description 14
- 102100038123 Teneurin-4 Human genes 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 14
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 claims description 9
- 102100027257 Melanoma-associated antigen D4 Human genes 0.000 claims description 9
- 102100023503 Chloride intracellular channel protein 5 Human genes 0.000 claims description 7
- 101000906624 Homo sapiens Chloride intracellular channel protein 5 Proteins 0.000 claims description 7
- 108010052285 Membrane Proteins Proteins 0.000 claims description 7
- 102100034955 Poly(rC)-binding protein 3 Human genes 0.000 claims description 7
- 108091058545 Secretory proteins Proteins 0.000 claims description 7
- 102000040739 Secretory proteins Human genes 0.000 claims description 7
- 102100034686 Tight junction protein ZO-1 Human genes 0.000 claims description 7
- 102100040152 Adenylyl-sulfate kinase Human genes 0.000 claims description 6
- 102100027153 Ankyrin repeat and sterile alpha motif domain-containing protein 1B Human genes 0.000 claims description 6
- 102100026437 Branched-chain-amino-acid aminotransferase, cytosolic Human genes 0.000 claims description 6
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 6
- 102100031047 Coiled-coil domain-containing protein 3 Human genes 0.000 claims description 6
- 102100030670 Core histone macro-H2A.2 Human genes 0.000 claims description 6
- 102100038698 Cytochrome P450 7B1 Human genes 0.000 claims description 6
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 claims description 6
- 102100038605 Death-associated protein kinase 2 Human genes 0.000 claims description 6
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 claims description 6
- 102100030068 Doublesex- and mab-3-related transcription factor 1 Human genes 0.000 claims description 6
- 102100027490 H2.0-like homeobox protein Human genes 0.000 claims description 6
- 101000610212 Homo sapiens Adenylyl-sulfate kinase Proteins 0.000 claims description 6
- 101000694607 Homo sapiens Ankyrin repeat and sterile alpha motif domain-containing protein 1B Proteins 0.000 claims description 6
- 101000766268 Homo sapiens Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 claims description 6
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 6
- 101000777372 Homo sapiens Coiled-coil domain-containing protein 3 Proteins 0.000 claims description 6
- 101000957674 Homo sapiens Cytochrome P450 7B1 Proteins 0.000 claims description 6
- 101000864807 Homo sapiens Doublesex- and mab-3-related transcription factor 1 Proteins 0.000 claims description 6
- 101000890757 Homo sapiens FH1/FH2 domain-containing protein 3 Proteins 0.000 claims description 6
- 101001081101 Homo sapiens H2.0-like homeobox protein Proteins 0.000 claims description 6
- 101001055106 Homo sapiens Metastasis-associated in colon cancer protein 1 Proteins 0.000 claims description 6
- 101000906927 Homo sapiens N-chimaerin Proteins 0.000 claims description 6
- 101000730665 Homo sapiens Phospholipase D1 Proteins 0.000 claims description 6
- 101000974715 Homo sapiens Potassium voltage-gated channel subfamily E member 3 Proteins 0.000 claims description 6
- 101000657326 Homo sapiens Protein TANC2 Proteins 0.000 claims description 6
- 101000983140 Homo sapiens Protein associated with UVRAG as autophagy enhancer Proteins 0.000 claims description 6
- 101000665486 Homo sapiens TBC1 domain family member 12 Proteins 0.000 claims description 6
- 101000652472 Homo sapiens Tubulin beta-6 chain Proteins 0.000 claims description 6
- 101001087422 Homo sapiens Tyrosine-protein phosphatase non-receptor type 13 Proteins 0.000 claims description 6
- 101000720948 Homo sapiens Ubiquitin thioesterase OTUB2 Proteins 0.000 claims description 6
- 101000585623 Homo sapiens Unconventional myosin-X Proteins 0.000 claims description 6
- 101000771662 Homo sapiens WD repeat and FYVE domain-containing protein 3 Proteins 0.000 claims description 6
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 claims description 6
- 102100026892 Metastasis-associated in colon cancer protein 1 Human genes 0.000 claims description 6
- 102100026108 Microfibrillar-associated protein 3-like Human genes 0.000 claims description 6
- 102100025273 Monocarboxylate transporter 5 Human genes 0.000 claims description 6
- 102100032966 Myomegalin Human genes 0.000 claims description 6
- 102100023648 N-chimaerin Human genes 0.000 claims description 6
- 102100032967 Phospholipase D1 Human genes 0.000 claims description 6
- 102100022753 Potassium voltage-gated channel subfamily E member 3 Human genes 0.000 claims description 6
- 102100025974 Pro-cathepsin H Human genes 0.000 claims description 6
- 102100034784 Protein TANC2 Human genes 0.000 claims description 6
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 claims description 6
- 102100038098 Protein-glutamine gamma-glutamyltransferase 5 Human genes 0.000 claims description 6
- 102100027753 Putative F-box/LRR-repeat protein 21 Human genes 0.000 claims description 6
- 102100021035 Regulator of G-protein signaling 18 Human genes 0.000 claims description 6
- 101710148110 Regulator of G-protein signaling 18 Proteins 0.000 claims description 6
- 102100027264 Solute carrier organic anion transporter family member 2B1 Human genes 0.000 claims description 6
- 102100038201 TBC1 domain family member 12 Human genes 0.000 claims description 6
- 102100024548 Tensin-3 Human genes 0.000 claims description 6
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims description 6
- 102100030303 Tubulin beta-6 chain Human genes 0.000 claims description 6
- 102100033014 Tyrosine-protein phosphatase non-receptor type 13 Human genes 0.000 claims description 6
- 102100025914 Ubiquitin thioesterase OTUB2 Human genes 0.000 claims description 6
- 102100031835 Unconventional myosin-VIIa Human genes 0.000 claims description 6
- 102100029827 Unconventional myosin-X Human genes 0.000 claims description 6
- 102100029465 WD repeat and FYVE domain-containing protein 3 Human genes 0.000 claims description 6
- 102100025593 Calmodulin-regulated spectrin-associated protein 2 Human genes 0.000 claims description 5
- 102100039497 Choline transporter-like protein 3 Human genes 0.000 claims description 5
- 102100025900 DNA damage-inducible transcript 4-like protein Human genes 0.000 claims description 5
- 102100036504 Dehydrogenase/reductase SDR family member 9 Human genes 0.000 claims description 5
- 102100024108 Dystrophin Human genes 0.000 claims description 5
- 102100032633 E3 ubiquitin-protein ligase SH3RF2 Human genes 0.000 claims description 5
- 102100035183 ERC protein 2 Human genes 0.000 claims description 5
- 102100027094 Echinoderm microtubule-associated protein-like 1 Human genes 0.000 claims description 5
- 102100040809 Failed axon connections homolog Human genes 0.000 claims description 5
- 102100040684 Fermitin family homolog 2 Human genes 0.000 claims description 5
- 102100035961 Hematopoietically-expressed homeobox protein HHEX Human genes 0.000 claims description 5
- 102100023937 Heparan sulfate glucosamine 3-O-sulfotransferase 1 Human genes 0.000 claims description 5
- 102100032511 Histamine H4 receptor Human genes 0.000 claims description 5
- 101000932961 Homo sapiens Calmodulin-regulated spectrin-associated protein 2 Proteins 0.000 claims description 5
- 101000906631 Homo sapiens Chloride intracellular channel protein 6 Proteins 0.000 claims description 5
- 101000720858 Homo sapiens DNA damage-inducible transcript 4-like protein Proteins 0.000 claims description 5
- 101000928746 Homo sapiens Dehydrogenase/reductase SDR family member 9 Proteins 0.000 claims description 5
- 101000654568 Homo sapiens E3 ubiquitin-protein ligase SH3RF2 Proteins 0.000 claims description 5
- 101000876444 Homo sapiens ERC protein 2 Proteins 0.000 claims description 5
- 101000892039 Homo sapiens Failed axon connections homolog Proteins 0.000 claims description 5
- 101000746078 Homo sapiens Gap junction gamma-1 protein Proteins 0.000 claims description 5
- 101001021503 Homo sapiens Hematopoietically-expressed homeobox protein HHEX Proteins 0.000 claims description 5
- 101001048058 Homo sapiens Heparan sulfate glucosamine 3-O-sulfotransferase 1 Proteins 0.000 claims description 5
- 101001016858 Homo sapiens Histamine H4 receptor Proteins 0.000 claims description 5
- 101001084682 Homo sapiens Histone H2B type 1-C/E/F/G/I Proteins 0.000 claims description 5
- 101000852852 Homo sapiens Innate immunity activator protein Proteins 0.000 claims description 5
- 101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 claims description 5
- 101001057249 Homo sapiens Mastermind-like domain-containing protein 1 Proteins 0.000 claims description 5
- 101001133091 Homo sapiens Mucin-20 Proteins 0.000 claims description 5
- 101000979498 Homo sapiens Ninein-like protein Proteins 0.000 claims description 5
- 101001109685 Homo sapiens Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 claims description 5
- 101001134210 Homo sapiens Otogelin-like protein Proteins 0.000 claims description 5
- 101001064783 Homo sapiens PX domain-containing protein 1 Proteins 0.000 claims description 5
- 101000583692 Homo sapiens Pleckstrin homology-like domain family A member 1 Proteins 0.000 claims description 5
- 101000933173 Homo sapiens Pro-cathepsin H Proteins 0.000 claims description 5
- 101000915000 Homo sapiens Probable C-mannosyltransferase DPY19L2 Proteins 0.000 claims description 5
- 101000976219 Homo sapiens Probable ribonuclease ZC3H12C Proteins 0.000 claims description 5
- 101001033274 Homo sapiens Protein IL-40 Proteins 0.000 claims description 5
- 101000657325 Homo sapiens Protein TANC1 Proteins 0.000 claims description 5
- 101000588033 Homo sapiens Protein spire homolog 1 Proteins 0.000 claims description 5
- 101000666135 Homo sapiens Protein-glutamine gamma-glutamyltransferase 5 Proteins 0.000 claims description 5
- 101000954762 Homo sapiens Proto-oncogene Wnt-3 Proteins 0.000 claims description 5
- 101000825404 Homo sapiens SH2 domain-containing adapter protein B Proteins 0.000 claims description 5
- 101000629631 Homo sapiens Sorbin and SH3 domain-containing protein 1 Proteins 0.000 claims description 5
- 101000633627 Homo sapiens Teashirt homolog 2 Proteins 0.000 claims description 5
- 101000626153 Homo sapiens Tensin-3 Proteins 0.000 claims description 5
- 101000802356 Homo sapiens Tight junction protein ZO-1 Proteins 0.000 claims description 5
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims description 5
- 101000597770 Homo sapiens Tropomodulin-1 Proteins 0.000 claims description 5
- 102100036724 Innate immunity activator protein Human genes 0.000 claims description 5
- 102100036712 Interleukin-27 subunit beta Human genes 0.000 claims description 5
- 102100027235 Mastermind-like domain-containing protein 1 Human genes 0.000 claims description 5
- 102100033060 Mitogen-activated protein kinase kinase kinase 4 Human genes 0.000 claims description 5
- 102100034242 Mucin-20 Human genes 0.000 claims description 5
- 108010009047 Myosin VIIa Proteins 0.000 claims description 5
- 102100023120 Ninein-like protein Human genes 0.000 claims description 5
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 claims description 5
- 102100034206 Otogelin-like protein Human genes 0.000 claims description 5
- 102100031888 PX domain-containing protein 1 Human genes 0.000 claims description 5
- 101710178747 Phosphatidate cytidylyltransferase 1 Proteins 0.000 claims description 5
- 102100030887 Pleckstrin homology-like domain family A member 1 Human genes 0.000 claims description 5
- 102100028694 Probable C-mannosyltransferase DPY19L2 Human genes 0.000 claims description 5
- 102100023886 Probable ribonuclease ZC3H12C Human genes 0.000 claims description 5
- 102100039063 Protein IL-40 Human genes 0.000 claims description 5
- 102100034764 Protein TANC1 Human genes 0.000 claims description 5
- 102100031617 Protein spire homolog 1 Human genes 0.000 claims description 5
- 102100029248 RNA-binding protein 20 Human genes 0.000 claims description 5
- 102100021269 Regulator of G-protein signaling 1 Human genes 0.000 claims description 5
- 101710140408 Regulator of G-protein signaling 1 Proteins 0.000 claims description 5
- 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 claims description 5
- 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 claims description 5
- 102100021289 Regulator of G-protein signaling 20 Human genes 0.000 claims description 5
- 101710148117 Regulator of G-protein signaling 20 Proteins 0.000 claims description 5
- 102100022648 Reticulon-2 Human genes 0.000 claims description 5
- 102100022342 SH2 domain-containing adapter protein B Human genes 0.000 claims description 5
- 108091006600 SLC16A4 Proteins 0.000 claims description 5
- 102100026834 Sorbin and SH3 domain-containing protein 1 Human genes 0.000 claims description 5
- 102100038648 Synaptogyrin-3 Human genes 0.000 claims description 5
- 102100029218 Teashirt homolog 2 Human genes 0.000 claims description 5
- 102100033738 Transmembrane protein 44 Human genes 0.000 claims description 5
- 102100035291 Tropomodulin-1 Human genes 0.000 claims description 5
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 claims description 5
- 101000892677 Homo sapiens Fermitin family homolog 2 Proteins 0.000 claims description 4
- 101001014567 Homo sapiens Membrane-spanning 4-domains subfamily A member 7 Proteins 0.000 claims description 4
- 101000823247 Homo sapiens Reticulon-2 Proteins 0.000 claims description 4
- 101000664940 Homo sapiens Synaptogyrin-3 Proteins 0.000 claims description 4
- 101000801298 Homo sapiens Transmembrane protein 44 Proteins 0.000 claims description 4
- 102100032512 Membrane-spanning 4-domains subfamily A member 7 Human genes 0.000 claims description 4
- 102000052549 Wnt-3 Human genes 0.000 claims description 4
- 101000956317 Homo sapiens Membrane-spanning 4-domains subfamily A member 4A Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 101150004658 BHLHE22 gene Proteins 0.000 claims 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims 2
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 claims 2
- 101001129365 Homo sapiens Prepronociceptin Proteins 0.000 claims 2
- 101000612139 Homo sapiens Procollagen C-endopeptidase enhancer 2 Proteins 0.000 claims 2
- 101000703681 Homo sapiens Single-minded homolog 1 Proteins 0.000 claims 2
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 claims 2
- 101000808114 Homo sapiens Uroplakin-1b Proteins 0.000 claims 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 101150103412 Ptprm gene Proteins 0.000 claims 2
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims 2
- 102100027485 Acid sphingomyelinase-like phosphodiesterase 3a Human genes 0.000 claims 1
- 102000013339 FBXL17 Human genes 0.000 claims 1
- 101150000662 FBXL17 gene Proteins 0.000 claims 1
- 102100032789 Formin-like protein 3 Human genes 0.000 claims 1
- 101150088021 GPR34 gene Proteins 0.000 claims 1
- 102100025624 Gap junction delta-3 protein Human genes 0.000 claims 1
- 101000872838 Hepatitis B virus genotype C subtype adr (isolate China/NC-1/1988) Small envelope protein Proteins 0.000 claims 1
- 102100030690 Histone H2B type 1-C/E/F/G/I Human genes 0.000 claims 1
- 101000936726 Homo sapiens Acid sphingomyelinase-like phosphodiesterase 3a Proteins 0.000 claims 1
- 101001084697 Homo sapiens Core histone macro-H2A.2 Proteins 0.000 claims 1
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 claims 1
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 claims 1
- 101001057941 Homo sapiens Echinoderm microtubule-associated protein-like 1 Proteins 0.000 claims 1
- 101000856663 Homo sapiens Gap junction delta-3 protein Proteins 0.000 claims 1
- 101001040875 Homo sapiens Glucosidase 2 subunit beta Proteins 0.000 claims 1
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 claims 1
- 101000977768 Homo sapiens Interleukin-1 receptor-associated kinase 3 Proteins 0.000 claims 1
- 101001005668 Homo sapiens Mastermind-like protein 3 Proteins 0.000 claims 1
- 101001055794 Homo sapiens Microfibrillar-associated protein 3-like Proteins 0.000 claims 1
- 101001018147 Homo sapiens Mitogen-activated protein kinase kinase kinase 4 Proteins 0.000 claims 1
- 101000589016 Homo sapiens Myomegalin Proteins 0.000 claims 1
- 101000945267 Homo sapiens Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform Proteins 0.000 claims 1
- 101000735360 Homo sapiens Poly(rC)-binding protein 3 Proteins 0.000 claims 1
- 101000862167 Homo sapiens Putative F-box/LRR-repeat protein 21 Proteins 0.000 claims 1
- 101001062129 Homo sapiens RNA-binding protein 20 Proteins 0.000 claims 1
- 101000734339 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 claims 1
- 102100023530 Interleukin-1 receptor-associated kinase 3 Human genes 0.000 claims 1
- 101150097991 L1CAM gene Proteins 0.000 claims 1
- 101000964266 Loxosceles laeta Dermonecrotic toxin Proteins 0.000 claims 1
- 102100025134 Mastermind-like protein 3 Human genes 0.000 claims 1
- 101150094768 Mcam gene Proteins 0.000 claims 1
- 102100033547 Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform Human genes 0.000 claims 1
- 108091007000 SLC44A3 Proteins 0.000 claims 1
- 108091006686 SLCO2B1 Proteins 0.000 claims 1
- 101001053942 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Diphosphomevalonate decarboxylase Proteins 0.000 claims 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 1
- 210000000068 Th17 cell Anatomy 0.000 abstract description 198
- 238000011895 specific detection Methods 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 description 95
- 230000004913 activation Effects 0.000 description 84
- 230000014509 gene expression Effects 0.000 description 74
- 102000040430 polynucleotide Human genes 0.000 description 69
- 108091033319 polynucleotide Proteins 0.000 description 69
- 239000002157 polynucleotide Substances 0.000 description 69
- 210000000447 Th1 cell Anatomy 0.000 description 51
- 210000004241 Th2 cell Anatomy 0.000 description 51
- 210000003289 regulatory T cell Anatomy 0.000 description 51
- 238000005259 measurement Methods 0.000 description 50
- 239000000523 sample Substances 0.000 description 41
- 239000012474 protein marker Substances 0.000 description 39
- 210000005259 peripheral blood Anatomy 0.000 description 30
- 239000011886 peripheral blood Substances 0.000 description 30
- 108010025714 CD146 Antigen Proteins 0.000 description 25
- 108020004635 Complementary DNA Proteins 0.000 description 25
- 102000049932 CD146 Antigen Human genes 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 101710087174 Procollagen C-endopeptidase enhancer 2 Proteins 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- 108010055438 prepronociceptin Proteins 0.000 description 22
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 108010004729 Phycoerythrin Proteins 0.000 description 19
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 18
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 18
- 229940098773 bovine serum albumin Drugs 0.000 description 18
- 101000764994 Homo sapiens Class E basic helix-loop-helix protein 22 Proteins 0.000 description 17
- 101710194139 Single-minded homolog 1 Proteins 0.000 description 17
- 238000003753 real-time PCR Methods 0.000 description 16
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 239000002853 nucleic acid probe Substances 0.000 description 15
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 14
- 108010004534 G-protein-coupled receptor 34 Proteins 0.000 description 14
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 14
- 108010016731 PPAR gamma Proteins 0.000 description 14
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 14
- 102100030263 Probable G-protein coupled receptor 34 Human genes 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 102100037850 Interferon gamma Human genes 0.000 description 13
- 102000004388 Interleukin-4 Human genes 0.000 description 13
- 108090000978 Interleukin-4 Proteins 0.000 description 13
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 13
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 13
- 239000011324 bead Substances 0.000 description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- 101000686034 Homo sapiens Nuclear receptor ROR-gamma Proteins 0.000 description 11
- 102100023421 Nuclear receptor ROR-gamma Human genes 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 230000003472 neutralizing effect Effects 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 10
- 229930182490 saponin Natural products 0.000 description 10
- 150000007949 saponins Chemical class 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000010195 expression analysis Methods 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 102100030703 Interleukin-22 Human genes 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 108091008104 nucleic acid aptamers Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102100033461 Interleukin-17A Human genes 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 6
- 102100036679 Interleukin-26 Human genes 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 101000864704 Bos taurus Doublesex and mab-3 related transcription factor 1 Proteins 0.000 description 5
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 5
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 5
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 5
- 101710167917 Carbonic anhydrase 2 Proteins 0.000 description 5
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 description 5
- 101710185000 Core histone macro-H2A.2 Proteins 0.000 description 5
- 101710127030 Dermatan-sulfate epimerase Proteins 0.000 description 5
- 101710126378 F-box/LRR-repeat protein 17 Proteins 0.000 description 5
- 102100027729 F-box/LRR-repeat protein 17 Human genes 0.000 description 5
- 101710126388 F-box/LRR-repeat protein 21 Proteins 0.000 description 5
- 102100040129 FH1/FH2 domain-containing protein 3 Human genes 0.000 description 5
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 5
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 5
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 5
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 5
- 101000662049 Homo sapiens Polyubiquitin-C Proteins 0.000 description 5
- 101000836226 Homo sapiens Solute carrier organic anion transporter family member 2B1 Proteins 0.000 description 5
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 5
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 5
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 5
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 5
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 5
- 101710174562 Microfibrillar-associated protein 3-like Proteins 0.000 description 5
- 101710184018 Myomegalin Proteins 0.000 description 5
- 102100037935 Polyubiquitin-C Human genes 0.000 description 5
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 5
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 4
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 4
- 101710203443 Echinoderm microtubule-associated protein-like 1 Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100039290 Gap junction gamma-1 protein Human genes 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 4
- 101000889279 Homo sapiens Choline transporter-like protein 3 Proteins 0.000 description 4
- 101000898898 Homo sapiens Histone H2B type 1-K Proteins 0.000 description 4
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 description 4
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 4
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 description 4
- 102100033454 Interleukin-17F Human genes 0.000 description 4
- 108010075647 MAP Kinase Kinase Kinase 4 Proteins 0.000 description 4
- 102100033118 Phosphatidate cytidylyltransferase 1 Human genes 0.000 description 4
- 101710206022 RNA-binding protein 20 Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 101710143997 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000012099 Alexa Fluor family Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 3
- 108010065637 Interleukin-23 Proteins 0.000 description 3
- 102000013264 Interleukin-23 Human genes 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 101100536692 Drosophila melanogaster Ten-m gene Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 101710195550 Interleukin-23 receptor Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 101150033052 MAS5 gene Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 101100344462 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YDJ1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 2
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 108091022886 phosphatidate cytidylyltransferase Proteins 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LTHJXDSHSVNJKG-UHFFFAOYSA-N 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C LTHJXDSHSVNJKG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150087690 ACTB gene Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 101150076800 B2M gene Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 108090000619 Cathepsin H Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 102000013444 Diacylglycerol Cholinephosphotransferase Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 101710108801 Fermitin family homolog 2 Proteins 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000777457 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 12 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101000577129 Homo sapiens Monocarboxylate transporter 5 Proteins 0.000 description 1
- 101000740122 Homo sapiens Sodium-dependent neutral amino acid transporter B(0)AT2 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 102100033096 Interleukin-17D Human genes 0.000 description 1
- 101710181612 Interleukin-26 Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 102000011845 Iodide peroxidase Human genes 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010029279 Member 3 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 description 1
- 102000001691 Member 3 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710089648 Poly(rC)-binding protein 3 Proteins 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 102100031750 Protein Shroom2 Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 102100037075 Proto-oncogene Wnt-3 Human genes 0.000 description 1
- 108091008778 RORγ2 Proteins 0.000 description 1
- 101710122678 Reticulon-2 Proteins 0.000 description 1
- 102100037252 Sodium-dependent neutral amino acid transporter B(0)AT2 Human genes 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 101710152208 Synaptogyrin-3 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 101710100619 Tensin-3 Proteins 0.000 description 1
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 description 1
- 108050000630 Transcription factor SOX-2 Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 101710191786 Transmembrane protein 163 Proteins 0.000 description 1
- 101710106897 Transmembrane protein 44 Proteins 0.000 description 1
- 102000009149 Tropomodulin-1 Human genes 0.000 description 1
- 108050000021 Tropomodulin-1 Proteins 0.000 description 1
- 101150109071 UBC gene Proteins 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 101000832077 Xenopus laevis Dapper 1-A Proteins 0.000 description 1
- 108700007340 Zonula Occludens-1 Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000029799 phosphatidate cytidylyltransferase Human genes 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 108010058721 transglutaminase 5 Proteins 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Definitions
- the present invention relates to a marker and reagent for detecting human IL-17-producing helper T-cells (hereinafter also referred to as “Th17 cells”) and a method for detecting human Th17 cells.
- RA Rheumatoid arthritis
- the state of RA is diagnosed by rational symptoms such as joint pain or by visual procedures such as the observations on the extent of swelling or bone X-ray.
- no quantitative index has been established.
- no quantitative method for continuously monitoring the treatment effects has been established under the current state of the art.
- RA pathogenesis of RA has not been elucidated. It is considered that bacterial infections and the like trigger an inflammation in joint tissues via complicated networks of immunocytes and cytokines.
- helper T-cells play a central role in immune reactions.
- Immature helper T-cells are differentiated into helper T-cells when an antigen is presented by antigen-presenting cells.
- helper T-cells are differentiated into four types of the cells, which are helper T-cells producing interferon (IFN)- ⁇ (Th1 cells), helper T-cells producing interleukin (IL)-4 (Th2 cells), helper T-cells producing IL-17 (Th17 cells) and regulatory T-cells having immunosuppressive effects (Treg cells).
- Th17 cells can be involved in the onset of RA.
- IL-17 is deeply involved in the formation of pathological conditions and in particular joint and bone deformities because the level of IL-17 is significantly higher in synovial fluid of RA patients than in that of the patients of osteoarthritis and T-cells in synovial tissue from RA patients include IL-17 positive cells (see Japanese Unexamined Patent Publication No. 2000-186046). Japanese Unexamined Patent Publication No. 2000-186046 also discloses that IL-17 can be used as a diagnostic marker of RA.
- Japanese Unexamined Patent Publication No. 2007-506100 discloses that the analysis of cytokines in peripheral blood serum of RA patients revealed that the levels of IFN- ⁇ , IL-1 ⁇ , TNF- ⁇ , G-CSF, GM-CSF, IL-6, IL-4, IL-10, IL-13, IL-5 and IL-7 were significantly high and the levels of IL-2, CXCL8/IL-8, IL-12 and CCL2/MCP-1 were not high in RA patients.
- the amount of IL-17 is measured by enzyme linked immunosorbent assay (ELISA) using antibodies specific to IL-17.
- ELISA enzyme linked immunosorbent assay
- Th17 cells and autoimmune diseases preferably RA may be more deeply understood by establishing a method which allows not only measurement of the amount of IL-17 but also detection of Th17 cells per se.
- the present inventors aimed to find molecular markers that allows specific detection of human Th17 cells.
- the present inventors isolated Th17 cells from peripheral blood of a healthy adult and identified the genes which are specifically expressed in the obtained Th17 cells, thereby completing the present invention.
- the present invention provides a polynucleotide marker for detecting human Th17 cells which is a polynucleotide having a nucleic acid sequence of at least one gene selected from the group consisting of:
- genes encoding secretory proteins consisting of: CXCL13 (chemokine (C—X—C motif) ligand 13), PCOLCE2 (procollagen C-endopeptidase enhancer 2), PNOC (prepronociceptin), SMPDL3A (sphingomyelin phosphodiesterase, acid-like 3A), TGFBI (transforming growth factor, beta-induced), C17orf99 (chromosome 17 open reading frame 99), EBI3 (Epstein-Barr virus induced 3), IL1A (interleukin 1, alpha) and WNT3 (wingless-type MMTV integration site family, member 3);
- genes encoding intracellular proteins consisting of: BCAT1 (branched chain aminotransferase 1, cytosolic), BHLHE22 (basic helix-loop-helix family, member e22), C13orf18 (LOC728970) (chromosome 13 open reading frame 18 (hypothetical LOC728970)), CA2 (carbonic anhydrase II), CCDC3 (coiled-coil domain containing 3), CDS1 (CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1), CHN1 (chimerin (chimaerin) 1), CLIC5 (LOC100131610) (chloride intracellular channel 5 (similar to chloride intracellular channel 5)), CTSH (cathepsin H), CYP7B1 (cytochrome P450, family 7, subfamily B, polypeptide 1), DAPK2 (death-associated protein kinase 2), DMRT1 (doublesex
- genes consisting of: C1orf106 (chromosome 1 open reading frame 106), C6orf145 (chromosome 6 open reading frame 145), LOC401097 (Similar to LOC166075), MAMLD1 (mastermind-like domain containing 1), ZC3H12C (zinc finger CCCH-type containing 12C), C12orf64 (chromosome 12 open reading frame 64), C6orf168 (chromosome 6 open reading frame 168), CAMSAP1L1 (calmodulin regulated spectrin-associated protein 1-like 1) and MAGED4 (MAGED4B) (melanoma antigen family D, 4, (melanoma antigen family D, 4B)); and
- the present invention also provides a protein marker for detecting human Th17 cells which is a protein encoded by at least one of the above genes or a functionally equivalent variant and fragment thereof.
- the present invention further provides a method for detecting human Th17 cells comprising detecting the presence of at least one polynucleotide marker for detecting human Th17 cells or at least one protein marker for detecting human Th17 cells in a sample containing cells derived from human.
- the present invention provides a reagent for detecting human Th17 cells comprising at least one substance selected from a nucleic acid probe which specifically hybridizes to the above polynucleotide marker; and a nucleic acid aptamer, antibody, ligand or receptor which specifically binds to the above protein marker.
- Human Th17 cells can be specifically detected by detecting at least one polynucleotide marker or protein marker for detecting human Th17 cells of the present invention. It may also allow detection of the possibility that a patient has a disease in which Th17 cells may be involved such as autoimmune diseases, e.g. RA.
- autoimmune diseases e.g. RA.
- FIG. 1 shows graphs of the expression levels of the genes which are known to be specifically expressed in Th17 cells (IL23R, IL17A, IL17F, IL22, IL26 and RORC) in Th1, Th2, Treg and Th17 cells;
- FIG. 2 shows histograms of fluorescent intensity obtained by the analysis of MCAM measurement samples
- FIG. 3 shows histograms of fluorescent intensity obtained by the analysis of PTPRM measurement samples
- FIG. 4 shows histograms of fluorescent intensity obtained by the analysis of GPR34 measurement samples
- FIG. 5 shows histograms of fluorescent intensity obtained by the analysis of CCR6 measurement samples
- FIG. 6 shows histograms of fluorescent intensity obtained by the analysis of IL-17A measurement samples
- FIG. 7 shows histograms of fluorescent intensity obtained by the analysis of IFN- ⁇ measurement samples
- FIG. 8 shows histograms of fluorescent intensity obtained by the analysis of IL-4 measurement samples.
- FIG. 9 shows histograms of fluorescent intensity obtained by the analysis of FOXP3 measurement samples.
- the polynucleotide marker for detecting human Th17 cells of the present invention is the polynucleotide having a nucleic acid sequence of at least one gene selected from the group consisting of the above genes, or a variant and fragment thereof.
- the polynucleotide has a nucleic acid sequence of at least one gene selected from the group consisting of:
- genes encoding intracellular proteins consisting of: BHLHE22, PPARG, SIM1 and SNAI2.
- the present polynucleotide marker for detecting human Th17 cells is the polynucleotide, variant or fragment thereof which has been found to be specifically present in Th17 cells rather than in other helper T-cells derived from human peripheral blood (Th1, Th2 and Treg cells).
- Th17 cells can be distinguished from Th1, Th2 and Treg cells and specifically identified, and an index for activity of diseases in vivo can be studied in which Th17 cells may be involved.
- the term “gene” has the same meaning as that is commonly recognized in the art, and refers to a part of a genome which is transcribed into mRNA and translated into a protein.
- genes containing at least one nucleic acid sequence selected from SEQ ID NOs: 147 to 151, 157 to 162 and 167 to 174 are the genes to be transcribed into mRNAs containing at least one of these nucleic acid sequences or a complementary sequence thereof.
- genes containing at least one nucleic acid sequence selected from SEQ ID NOs: 147 to 151, 157 to 162 and 167 to 174 comprise genes containing a nucleic acid sequence complementary to at least one nucleic acid sequence selected from SEQ ID NOs: 147 to 151, 157 to 162 and 167 to 174.
- a membrane protein means a protein existing in a cell membrane and being contained in a membrane fraction of cells.
- a secretory protein means a protein synthesized in cells and secreted to the outside of the cell membrane.
- An intracellular protein means a protein which is mainly present in cells.
- a polynucleotide is “specifically expressed” in Th17 cells means that the expression level of the polynucleotide in Th17 cells is significantly higher than the expression level of the polynucleotide in cells other than Th17 cells.
- the expression level of the polynucleotide in Th17 cells is about two times or more of the expression level of the polynucleotide in cells other than Th17 cells.
- the expression level of the polynucleotide in Th17 cells is about two times or more of the expression level of the polynucleotide in helper T-cells other than Th17 cells (Th1, Th2 and Treg cells).
- nucleotide sequences of the present polynucleotide markers are already known. They can be obtained from, for example, Unigene (a database provided by National Center for Biotechnology Information (NCBI) of National Library of Medicine). Unigene codes for the nucleic acid sequences of the present polynucleotide markers are specified in Table 9.
- variant of a polynucleotide means a polynucleotide into which a mutation has been introduced that does not alter the nature of the protein encoded by the above gene. Such mutation includes a deletion, substitution or addition of one or more nucleotides to the nucleic acid sequence of the above gene.
- fragment of a polynucleotide means a polynucleotide having a contiguous part of the nucleic acid sequence of the above gene and having a length which allows its specific hybridization with a nucleic acid probe for detecting human Th17 cells described hereinafter.
- the variant of the polynucleotide as the present polynucleotide marker for detecting human Th17 cells has generally at least 80%, more preferably at least 85%, further preferably at least 90% and particularly preferably at least 95% homology with the nucleic acid sequence of the above gene.
- nucleic acid and amino acid sequences are calculated in BLASTN, BLASTP, BLASTX or TBLASTN (e.g. available from http://www.ncbi.nlm.nih.gov) with default settings.
- the polynucleotide marker may be any of DNA or RNA, and may be the gene per se (DNA), mRNA, cDNA or cRNA.
- Human Th17 cells can also be detected by detecting at least one protein encoded by the above gene.
- the present invention also provides the protein marker for detecting human Th17 cells consisting of the protein encoded by at least one of the above genes or a functionally equivalent variant and fragment thereof.
- the above protein is encoded by at least one gene selected from the group consisting of:
- the above protein is a membrane protein encoded by at least one gene selected from the group consisting of GPR34, MCAM and PTPRM.
- the amino acid sequence of such protein marker can be obtained based on the nucleic acid sequence of the polynucleotide marker obtained from Unigene and the like. It can also be obtained from databases provided by NCBI and the like. NCBI code numbers for the amino acid sequences of the present protein markers for detecting human Th17 cells are specified in Table 9.
- the protein marker for detecting human Th17 cells is the protein encoded by the above gene, a functionally equivalent variant or fragment thereof.
- “functionally equivalent variant” of a protein means a protein into which a mutation has been introduced that does not alter functions of the protein. Such mutation includes a deletion, substitution or addition of one or more amino acids to the known amino acid sequence of the protein.
- fragment of a protein means a protein having a contiguous amino acid sequence of the protein encoded by the above gene or a functionally equivalent variant thereof and being able to specifically bind to a nucleic acid aptamer, antibody, ligand or receptor for detecting human Th17 cells described hereinafter.
- the functionally equivalent variant of the protein corresponding to the present protein marker for detecting human Th17 cells has generally at least 80%, preferably at least 85%, more preferably at least about 90% and particularly preferably at least 95% homology with the known amino acid sequence of the protein encoded by the above gene.
- a molecule that can specifically hybridize to the present polynucleotide marker can be used for detection of the marker, making it useful as a probe for detecting human Th17 cells.
- the probe may be a nucleic acid probe such as DNA or RNA, or a peptide probe that can specifically hybridize to the polynucleotide marker.
- the probe for detecting human Th17 cells is preferably a nucleic acid probe, particularly a DNA probe for detecting the polynucleotide marker.
- the phrase “can specifically hybridize” means that it can hybridize to a target nucleic acid molecule (the polynucleotide marker) under a stringent condition.
- stringent condition means a condition under which the probe for detecting human Th17 cells can hybridize to the target polynucleotide marker with a detectably higher extent than it does to a polynucleotide other than the target polynucleotide marker (e.g. more than at least two times of the background).
- the stringent condition generally depends on the sequences and varies depending on various circumstances. Generally, the stringent condition is selected so that it is about 5° C. lower than a thermal melting point of the specific sequence under a certain ionic strength and pH. This Tm is a temperature at which 50% of the complementary probe hybridizes to the target sequence in equilibrium (under a certain ionic strength, pH and nucleic acid composition).
- Such condition may be those which are used in conventional hybridization techniques between polynucleotides such as PCR, microarray or Southern blotting.
- the stringent condition in microarray technique includes the hybridization at 37° C. in 50% formamide, 1M NaCl and 1% SDS and washing at 60 to 65° C. in 0.1 ⁇ SSC.
- the stringent condition in PCR technique includes a condition of pH 7 to 9, 0.01 to 0.1 M Tris-HCl, 0.05 to 0.15 M potassium ion concentration (or other salt) and at least about 55° C.
- sequence of the nucleic acid probe for detecting human Th17 cells can be appropriately selected by a person skilled in the art based on the common technical knowledge in the art and the sequence of the polynucleotide marker so that it can specifically hybridize to the polynucleotide marker.
- the nucleic acid probe for detecting human Th17 cells can be designed by using, for example, a commonly available primer designing software (e.g. Primer3 (available from frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) or DNASIS Pro (Hitachi Software Engineering Co., Ltd.)).
- Primer3 available from frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi
- DNASIS Pro Haitachi Software Engineering Co., Ltd.
- the nucleic acid probe for detecting human Th17 cells can be prepared according to polynucleotide synthesis methods which are well-known in the art.
- the nucleic acid probe for detecting human Th17 cells may be labeled with a labeling substance normally used in the art.
- the labeled nucleic acid probe allows an easy detection of the polynucleotide marker for detecting human Th17 cells, namely of human Th17 cells.
- the labeling substance may be a labeling substance generally used in the art including radioisotopes such as 32 P, fluorescent substances such as fluorescein, enzymes such as alkaline phosphatase and horseradish peroxidase, and biotin.
- radioisotopes such as 32 P
- fluorescent substances such as fluorescein
- enzymes such as alkaline phosphatase and horseradish peroxidase
- biotin biotin
- Human Th17 cells can be specifically detected by using one or more nucleic acid probes for detecting human Th17 cells.
- a DNA chip or microarray for detecting the polynucleotide marker for detecting human Th17 cells can be obtained by immobilizing one or more probes on a substrate according to a method well-known in the art.
- the nucleic acid probe for detecting human Th17 cells may include a set of two or more primers for amplifying the polynucleotide marker by nucleic acid amplification methods such as PCR technique, for example.
- a molecule that can specifically bind to the present protein marker can be used for the detection of the marker, making it useful in the detection of human Th17 cells.
- Such molecule may be a nucleic acid aptamer such as DNA or RNA, an antibody, a ligand or a receptor that can specifically bind to the present protein marker, and preferably an antibody.
- the protein marker for detecting human Th17 cells is an enzyme, it can be detected by applying a substrate for the enzyme to develop color or emit light or fluorescent.
- the antibody for detecting human Th17 cells can be prepared by the following well-known procedure, for example.
- a DNA molecule encoding a protein having an amino acid sequence of the present protein marker is prepared based on the nucleic acid sequence of the present polynucleotide marker or the amino acid sequence of the present protein marker, and is introduced into an appropriate expression vector.
- the obtained expression vector is introduced into an appropriate host cells, and the obtained transformed cells are cultured to obtain a desired protein.
- the obtained protein is purified and used as an immunogen optionally with an adjuvant to immunize an appropriate mammal such as rat or mouse. Spleen cells of the immunized animals are screened for antibody producing cells that produce an antibody directed to the target immunogen.
- the selected antibody producing cells are fused with myeloma cells to obtain hybridomas. These hybridomas are screened for antibody producing hybridomas that produce an antibody having specific binding property to the protein encoded by the gene.
- the desired antibody can be obtained by culturing the obtained antibody producing hybridomas.
- the nucleic acid aptamer that can be used for detecting human Th17 cells can be prepared by the following well-known procedure, for example.
- a nucleic acid library including random nucleic acid sequences is prepared according to the known technique, and an aptamer that specifically binds to the target protein (the protein marker) can be selected by the systematic evolution of ligands by exponential enrichment method (SELEX method) or the like.
- the molecule which can specifically bind to the protein marker for detecting human Th17 cells may be labeled with a labeling substance normally used in the art.
- the labeled antibody for detecting human Th17 cells allows an easy detection of the protein marker for detecting human Th17 cells, namely of human Th17 cells.
- the labeling substance may be a labeling substance generally used in the art including radioisotopes such as 32 P, fluorescent substances such as fluorescein, enzymes such as alkaline phosphatase and horseradish peroxidase, and biotin.
- radioisotopes such as 32 P
- fluorescent substances such as fluorescein
- enzymes such as alkaline phosphatase and horseradish peroxidase
- biotin biotin
- a method for detecting human Th17 cells by detecting the presence of at least one polynucleotide or protein marker for detecting human Th17 cells in a sample containing cells derived from human is also within the scope of the present invention.
- two or more polynucleotide markers or protein markers for detecting human Th17 cells are detected in order to improve the detection sensitivity.
- the sample containing cells derived from human includes a biological sample obtained from human or a sample containing cultured human cells.
- the biological sample includes blood, tissue, synovial fluid, cerebrospinal fluid, pleural fluid, ascitic fluid and the like.
- Nucleic acid is extracted from a sample containing cells derived from human by a well-known method in the art such as the one using a phenolic extraction and ethanol precipitation or a commercial DNA extraction kit.
- the presence of the polynucleotide marker in the obtained nucleic acid sample is detected, preferably using the nucleic acid probe for detecting human Th17 cells.
- the nucleic acid probe for detecting human Th17 cells is preferably a primer set for amplifying the polynucleotide marker by a nucleic acid amplification method.
- the presence of the polynucleotide marker for detecting human Th17 cells may also be detected by well-known methods in the art, for example hybridization methods such as Southern hybridization, Northern hybridization, fluorescence in situ hybridization (FISH), or DNA chip or microarray. Such methods are carried out under the stringent condition, and the hybridization of the nucleic acid probe for detecting human Th17 cells is detected by detecting the labeling substance and the like to detect the presence of the polynucleotide marker.
- hybridization methods such as Southern hybridization, Northern hybridization, fluorescence in situ hybridization (FISH), or DNA chip or microarray.
- FISH fluorescence in situ hybridization
- proteins are extracted from a sample containing cells derived from human by using well-known methods in the art.
- the extraction of proteins from a sample can be accomplished by known methods such as disruption of the cells by ultrasonic, lysis of the cells with a cell lysis solution.
- the protein marker in the obtained protein extract can be detected by using the molecule which specifically binds to the protein marker.
- the protein marker for detecting human Th17 cells can be detected by well-known methods in the art such as ELISA or Western blotting.
- the molecule which specifically binds to the protein marker in the detection is preferably the above nucleic acid aptamer, antibody, ligand or receptor, and more preferably the antibody for detecting human Th17 cells.
- the target protein marker is a secretory protein
- the protein marker secreted in the sample containing the cells can be detected by using the molecule which specifically binds to the protein marker.
- the cells are recovered from the sample containing the cells from human and the obtained cells are stimulated with anti-CD3 antibody, anti-CD28 antibody, concanavalin A, phytohemagglutinin (PHA), phorbol myristate acetate (PMA), ionomycin or the like. Then, the secreted protein marker can be detected by using the molecule which specifically binds to the protein marker.
- the protein marker can be detected by well-known methods in the art such as ELISA or Western blotting.
- the molecule which specifically binds to the protein marker in the detection is preferably the above nucleic acid aptamer, antibody, ligand or receptor, and more preferably the antibody for detecting human Th17 cells.
- the target protein marker is a protein located on the cell surface
- the protein marker located on the cell surface in the sample containing the cells derived from human can be detected by using the molecule which specifically binds to the protein marker.
- a membrane fraction of the cells is obtained from the sample containing the cells derived from human and the protein marker in the membrane fraction can be detected by using the molecule which specifically binds to the protein marker.
- the protein marker can be detected by well-known methods in the art such as ELISA, Western blotting or a method based on flow cytometry (FCM).
- FCM flow cytometry
- the molecule which specifically binds to the protein marker in the detection is preferably the above nucleic acid aptamer, antibody, ligand or receptor, and more preferably the antibody for detecting human Th17 cells.
- the protein marker for detecting human Th17 cells can be detected by FCM as follows.
- the sample containing the cells derived from human is brought into contact with the antibody for detecting human Th17 cells labeled with an appropriate labeling substance.
- Human Th17 cells when exist, bind to the labeled antibody on their surfaces.
- the sample containing the cells bound to the labeling substance can be applied to a flow cytometer to detect human Th17 cells.
- Human Th17 cells that have bound to the labeling substance can optionally be classified and fractionated by using a cell sorter.
- the present invention also provides a reagent for detecting human Th17 cells which can be used in the present method for detecting human Th17 cells
- the reagent comprises at least one substance selected from a nucleic acid probe which specifically hybridizes to the polynucleotide marker for detecting human Th17 cells, and a nucleic acid aptamer, antibody, ligand and receptor which specifically binds to the protein marker for detecting human Th17 cells.
- Buffy coat obtained from peripheral blood of a healthy adult was overlaid on Ficoll-paque plus solution (GE Healthcare Bioscience) and centrifuged to obtain a monocyte fraction. Crude CD4 positive cells were purified from the fraction by using magnetic beads bound to anti-CD4 antibody (Miltenyi Biotec).
- the obtained CD4 positive cells were stained with the fluorescence labeled antibodies shown in Table 1 and then Th1, Th2 and Th17 cells were separated by a cell sorter (FACS Aria: Becton Dickinson). The separation was carried out with the gating shown in Table 2.
- CD4 positive cells obtained in the same manner as the above (1) were stained with the fluorescence labeled antibodies shown in Table 3, and CD4high CD25high CD127internal-negative cells were purified as Treg cells by using the above cell sorter.
- (1) were respectively plated in a 96-well plate at the density of 1.5 ⁇ 10 5 cells/0.3 ml/well.
- the medium used was Yssel medium (IMDM, 1% human serum of AB-type, 0.25% BSA, 1.8 mg/l 2-aminomethanol, 40 mg/l transferrin, 5 mg/l insulin, 2 mg/l linoleic acid, 2 mg/l oleic acid, 2 mg/l palmitic acid, 1% penicillin/streptomycin).
- antibody beads For activation and proliferation of the above cells, magnetic beads coated with anti-CD2/3/28 antibody (Miltenyi Biotec) (hereinafter also referred to as “antibody beads”) were added at 0.75 ⁇ 10 5 per well. After addition of cytokines and neutralizing antibody(s) suitable for differentiation culture of respective Th1, Th2 and Th17 cells, cells were incubated in an incubator at 37° C. with 5% CO 2 . Cytokines and neutralizing antibodies used are shown in Table 4.
- the concentrations of the above cytokines were 50 ng/ml for IL-6 and 10 ng/ml for other than IL-6.
- the concentrations of antibodies were 10 ⁇ g/ml for anti-IFN- ⁇ antibody and 2.5 ⁇ g/ml for anti-IL-4 antibody.
- the cytokines and neutralizing antibodies were obtained from R&D systems and eBioscience, respectively.
- cells were diluted three-fold with the medium containing the above cytokines and antibody(s) and cultured for further seven days (10 days in total).
- Th1, Th2 and Th17 cells were respectively divided into two equal parts, and one was washed with Yssel medium and PBS before centrifugation to collect cells, which were stored at ⁇ 80° C. until the subsequent RNA extraction step. These cells were designated as Th1, Th2 and Th17 cells “without activation stimulation”. The other half was added with the antibody beads and cultured for three more hours to re-activate the cells. The cells were collected by centrifugation and similarly stored at ⁇ 80° C. These cells were designated as Th1, Th2 and Th17 cells “with activation stimulation”.
- Treg cells obtained in the above step 1. (2) were cultured in the same manner in Yssel medium as the above step 2. (1) and activated with the antibody beads. To the medium were added cytokines IL-2 and TGF- ⁇ 1 (R&D systems), and neutralizing antibodies anti-IFN- ⁇ antibody, anti-IL-4 antibody (eBioscience) and anti-IL-6 antibody (BD Bioscience).
- cytokines IL-2 and TGF- ⁇ 1 R&D systems
- neutralizing antibodies anti-IFN- ⁇ antibody, anti-IL-4 antibody eBioscience
- anti-IL-6 antibody BD Bioscience
- cytokines and neutralizing antibodies were used at the concentrations of 10 ng/ml and 5 ⁇ g/ml, respectively.
- cells were added with the cytokines and neutralizing antibodies at the same amounts as those at the start of the culture. After culturing for three more days, cells were divided into two equal parts, one half was not added with the antibody beads used for activation and the other half was added with the antibody beads before culturing further three hours, thereby obtaining Treg cells “without activation stimulation” and Treg cells “with activation stimulation”, respectively. The cells were then collected by centrifugation and stored at ⁇ 80° C. until the subsequent RNA extraction step.
- the cells obtained as the above step 2. were subjected to extraction of total RNAs using RNeasy Plus Mini kit and RNeasy micro kit (QIAGEN).
- RNAs (10 to 100 ng) extracted from the cells as the above step 3. were reverse-transcribed to cDNAs with Two-Cycle Target Labeling and Control Reagents (Affymetrix), and further transcribed to biotinylated-cRNAs.
- the amplified biotinylated-cRNAs (20 ⁇ g) were fragmented. The specific procedures were according to the attached instruction of the kit.
- biotinylated-cRNAs derived from the cells as obtained above (15 ⁇ g) were applied to GeneChip Human Genome U-133 Plus 2.0 Array (Affymetrix) as samples, transferred to GeneChip Hybridization Oven 640 (Affymetrix) and hybridized under the conditions of 45° C. and 60 rpm for 16 hours.
- the microarray was washed and fluorescence-labeled in GeneChip Fluidic Station 450 (Affymetrix), and scanned in GeneChip Scanner 3000 7G (Affymetrix) to obtain fluorescent intensity data.
- the fluorescent data obtained in the above step 4. was standardized with the expression analysis software GeneSpring Ver. 10 (Agilent Technologies) based on MAS5 algorithm. Relative fluorescent intensities of the genes from Th17 cells were compared with those from Th1, Th2 and Treg cells.
- the genes whose relative fluorescent intensities in Th17 cells were three or more times higher than any of those of Th1, Th2 and Treg cells and which were significantly expressed were identified as the genes which were specifically expressed in Th17 cells.
- Th1, Th2, Treg and Th17 cells obtained in the above step 2. were analyzed with microarray as described above. It was found that those genes were expressed 4 to 950 times higher in Th17 cells than in Th1, Th2 and Treg cells. These results are shown in FIG. 1 . These results indicated that the above cells are suitable for investigation of markers for detecting Th17 cells.
- the present inventors have identified novel polynucleotide markers for detecting Th17 cells by excluding the genes shown in Table 8 from those obtained as above. These novel polynucleotide markers are shown in Table 9.
- “Condition” means with or without activation stimulation of cells.
- the genes designated as “Common” in the column of “Condition” are the genes specifically expressed in both Th17 cells with stimulation and without stimulation.
- the genes designated as “With stimulation” and “Without stimulation” are the genes specifically expressed either in Th17 cells with stimulation or without stimulation, respectively.
- Th17 cells “without activation stimulation” (5 ⁇ 10 6 cells/ml) prepared in Example 1 under the paragraph “2.
- Cell culture was added a phycoerythrin (PE)-labeled anti-MCAM antibody (BioLegend) to a final concentration of 1.25 ⁇ g/ml and reaction was carried out at 4° C. for 20 minutes.
- PE phycoerythrin
- Th17 cells were washed by adding phosphate buffered saline (PBS) containing 0.5% BSA and centrifuging to collect the cells.
- PBS phosphate buffered saline
- the washed Th17 cells were suspended in PBS containing 0.5 ⁇ g/ml 7-amino-actinomycin D (7-AAD) and 0.5% BSA to prepare a MCAM measurement sample of Th17 cells (5 ⁇ 10 6 cells/ml).
- Th1 cells 5 ⁇ 10 6 cells/ml
- Th2 cells 5 ⁇ 10 6 cells/ml
- Treg cells 5 ⁇ 10 6 cells/ml
- a negative control sample (5 ⁇ 10 6 cells/ml) was prepared by adding a PE-labeled mouse IgG2a isotype control (BioLegend) to a final concentration of 1.0 ⁇ g/ml instead of the PE-labeled MCAM antibody and reacting at 4° C. for 20 minutes.
- Th17 cells “without activation stimulation” (5 ⁇ 10 6 cells/ml) prepared in Example 1 under the paragraph “2.
- Cell culture was added an anti-PTPRM antibody (Abcam) to a final concentration of 2.0 ⁇ g/ml and reaction was carried out at 4° C. for 20 minutes.
- Th17 cells were added with PBS containing 0.5% BSA and centrifuged to collect the cells.
- the collected Th17 cells were suspended in PBS containing 0.5% BSA.
- the suspension was added with a PE-labeled anti-mouse IgG antibody (BioLegend) to a final concentration of 1.0 ⁇ g/ml and reaction was carried out at 4° C. for 20 minutes.
- Th17 cells were washed by adding PBS containing 0.5% BSA and centrifuging to collect the cells.
- the washed Th17 cells were suspended in PBS containing 0.5 ⁇ g/ml 7-amino-actinomycin D (7-AAD) and 0.5% BSA to prepare a PTPRM measurement sample of Th17 cells (5 ⁇ 10 6 cells/ml).
- Th1 cells 5 ⁇ 10 6 cells/ml
- Th2 cells 5 ⁇ 10 6 cells/ml
- Treg cells 5 ⁇ 10 6 cells/ml
- a negative control sample (5 ⁇ 10 6 cells/ml) was prepared by adding a mouse IgG2a isotype control (BioLegend) to a final concentration of 1.0 ⁇ g/ml instead of the anti-PTPRM antibody and reacting at 4° C. for 20 minutes.
- CCR6 measurement samples of Th17 cells (5 ⁇ 10 6 cells/ml), of Th1 cells (5 ⁇ 10 6 cells/ml), of Th2 cells (5 ⁇ 10 6 cells/ml) and of Treg cells (5 ⁇ 10 6 cells/ml) were prepared in the similar manner as the above paragraph “(1) Preparation of MCAM measurement samples” except that a PE-labeled anti-CCR6 antibody (BD Bioscience) was used at a final concentration of 1.0 ⁇ g/ml instead of the PE-labeled anti-MCAM antibody.
- BD Bioscience PE-labeled anti-CCR6 antibody
- a negative control sample (5 ⁇ 10 6 cells/ml) was prepared by adding a PE-labeled mouse IgG1 isotype control (BioLegend) to a final concentration of 1.0 ⁇ g/ml instead of the PE-labeled anti-CCR6 antibody and reacting at 4° C. for 20 minutes.
- Th17 cells “without activation stimulation” (5 ⁇ 10 6 cells/ml) prepared in Example 1 under the paragraph “2.
- Cell culture” were fixed and permeability of the cell membranes was increased using FOXP3 staining buffer set (eBioscience) before addition of a PE-labeled anti-FOXP3 antibody (BioLegend) to a final concentration of 3.125 ⁇ g/ml and reaction at 4° C. for 20 minutes.
- Th17 cells were washed by adding phosphate buffered saline (PBS) containing 0.5% BSA and centrifuging to collect the cells.
- PBS phosphate buffered saline
- the washed Th17 cells were suspended in PBS containing 0.5% BSA to prepare a FOXP3 measurement sample of Th17 cells (5 ⁇ 10 6 cells/ml).
- Th1 cells 5 ⁇ 10 6 cells/ml
- Th2 cells 5 ⁇ 10 6 cells/ml
- Treg cells 5 ⁇ 10 6 cells/ml
- a negative control sample (5 ⁇ 10 6 cells/ml) was prepared by adding a PE-labeled mouse IgG1 isotype control (BioLegend) to a final concentration of 1.0 ⁇ g/ml instead of the PE-labeled FOXP3 antibody and reacting at 4° C. for 20 minutes.
- Th17 cells “without activation stimulation” prepared in Example 1 under the paragraph “2.
- Cell culture were prepared in 5% FBS/RPMI at 2.5 ⁇ 10 5 cells/ml.
- Phorbol myristate acetate at a final concentration of 50 ng/ml and ionomycin at a final concentration of 1 ⁇ M were added and incubated at 37° C. for 4 hours to stimulate Th17 cells.
- brefeldin A was added to a final concentration of 10 ⁇ g/ml and incubated at 37° C. for 2 hours.
- Th17 cells were washed twice by adding phosphate buffered saline (PBS) containing 0.5% BSA and centrifuging to collect the cells. The washed Th17 cells were added with 2% paraformaldehyde to fix the cells. After fixing the cells, a saponin buffer (0.5% saponin, 0.5% bovine serum albumin (BSA), 1 mM sodium azide (in PBS)) was added to accelerate cell membrane permeability of Th17 cells.
- PBS phosphate buffered saline
- BSA bovine serum albumin
- in PBS 1 mM sodium azide
- the sample after saponin treatment was added with an anti-GPR34 antibody (Lifespan Biosciences) to a final concentration of 25.0 ⁇ g/ml and reaction was carried out at 4° C. for 20 minutes.
- the saponin buffer was added and Th17 cells were collected by centrifugation. The collected Th17 cells were suspended in the saponin buffer.
- the suspension was added with a PE-labeled anti-mouse IgG antibody (BioLegend) to a final concentration of 1.0 ⁇ g/ml and reaction was carried out at 4° C. for 20 minutes.
- Th17 cells were washed twice by adding the saponin buffer and centrifuging to collect the cells.
- the washed Th17 cells were suspended in PBS containing 0.5% BSA to prepare a GRP34 measurement sample of Th17 cells (2.5 ⁇ 10 5 cells/ml).
- GRP34 measurement samples of Th1 cells, of Th2 cells and of Treg cells were prepared in the similar manner as above except that Th1, Th2 and Treg cells “without activation stimulation”, respectively, were used instead of Th17 cells “without activation stimulation”.
- a negative control sample (2.5 ⁇ 10 6 cells/ml) was prepared by adding a mouse IgG2a isotype control (BioLegend) to a final concentration of 1.0 ⁇ g/ml instead of the anti-GPR34 antibody and reacting at 4° C. for 20 minutes.
- Th17 cells “without activation stimulation” prepared in Example 1 under the paragraph “2.
- Cell culture were prepared in 5% FBS/RPMI at 2.5 ⁇ 10 5 cells/ml.
- Phorbol myristate acetate at a final concentration of 50 ng/ml and ionomycin at a final concentration of 1 ⁇ M were added and incubated at 37° C. for 4 hours to stimulate Th17 cells.
- brefeldin A was added to a final concentration of 10 ⁇ g/ml and incubated at 37° C. for 2 hours.
- Th17 cells were washed by adding phosphate buffered saline (PBS) containing 0.5% BSA and centrifuging to collect the cells. The washed Th17 cells were added with 2% paraformaldehyde to fix the cells. After fixing the cells, a saponin buffer (0.5% saponin, 0.5% bovine serum albumin (BSA), 1 mM sodium azide (in PBS)) was added to accelerate cell membrane permeability of Th17 cells.
- PBS phosphate buffered saline
- BSA bovine serum albumin
- in PBS 1 mM sodium azide
- the sample after saponin treatment was added with a PerCP-Cy5.5-labeled anti-IL-17A antibody (eBioscience) to a final concentration of 0.15 ⁇ g/ml and reaction was carried out at 4° C. for 20 minutes.
- a PerCP-Cy5.5-labeled anti-IL-17A antibody eBioscience
- Th17 cells were washed by adding the saponin buffer and centrifuging to collect cells.
- the washed Th17 cells were suspended in PBS containing 0.5% BSA to prepare a IL-17A measurement sample of Th17 cells (2.5 ⁇ 10 5 cells/ml).
- a negative control sample (2.5 ⁇ 10 6 cells/ml) was prepared by adding a PerCP-Cy5.5-labeled mouse IgG1 isotype control (eBioscience) to a final concentration of 1.0 ⁇ g/ml instead of the PerCP-Cy5.5-labeled anti-IL-17A antibody.
- IFN- ⁇ measurement samples of Th17 cells 2.5 ⁇ 10 5 cells/ml
- Th1 cells 2.5 ⁇ 10 5 cells/ml
- Th2 cells 2.5 ⁇ 10 5 cells/ml
- Treg cells 2.5 ⁇ 10 5 cells/ml
- a negative control sample (2.5 ⁇ 10 6 cells/ml) was prepared by adding an Alex488-labeled mouse IgG 1 isotype control (BioLegend) to a final concentration of 1.0 ⁇ g/ml instead of the Alexa488-labeled anti-IFN- ⁇ antibody and reacting at 4° C. for 20 minutes.
- IL-4 measurement samples of Th17 cells 2.5 ⁇ 10 5 cells/ml
- Th1 cells 2.5 ⁇ 10 5 cells/ml
- Th2 cells 2.5 ⁇ 10 5 cells/ml
- Treg cells 2.5 ⁇ 10 5 cells/ml
- a negative control sample (2.5 ⁇ 10 6 cells/ml) was prepared by adding an APC-labeled rat IgG1 isotype control (BioLegend) to a final concentration of 1.0 ⁇ g/ml instead of the APC-labeled anti-IL-4 antibody and reacting at 4° C. for 20 minutes.
- the prepared measurement samples were analyzed by FACSCanto II (BD Bioscienct) and FACS DIVA software (BD Bioscience). Histograms (particle size distribution) of fluorescent intensities obtained by the analysis are shown in FIGS. 2 to 9 , which correspond respectively to the histograms obtained from MCAM measurement samples, PTPRM measurement samples, GPR34 measurement samples, CCR6 measurement samples, IL-17A measurement samples, IFN- ⁇ measurement samples, IL-4 measurement samples, and FOXP3 measurement samples.
- the vertical axis of the histograms shows the number of cells and the horizontal axis shows the fluorescent intensity.
- the numbers at the upper right of the histograms correspond to the ratio (%) of positive cells for the marker gene relative to the number of total cells in the respective measurement samples.
- the cells were determined as positive or negative based on the maximal fluorescent intensity in the negative control. Namely, the cells having higher fluorescent intensity than the maximal fluorescent intensity of the negative control were determined as positive, while the cells having a fluorescent intensity equal to or lower than the maximal fluorescent intensity of the negative control were determined as negative.
- the ratio of positive cells was calculated as the ratio of the number of positive cells relative to the number of total cells.
- CCR6 and IL-17A are known markers for Th17 cells.
- FIGS. 5 and 6 show that the expression levels of CCR6 and IL-17A proteins are high in Th17 cells.
- IFN- ⁇ is a known marker for Th1 cells.
- FIG. 7 shows that the expression level of IFN- ⁇ protein is high in Th1 cells.
- IL-4 is a known marker for Th2 cells.
- FIG. 8 shows that the expression level of IL-4 protein is high in Th2 cells.
- FOXP3 is a known marker for Treg cells.
- FIG. 9 shows that the expression level of FOXP3 protein is high in Treg cells. Thus, it is indicated that these measurement samples are suitable for expression analysis of protein markers.
- FIGS. 2 to 4 show that the expression levels of MCAM, PTPRM and GPR34 proteins are high in Th17 cells. It is also found that the ratios of positive cells in the MCAM measurement sample, PTPRM measurement sample and GPR34 measurement sample of Th17 cells were equal to or higher than the ratios of positive cells in the CCR6 measurement sample and IL-17A measurement sample. This reveals that the proteins encoded by the genes MCAM, PTPRM and GPR34 which were identified in Example 1 as the polynucleotide markers for detecting Th17 cells can also be used as protein markers for detecting Th17 cells.
- RNA 0.1 ⁇ g of Th17 cells “without activation stimulation” extracted in Example 1 under the paragraph “3. Extraction of total RNA” was reverse-transcribed with a poly dT primer (Hokkaido System Science Co., Ltd.), random primers (Hokkaido System Science Co., Ltd.) and Superscript III reverse transcriptase (Invitrogen Corporation) to obtain cDNA of Th17 cells “without activation stimulation”. Reverse transcription was carried out according to the attached instructions.
- a poly dT primer Hokkaido System Science Co., Ltd.
- random primers Hokkaido System Science Co., Ltd.
- Superscript III reverse transcriptase Invitrogen Corporation
- cDNAs of Th1 cells “without activation stimulation”, of Th2 cells “without activation stimulation” and of Treg cells “without activation stimulation” were prepared in the similar manner as above except that total RNAs (0.1 ⁇ g) of Th1 cells, Th2 cells and Treg cells “without activation stimulation” were used instead of total RNA (0.1 ⁇ g) of Th17 cells “without stimulation”.
- Th1 cells Th2 cells
- Th17 cells Treg cells w/o activation stimulation 5 5 5 4
- Th17 cells “without activation stimulation” prepared in Example 1 under the paragraph “2.
- Cell culture were prepared in 5% FBS/RPMI at 2.5 ⁇ 10 5 cells/ml.
- Th17 cells were stimulated by incubating the cells at 37° C. for 3 hours with T cell activation/expansion kit (Miltenyi Biotec). These Th17 cells “with activation stimulation” were subjected to extraction of total RNA in the same manner as Example 1, “3. Extraction of total RNA”.
- the extracted total RNA (0.1 ⁇ g) of Th17 cells “with activation stimulation” was reverse-transcribed with a poly dT primer (Hokkaido System Science Co., Ltd.), random primers (Hokkaido System Science Co., Ltd.) and Superscript III reverse transcriptase (Invitrogen Corporation) to obtain cDNA of Th17 cells “with activation stimulation”. Reverse transcription was carried out according to the attached instructions.
- cDNAs of Th1 cells “with activation stimulation”, of Th2 cells “with activation stimulation” and of Treg cells “with activation stimulation” were prepared in the similar manner as above except that total RNAs (0.1 ⁇ g) of Th1 cells, Th2 cells and Treg cells “with activation stimulation” were used instead of total RNA (0.1 ⁇ g) of Th17 cells “with activation stimulation”.
- Th1 cells Th2 cells
- Th17 cells Treg cells w/ activation stimulation 5 5 5 3
- Primer sets were designed for the genes ADAM12, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, L1CAM, MCAM, SHROOM2, TMEM163, UPK1B, DRD2, PGBD5 (LOC100134440), ODZ4, SLC6A15, AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC, TGFBI, IL1A, BHLHE22, PPARG, SIM1 and SNAI2, which were detected in Example 1 as the polynucleotide markers for detecting Th17 cells.
- Primer sets were designed for known gene markers for Th17 cells, CCR6, RORC and IL-17A.
- Primer sets were designed for known gene markers for Th1 cells, TBX21 and IFN- ⁇ .
- Primer sets were designed for known gene markers for Th2 cells, GATA3 and IL-4.
- Primer sets were designed for a known gene marker for Treg cells, FOXP3.
- Primer sets were designed for internal control genes, Gapdh, ACTB, B2M and UBC.
- cDNAs of Th17 cells “without activation stimulation” obtained from samples in the above “1. Preparation of cDNA” were respectively used as a template.
- the primer sets used were the primer sets for ADAM12, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, L1CAM, MCAM, SHROOM2, TMEM163, UPK1B, DRD2, PGBD5, ODZ4, SLC6A15, AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC, TGFBI, IL1A, BHLHE22, PPARG, SIM1, SNAI2, TBX21, GATA3, FOXP3, CCR6, RORC, GAPDH, ACTB, B2M and UBC, which were designed as described in “2.
- Real-time PCR was also carried out in the similar manner as above except that cDNAs of Th1 cells “without activation stimulation” obtained from 5 samples, cDNAs of Th2 cells “without activation stimulation” obtained from 5 samples and cDNAs of Treg cells “without activation stimulation” obtained from 4 samples were used as a template instead of cDNAs of Th17 cells “without activation stimulation”, and Ct values for the genes were measured.
- cDNAs of Th17 cells “with activation stimulation” obtained from 5 samples in the above “1.
- Preparation of cDNA were used as a template.
- the primer sets used were the primer sets for AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC, TGFBI, IFNG, IL4, IL17A, GAPDH, ACTB, B2M and UBC, which were designed as described in “2. Design of primer sets”.
- Real-time PCR was carried out with the template, primer sets and Power SYBR Green PCR Master Mix (Applied Biosystems) in 7300 Real Time PCR System (Applied Biosystems) and Ct value of each gene was measured. PCR was carried out at 50° C. for 2 minutes, 95° C.
- Ct value was measured by automatic calculation on 7300 Fast SDS software (Applied Biosystems).
- Real-time PCR was also carried out in the similar manner as above except that cDNAs of Th1 cells “with activation stimulation” obtained from 5 samples, cDNAs of Th2 cells “with activation stimulation” obtained from 5 samples and cDNAs of Treg cells “with activation stimulation” obtained from 3 samples were used as a template instead of cDNAs of Th17 cells “with activation stimulation”, and Ct values for the genes were measured.
- the expression level of each gene marker in Th17 cells “without activation stimulation” was obtained as an average of the expression levels of the gene marker in question obtained from five cDNAs used as templates.
- the expression level of each gene marker in Th17 cells “with activation stimulation” was also obtained as an average of the expression levels of the gene marker in question obtained from five cDNAs used as templates.
- the expression level of each gene marker in Th1 cells or Th2 cells “without activation stimulation” or “with activation stimulation” was obtained as an average of the expression levels of the gene marker in question obtained from five cDNAs used as templates.
- the expression level of each gene marker in Treg cells “without activation expression” was obtained as an average of the expression levels of the gene marker in question obtained from four cDNAs used as templates.
- the expression level of each gene marker in Treg cells “with activation stimulation” was obtained as an average of the expression levels of the gene marker in question obtained from three cDNAs used as templates.
- Table 13 shows expression levels of gene markers in Th1, Th2, Treg and Th17 cells “without activation stimulation” and Table 14 shows expression levels of gene markers in Th1, Th2, Treg and Th17 cells “with activation stimulation”
- Expression levels of gene markers in Th17 cells and ratios thereof relative to the expression levels of the gene markers in Th1, Th2 and Treg cells are shown in Tables 15 and 16.
- Table 15 shows expression levels of gene markers in Th17 cells “without activation stimulation” and ratios thereof relative to the expression levels of the gene markers in Th1, Th2 and Treg cells “without activation stimulation”.
- Table 16 shows expression levels of gene markers in Th17 cells “with activation stimulation” and ratios thereof relative to the expression levels of the gene markers in Th1, Th2 and Treg cells “with activation stimulation”.
- Th 17/ Th 1 (Expression level in Th 17 cells)/(Expression level in Th 1 cells)
- Th 17/ Th 2 (Expression level in Th 17 cells)/(Expression level in Th 2 cells)
- Th 17/ Treg (Expression level in Th 17 cells)/(Expression level in Treg cells)
- Table 15 shows that the expression levels of ADAM12, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, L1CAM, MCAM, SHROOM2, TMEM163, UPK1B, DRD2, PGBD5, ODZ4, SLC6A15, AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC, TGFBI, IL1A, BHLHE22, PPARG, SIM1 and SNAI2 in Th17 cells “without activation stimulation” are two or more times higher than that in Th1, Th2 and Treg cells “without activation stimulation”.
- Table 16 shows that the expression levels of AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC and TGFBI in Th17 cells “with activation stimulation” are two or more times higher than that in Th1, Th2 and Treg cells “with activation stimulation”.
- Peripheral blood from healthy adults (healthy subjects) and patients with rheumatoid arthritis was collected in blood collecting tubes NP-HE0557 (NIPRO) and peripheral blood CD4 positive cells were isolated with magnetic beads bound to anti-CD4 antibody (Miltenyi Biotec). Isolation of CD4 positive cells using anti-CD4 antibody beads was carried out according to the attached instruction.
- Total RNA was extracted from the isolated peripheral blood CD4 positive cells in the same manner as Example 1, “3. Extraction of total RNA”.
- the extracted total RNA (0.1 ⁇ g) of peripheral blood CD4 positive cells were reverse-transcribed with a poly dT primer (Hokkaido System Science Co., Ltd.), random primers (Hokkaido System Science Co., Ltd.) and Superscript III reverse transcriptase (Invitrogen Corporation) to obtain cDNA of peripheral blood CD4 positive cells. Reverse transcription was carried out according to the attached instructions.
- cDNAs of peripheral blood CD4 positive cells obtained from nine healthy subjects and nine patients with rheumatoid arthritis as prepared in the above “2. Preparation of cDNA from peripheral blood CD4 positive cells” were used as templates.
- the primer sets used were the primer sets for ATP6V0A4, BVES, C5orf40, UPK1B, DRD2, PCOLCE2, PNOC, TGFBI, BHLHE22, SIM1, CCR6, RORC, GAPDH, ACTB, B2M, and UBC, which were designed as described in “2. Design of primer sets”.
- Real-time PCR was carried out with the template, primer sets and Power SYBR Green PCR Master Mix (Applied Biosystems) in 7300 Real Time PCR System (Applied Biosystems) and Ct value of each gene was measured. PCR was carried out at 50° C. for 2 minutes, 95° C. for 10 minutes followed by 45 cycles of 95° C. for 15 seconds and 60° C. for 1 minute and two cycles of 95° C. for 15 seconds and 60° C. for 1 minute. Ct value was measured by automatic calculation on 7300 Fast SDS software (Applied Biosystems).
- Expression levels of the gene markers were calculated according to the above formula (I).
- the expression level of each gene marker in peripheral blood CD4 positive cells of the patients with rheumatoid arthritis was obtained as an average of the expression levels of the gene marker in question obtained from nine cDNAs used as templates.
- the expression level of each gene marker in peripheral blood CD4 positive cells of the healthy subjects was obtained as an average of the expression levels of the gene marker in question obtained from nine cDNAs used as templates.
- RA denotes patients with rheumatoid arthritis
- HC denotes healthy subjects.
- Table 18 shows that the expression levels of ATP6V0A4, BVES, C5orf40, UPK1B, DRD2, PCOLCE2, PNOC, TGFBI, BHLHE22 and SIM1 in the RA group were three or more times higher than that in the HC group. This indicates that these genes are useful as polynucleotide markers for screening of patients with rheumatoid arthritis.
- Buffy coat obtained from peripheral blood of a healthy adult was overlaid on Ficoll-paque plus solution (GE Healthcare Bioscience) and centrifuged to obtain a monocyte fraction. Crude CD4 positive cells were purified from the fraction by using magnetic beads bound to anti-CD4 antibody (Miltenyi Biotec).
- the obtained CD4 positive cells were stained with the fluorescence labeled antibodies shown in Table 19 and then Th17 and Th22 cells were separated by a cell sorter (FACS Aria: Becton Dickinson). The separation was carried out with the gating shown in Table 20.
- Th17 and Th22 cells derived from adult peripheral blood obtained in the above step 1. were respectively plated in a 96-well plate at the density of 1.5 ⁇ 10 5 cells/0.3 ml/well.
- the medium used was Yssel medium (IMDM, 1% human serum of AB-type, 0.25% BSA, 1.8 mg/l 2-aminomethanol, 40 mg/l transferrin, 5 mg/l insulin, 2 mg/l linoleic acid, 2 mg/l oleic acid, 2 mg/l palmitic acid, 1% penicillin/streptomycin).
- antibody beads For activation and proliferation of the above cells, magnetic beads coated with anti-CD2/3/28 antibody (Miltenyi Biotec) (hereinafter also referred to as “antibody beads”) were added at 0.75 ⁇ 10 5 per well. After addition of cytokines and neutralizing antibodies suitable for differentiation culture of respective Th17 and Th22 cells, cells were incubated in an incubator at 37° C. with 5% CO 2 . Cytokines and neutralizing antibodies used are shown in Table 21.
- the concentrations of the above cytokines were 50 ng/ml for IL-6 and 10 ng/ml for other than IL-6.
- the concentrations of antibodies were 10 ⁇ g/ml for anti-IFN- ⁇ antibody, 2.5 ⁇ g/ml for anti-IL-4 antibody and 2.5 ⁇ g/ml for anti-TGF- ⁇ antibody.
- the cytokines and neutralizing antibodies were obtained from R&D systems and eBioscience, respectively.
- cells were diluted three-fold with the medium containing the above cytokines and antibodies and cultured for further seven days (10 days in total).
- Th17 and Th22 cells were respectively divided into two equal parts, and one was washed with Yssel medium and PBS before centrifugation to collect cells, which were stored at ⁇ 80° C. until the subsequent RNA extraction step. These cells were designated as Th17 and Th22 cells “without activation stimulation”. The other half was added with the antibody beads and cultured for three more hours to re-activate the cells. The cells were collected by centrifugation and similarly stored at ⁇ 80° C. These cells were designated as Th17 and Th22 cells “with activation stimulation”.
- the cells obtained as the above step 2. were subjected to extraction of total RNAs using RNeasy Plus Mini kit and RNeasy micro kit (QIAGEN). The specific procedures were according to the attached instructions of the kits.
- RNAs (10 to 100 ng) extracted from the cells as the above step 3. were reverse-transcribed to cDNAs with Two-Cycle Target Labeling and Control Reagents (Affymetrix), and further transcribed to biotinylated-cRNAs.
- the amplified biotinylated-cRNAs (20 ⁇ g) were fragmented. The specific procedures were according to the attached instructions of the kit.
- biotinylated-cRNAs derived from the cells as obtained above (15 ⁇ g) were applied to GeneChip Human Genome U-133 Plus 2.0 Array (Affymetrix) as samples, transferred to GeneChip Hybridization Oven 640 (Affymetrix) and hybridized under the conditions of 45° C. and 60 rpm for 16 hours.
- the microarray was washed and fluorescence-labeled in GeneChip Fluidic Station 450 (Affymetrix), and scanned in GeneChip Scanner 3000 7G (Affymetrix) to obtain fluorescent intensity data.
- the fluorescent data obtained were standardized with the expression analysis software GeneSpring Ver.11 (Agilent Technologies) based on MAS5 algorithm to obtain relative fluorescent intensities of the genes in the cells.
- the relative fluorescent intensities correspond to the expression levels of the genes in these cells.
- Tables 22 and 23 show the results of the relative fluorescent intensities of the genes corresponding to the polynucleotide markers in Th17 cells obtained in Example 1 compared to those in Th22 cells.
- Table 22 shows expression ratios of the polynucleotide markers in Th17 and Th22 cells “without activation stimulation” and Table 23 shows expression ratios of the polynucleotide markers in Th17 and Th22 cells “with activation stimulation”.
- values in the column “Th17/Th22” correspond to the values obtained by dividing the relative fluorescent intensity of a gene corresponding to a polynucleotide marker in Th17 cells by that in Th22 cells.
- Tables 22 and 23 clearly indicate that the polynucleotide markers in Th17 cells obtained in Example 1 are expressed three or more times higher in Th17 cells than in Th22 cells. Thus, it is demonstrated that the polynucleotide markers shown in Tables 22 and 23 are useful for detection of Th17 cells.
Abstract
The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells.
Description
This is a divisional of U.S. patent application Ser. No. 13/360,324, filed Jan. 27, 2012, which is a continuation of International Application PCT/JP2010/062807 filed Jul. 29, 2010, which claims benefit of JP 2009-176755, filed Jul. 29, 2009, all of which are incorporated herein by reference in their entirety.
1. Field of the Invention
The present invention relates to a marker and reagent for detecting human IL-17-producing helper T-cells (hereinafter also referred to as “Th17 cells”) and a method for detecting human Th17 cells.
2. Description of the Related Art
Rheumatoid arthritis (hereinafter referred to as “RA”) is the systemic inflammatory autoimmune disease whose main clinical symptom is arthritis. The state of RA is diagnosed by rational symptoms such as joint pain or by visual procedures such as the observations on the extent of swelling or bone X-ray. However, no quantitative index has been established. Thus, no quantitative method for continuously monitoring the treatment effects has been established under the current state of the art.
The pathogenesis of RA has not been elucidated. It is considered that bacterial infections and the like trigger an inflammation in joint tissues via complicated networks of immunocytes and cytokines.
Helper T-cells play a central role in immune reactions. Immature helper T-cells (naïve T-cells) are differentiated into helper T-cells when an antigen is presented by antigen-presenting cells. When specific cytokines are present at this time, naïve T-cells are differentiated into four types of the cells, which are helper T-cells producing interferon (IFN)-γ (Th1 cells), helper T-cells producing interleukin (IL)-4 (Th2 cells), helper T-cells producing IL-17 (Th17 cells) and regulatory T-cells having immunosuppressive effects (Treg cells).
It has been shown that among these helper T-cells, Th17 cells can be involved in the onset of RA.
It has been suggested that IL-17 is deeply involved in the formation of pathological conditions and in particular joint and bone deformities because the level of IL-17 is significantly higher in synovial fluid of RA patients than in that of the patients of osteoarthritis and T-cells in synovial tissue from RA patients include IL-17 positive cells (see Japanese Unexamined Patent Publication No. 2000-186046). Japanese Unexamined Patent Publication No. 2000-186046 also discloses that IL-17 can be used as a diagnostic marker of RA.
Japanese Unexamined Patent Publication No. 2007-506100 discloses that the analysis of cytokines in peripheral blood serum of RA patients revealed that the levels of IFN-γ, IL-1β, TNF-α, G-CSF, GM-CSF, IL-6, IL-4, IL-10, IL-13, IL-5 and IL-7 were significantly high and the levels of IL-2, CXCL8/IL-8, IL-12 and CCL2/MCP-1 were not high in RA patients.
According to the studies by Ivanov et al. (“The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells”, Cell, 2006, 126, p. 1121-1133), Stumhofer et al. (“Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system”, Nature Immunology, 2006, vol. 7, p. 937-945), and Wilson et al. (“Development, cytokine profile and function of human interleukin 17-producing helper T cells”, Nature Immunology, 2007, vol. 8, p. 950-95′7), the following facts have been shown about Th17 cells:
-
- a nuclear receptor called RORγt has an important role in the differentiation of Th17 cells;
- IL-6, IL-23 and TGF-β induce the differentiation of immature helper T-cells (naïve T-cells) to Th17 cells;
- they express IL-17A, IL-17F, IL-6, IL-22, IL-26, TNF, IFN-γ and CCL20; and
- IL-23 receptor and IL-12 receptor β are located on the surface of Th17 cells.
In the above documents by Ivanov et al., Stumhofer et al. and Wilson et al., the amount of IL-17 is measured by enzyme linked immunosorbent assay (ELISA) using antibodies specific to IL-17.
The relations between Th17 cells and autoimmune diseases, preferably RA may be more deeply understood by establishing a method which allows not only measurement of the amount of IL-17 but also detection of Th17 cells per se.
The present inventors aimed to find molecular markers that allows specific detection of human Th17 cells.
The present inventors isolated Th17 cells from peripheral blood of a healthy adult and identified the genes which are specifically expressed in the obtained Th17 cells, thereby completing the present invention.
Thus, the present invention provides a polynucleotide marker for detecting human Th17 cells which is a polynucleotide having a nucleic acid sequence of at least one gene selected from the group consisting of:
-
- genes encoding membrane proteins consisting of: ADAM12 (ADAM metallopeptidase domain 12), ANKS1B (ankyrin repeat and sterile alpha motif domain containing 1B), ATP6V0A4 (ATPase, H+ transporting, lysosomal V0 subunit a4), ATP9A (ATPase, class II, type 9A), BVES (blood vessel epicardial substance), C5orf40 (chromosome 5 open reading frame 40), CDH4 (
cadherin 4,type 1, R-cadherin (retinal)), DIO2 (deiodinase, iodothyronine, type II), DMD (dystrophin), GPR34 (G protein-coupled receptor 34), IRS2 (insulin receptor substrate 2), KCNE3 (potassium voltage-gated channel, Isk-related family, member 3), L1CAM (L1 cell adhesion molecule), MCAM (melanoma cell adhesion molecule), MFAP3L (microfibrillar-associated protein 3-like), MYO7A (myosin VIIA), PTPRM (protein tyrosine phosphatase, receptor type, M), SHROOM2 (shroom family member 2), SLC16A4 (solute carrier family 16, member 4 (monocarboxylic acid transporter 5)), SLCO2B1 (solute carrier organic anion transporter family, member 2B1), TANC2 (tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2), TJP1 (tight junction protein 1 (zona occludens 1)), TMEM163 (transmembrane protein 163), TNS3 (tensin 3), UPK1B (uroplakin 1B), WDFY3 (WD repeat and FYVE domain containing 3), DRD2 (dopamine receptor D2), GJC1 (gap junction protein,gamma 1, 45 kDa), PGBD5 (LOC100134440) (piggyBac transposable element derived 5 (similar to PGBD5 protein)), MS4A 7 (membrane-spanning 4-domains, subfamily A, member 7), ODZ4 (odz, odd Oz/ten-m homolog 4), PHKA1 (phosphorylase kinase, alpha 1), RGS1 (regulator of G-protein signaling 1), SHB (Src homology 2 domain containing adaptor protein B), SLC44A3 (solute carrier family 44, member 3), SLC6A15 (solute carrier family 6 (neutral amino acid transporter), member 15), SYNGR3 (synaptogyrin 3), AKAP12 (A kinase (PRKA) anchor protein 12), C9orf125 (chromosome 9 open reading frame 125), DPY19L2 (dpy-19-like 2), HRH4 (histamine receptor H4), MUC20 (mucin 20, cell surface associated), POPDC3 (popeye domain containing 3), SORBS1 (sorbin and SH3 domain containing 1), TANC1 (tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1), TMEM44 (transmembrane protein 44) and UNC13C (unc-13 homolog C);
- genes encoding membrane proteins consisting of: ADAM12 (ADAM metallopeptidase domain 12), ANKS1B (ankyrin repeat and sterile alpha motif domain containing 1B), ATP6V0A4 (ATPase, H+ transporting, lysosomal V0 subunit a4), ATP9A (ATPase, class II, type 9A), BVES (blood vessel epicardial substance), C5orf40 (chromosome 5 open reading frame 40), CDH4 (
genes encoding secretory proteins consisting of: CXCL13 (chemokine (C—X—C motif) ligand 13), PCOLCE2 (procollagen C-endopeptidase enhancer 2), PNOC (prepronociceptin), SMPDL3A (sphingomyelin phosphodiesterase, acid-like 3A), TGFBI (transforming growth factor, beta-induced), C17orf99 (chromosome 17 open reading frame 99), EBI3 (Epstein-Barr virus induced 3), IL1A (interleukin 1, alpha) and WNT3 (wingless-type MMTV integration site family, member 3);
genes encoding intracellular proteins consisting of: BCAT1 (branched chain aminotransferase 1, cytosolic), BHLHE22 (basic helix-loop-helix family, member e22), C13orf18 (LOC728970) (chromosome 13 open reading frame 18 (hypothetical LOC728970)), CA2 (carbonic anhydrase II), CCDC3 (coiled-coil domain containing 3), CDS1 (CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1), CHN1 (chimerin (chimaerin) 1), CLIC5 (LOC100131610) (chloride intracellular channel 5 (similar to chloride intracellular channel 5)), CTSH (cathepsin H), CYP7B1 (cytochrome P450, family 7, subfamily B, polypeptide 1), DAPK2 (death-associated protein kinase 2), DMRT1 (doublesex and mab-3 related transcription factor 1), DSE (dermatan sulfate epimerase), FBXL17 (F-box and leucine-rich repeat protein 17), FBXL21 (F-box and leucine-rich repeat protein 21), FHOD3 (formin homology 2 domain containing 3), H2AFY2 (H2A histone family, member Y2), HLX (H2.0-like homeobox), IRAK3 (interleukin-1 receptor-associated kinase 3), MACC1 (metastasis associated in colon cancer 1), MAML3 (mastermind-like 3), MYO10 (myosin X), OTUB2 (OTU domain, ubiquitin aldehyde binding 2), PAPSS2 (3′-phosphoadenosine 5′-phosphosulfate synthase 2), PCBP3 (Poly (rC) binding protein 3 (PCBP3), transcript variant 2), PDE4DIP (phosphodiesterase 4D interacting protein), PLD1 (phospholipase D1, phosphatidylcholine-specific), PPARG (peroxisome proliferator-activated receptor gamma), PTPN13 (Protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)), RGS18 (regulator of G-protein signaling 18), SIM1 (single-minded homolog 1), SNAI2 (snail homolog 2), SOX2 (SRY (sex determining region Y)-box 2), SPIRE1 (spire homolog 1), TBC1D12 (TBC1 domain family, member 12), TGM5 (transglutaminase 5), TMOD1 (tropomodulin 1), TUBB6 (tubulin, beta 6), DDIT4L (DNA-damage-inducible transcript 4-like), DHRS9 (dehydrogenase/reductase (SDR family) member 9), ERC2 (ELKS/RAB6-interacting/CAST family member 2), FERMT2 (fermitin family homolog 2), HHEX (hematopoietically expressed homeobox), HS3ST1 (heparan sulfate (glucosamine) 3-O-sulfotransferase 1), NR5A2 (nuclear receptor subfamily 5, group A, member 2), PHLDA1 (pleckstrin homology-like domain, family A, member 1), RBM20 (RNA binding motif protein 20), NINL (ninein-like), RTN2 (reticulon 2), SH3RF2 (SH3 domain containing ring finger 2), TSHZ2 (teashirt zinc finger homeobox 2), EML1 (echinoderm microtubule associated protein like 1), HIST1H2BC (histone cluster 1, H2bc), MAP3K4 (mitogen-activated protein kinase kinase kinase 4), PDK4 (pyruvate dehydrogenase kinase, isozyme 4), RGS2 (regulator of G-protein signaling 2) and RGS20 (regulator of G-protein signaling 20);
genes consisting of: C1orf106 (chromosome 1 open reading frame 106), C6orf145 (chromosome 6 open reading frame 145), LOC401097 (Similar to LOC166075), MAMLD1 (mastermind-like domain containing 1), ZC3H12C (zinc finger CCCH-type containing 12C), C12orf64 (chromosome 12 open reading frame 64), C6orf168 (chromosome 6 open reading frame 168), CAMSAP1L1 (calmodulin regulated spectrin-associated protein 1-like 1) and MAGED4 (MAGED4B) (melanoma antigen family D, 4, (melanoma antigen family D, 4B)); and
-
- genes comprising at least one nucleic acid sequence selected from SEQ ID NOs:147 to 151, 157 to 162 and 167 to 174;
- or a variant and fragment thereof.
The present invention also provides a protein marker for detecting human Th17 cells which is a protein encoded by at least one of the above genes or a functionally equivalent variant and fragment thereof.
The present invention further provides a method for detecting human Th17 cells comprising detecting the presence of at least one polynucleotide marker for detecting human Th17 cells or at least one protein marker for detecting human Th17 cells in a sample containing cells derived from human.
In addition, the present invention provides a reagent for detecting human Th17 cells comprising at least one substance selected from a nucleic acid probe which specifically hybridizes to the above polynucleotide marker; and a nucleic acid aptamer, antibody, ligand or receptor which specifically binds to the above protein marker.
Human Th17 cells can be specifically detected by detecting at least one polynucleotide marker or protein marker for detecting human Th17 cells of the present invention. It may also allow detection of the possibility that a patient has a disease in which Th17 cells may be involved such as autoimmune diseases, e.g. RA.
The polynucleotide marker for detecting human Th17 cells of the present invention is the polynucleotide having a nucleic acid sequence of at least one gene selected from the group consisting of the above genes, or a variant and fragment thereof.
Preferably, the polynucleotide has a nucleic acid sequence of at least one gene selected from the group consisting of:
-
- genes encoding membrane proteins consisting of: ADAM12, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, GPR34, L1CAM, MCAM, PTPRM, SHROOM2, TMEM163, UPK1B, DRD2, PGBD5 (LOC100134440), ODZ4, SLC6A15, AKAP12, C9orf125, POPDC3 and UNC13C;
- genes encoding secretory proteins consisting of: PCOLCE2, PNOC, TGFBI and IL1A; and
genes encoding intracellular proteins consisting of: BHLHE22, PPARG, SIM1 and SNAI2.
The present polynucleotide marker for detecting human Th17 cells is the polynucleotide, variant or fragment thereof which has been found to be specifically present in Th17 cells rather than in other helper T-cells derived from human peripheral blood (Th1, Th2 and Treg cells).
Therefore, by detecting at least one of the above polynucleotide markers, Th17 cells can be distinguished from Th1, Th2 and Treg cells and specifically identified, and an index for activity of diseases in vivo can be studied in which Th17 cells may be involved.
As used herein, the term “gene” has the same meaning as that is commonly recognized in the art, and refers to a part of a genome which is transcribed into mRNA and translated into a protein.
In the present specification, genes containing at least one nucleic acid sequence selected from SEQ ID NOs: 147 to 151, 157 to 162 and 167 to 174 are the genes to be transcribed into mRNAs containing at least one of these nucleic acid sequences or a complementary sequence thereof. Thus, genes containing at least one nucleic acid sequence selected from SEQ ID NOs: 147 to 151, 157 to 162 and 167 to 174 comprise genes containing a nucleic acid sequence complementary to at least one nucleic acid sequence selected from SEQ ID NOs: 147 to 151, 157 to 162 and 167 to 174.
As used herein, a membrane protein means a protein existing in a cell membrane and being contained in a membrane fraction of cells. A secretory protein means a protein synthesized in cells and secreted to the outside of the cell membrane. An intracellular protein means a protein which is mainly present in cells.
As used herein, the phrase that a polynucleotide is “specifically expressed” in Th17 cells means that the expression level of the polynucleotide in Th17 cells is significantly higher than the expression level of the polynucleotide in cells other than Th17 cells.
Specifically, it means that the expression level of the polynucleotide in Th17 cells is about two times or more of the expression level of the polynucleotide in cells other than Th17 cells. Preferably, the expression level of the polynucleotide in Th17 cells is about two times or more of the expression level of the polynucleotide in helper T-cells other than Th17 cells (Th1, Th2 and Treg cells).
The nucleotide sequences of the present polynucleotide markers are already known. They can be obtained from, for example, Unigene (a database provided by National Center for Biotechnology Information (NCBI) of National Library of Medicine). Unigene codes for the nucleic acid sequences of the present polynucleotide markers are specified in Table 9.
As used herein, “variant” of a polynucleotide means a polynucleotide into which a mutation has been introduced that does not alter the nature of the protein encoded by the above gene. Such mutation includes a deletion, substitution or addition of one or more nucleotides to the nucleic acid sequence of the above gene.
As used herein, “fragment” of a polynucleotide means a polynucleotide having a contiguous part of the nucleic acid sequence of the above gene and having a length which allows its specific hybridization with a nucleic acid probe for detecting human Th17 cells described hereinafter.
The variant of the polynucleotide as the present polynucleotide marker for detecting human Th17 cells has generally at least 80%, more preferably at least 85%, further preferably at least 90% and particularly preferably at least 95% homology with the nucleic acid sequence of the above gene.
As used herein, the homology of nucleic acid and amino acid sequences is calculated in BLASTN, BLASTP, BLASTX or TBLASTN (e.g. available from http://www.ncbi.nlm.nih.gov) with default settings.
The polynucleotide marker may be any of DNA or RNA, and may be the gene per se (DNA), mRNA, cDNA or cRNA.
Human Th17 cells can also be detected by detecting at least one protein encoded by the above gene. Thus, the present invention also provides the protein marker for detecting human Th17 cells consisting of the protein encoded by at least one of the above genes or a functionally equivalent variant and fragment thereof.
Preferably, the above protein is encoded by at least one gene selected from the group consisting of:
-
- genes encoding membrane proteins consisting of: ADAM12, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, GPR34, L1CAM, MCAM, PTPRM, SHROOM2, TMEM163, UPK1B, DRD2, PGBD5 (LOC100134440), ODZ4, SLC6A15, AKAP12, C9orf125, POPDC3 and UNC13C;
- genes encoding secretory proteins consisting of: PCOLCE2, PNOC, TGFBI and IL1A; and
- genes encoding intracellular proteins consisting of: BHLHE22, PPARG, SIM1 and SNAI2.
More preferably, the above protein is a membrane protein encoded by at least one gene selected from the group consisting of GPR34, MCAM and PTPRM.
The amino acid sequence of such protein marker can be obtained based on the nucleic acid sequence of the polynucleotide marker obtained from Unigene and the like. It can also be obtained from databases provided by NCBI and the like. NCBI code numbers for the amino acid sequences of the present protein markers for detecting human Th17 cells are specified in Table 9.
The protein marker for detecting human Th17 cells is the protein encoded by the above gene, a functionally equivalent variant or fragment thereof.
As used herein, “functionally equivalent variant” of a protein means a protein into which a mutation has been introduced that does not alter functions of the protein. Such mutation includes a deletion, substitution or addition of one or more amino acids to the known amino acid sequence of the protein.
As used herein, “fragment” of a protein means a protein having a contiguous amino acid sequence of the protein encoded by the above gene or a functionally equivalent variant thereof and being able to specifically bind to a nucleic acid aptamer, antibody, ligand or receptor for detecting human Th17 cells described hereinafter.
The functionally equivalent variant of the protein corresponding to the present protein marker for detecting human Th17 cells has generally at least 80%, preferably at least 85%, more preferably at least about 90% and particularly preferably at least 95% homology with the known amino acid sequence of the protein encoded by the above gene.
A molecule that can specifically hybridize to the present polynucleotide marker can be used for detection of the marker, making it useful as a probe for detecting human Th17 cells. The probe may be a nucleic acid probe such as DNA or RNA, or a peptide probe that can specifically hybridize to the polynucleotide marker. The probe for detecting human Th17 cells is preferably a nucleic acid probe, particularly a DNA probe for detecting the polynucleotide marker.
As used herein, the phrase “can specifically hybridize” means that it can hybridize to a target nucleic acid molecule (the polynucleotide marker) under a stringent condition.
As used herein, “stringent condition” means a condition under which the probe for detecting human Th17 cells can hybridize to the target polynucleotide marker with a detectably higher extent than it does to a polynucleotide other than the target polynucleotide marker (e.g. more than at least two times of the background).
The stringent condition generally depends on the sequences and varies depending on various circumstances. Generally, the stringent condition is selected so that it is about 5° C. lower than a thermal melting point of the specific sequence under a certain ionic strength and pH. This Tm is a temperature at which 50% of the complementary probe hybridizes to the target sequence in equilibrium (under a certain ionic strength, pH and nucleic acid composition).
Such condition may be those which are used in conventional hybridization techniques between polynucleotides such as PCR, microarray or Southern blotting.
Specifically, it may be a condition of pH 7.0 to 9.0, a salt concentration of lower than about 1.5M Na-ion, more specifically about 0.01 to 1.0 M Na-ion concentration (or other salt) and a temperature of at least about 30° C. More specifically, the stringent condition in microarray technique includes the hybridization at 37° C. in 50% formamide, 1M NaCl and 1% SDS and washing at 60 to 65° C. in 0.1×SSC.
The stringent condition in PCR technique includes a condition of pH 7 to 9, 0.01 to 0.1 M Tris-HCl, 0.05 to 0.15 M potassium ion concentration (or other salt) and at least about 55° C.
The sequence of the nucleic acid probe for detecting human Th17 cells can be appropriately selected by a person skilled in the art based on the common technical knowledge in the art and the sequence of the polynucleotide marker so that it can specifically hybridize to the polynucleotide marker.
The nucleic acid probe for detecting human Th17 cells can be designed by using, for example, a commonly available primer designing software (e.g. Primer3 (available from frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) or DNASIS Pro (Hitachi Software Engineering Co., Ltd.)).
The nucleic acid probe for detecting human Th17 cells can be prepared according to polynucleotide synthesis methods which are well-known in the art.
The nucleic acid probe for detecting human Th17 cells may be labeled with a labeling substance normally used in the art. The labeled nucleic acid probe allows an easy detection of the polynucleotide marker for detecting human Th17 cells, namely of human Th17 cells.
The labeling substance may be a labeling substance generally used in the art including radioisotopes such as 32P, fluorescent substances such as fluorescein, enzymes such as alkaline phosphatase and horseradish peroxidase, and biotin.
Human Th17 cells can be specifically detected by using one or more nucleic acid probes for detecting human Th17 cells. For example, a DNA chip or microarray for detecting the polynucleotide marker for detecting human Th17 cells can be obtained by immobilizing one or more probes on a substrate according to a method well-known in the art.
The nucleic acid probe for detecting human Th17 cells may include a set of two or more primers for amplifying the polynucleotide marker by nucleic acid amplification methods such as PCR technique, for example.
A molecule that can specifically bind to the present protein marker can be used for the detection of the marker, making it useful in the detection of human Th17 cells. Such molecule may be a nucleic acid aptamer such as DNA or RNA, an antibody, a ligand or a receptor that can specifically bind to the present protein marker, and preferably an antibody.
When the protein marker for detecting human Th17 cells is an enzyme, it can be detected by applying a substrate for the enzyme to develop color or emit light or fluorescent.
The antibody for detecting human Th17 cells can be prepared by the following well-known procedure, for example. A DNA molecule encoding a protein having an amino acid sequence of the present protein marker is prepared based on the nucleic acid sequence of the present polynucleotide marker or the amino acid sequence of the present protein marker, and is introduced into an appropriate expression vector. The obtained expression vector is introduced into an appropriate host cells, and the obtained transformed cells are cultured to obtain a desired protein. The obtained protein is purified and used as an immunogen optionally with an adjuvant to immunize an appropriate mammal such as rat or mouse. Spleen cells of the immunized animals are screened for antibody producing cells that produce an antibody directed to the target immunogen. The selected antibody producing cells are fused with myeloma cells to obtain hybridomas. These hybridomas are screened for antibody producing hybridomas that produce an antibody having specific binding property to the protein encoded by the gene. The desired antibody can be obtained by culturing the obtained antibody producing hybridomas.
The nucleic acid aptamer that can be used for detecting human Th17 cells can be prepared by the following well-known procedure, for example. A nucleic acid library including random nucleic acid sequences is prepared according to the known technique, and an aptamer that specifically binds to the target protein (the protein marker) can be selected by the systematic evolution of ligands by exponential enrichment method (SELEX method) or the like.
The molecule which can specifically bind to the protein marker for detecting human Th17 cells may be labeled with a labeling substance normally used in the art. The labeled antibody for detecting human Th17 cells allows an easy detection of the protein marker for detecting human Th17 cells, namely of human Th17 cells.
The labeling substance may be a labeling substance generally used in the art including radioisotopes such as 32P, fluorescent substances such as fluorescein, enzymes such as alkaline phosphatase and horseradish peroxidase, and biotin.
A method for detecting human Th17 cells by detecting the presence of at least one polynucleotide or protein marker for detecting human Th17 cells in a sample containing cells derived from human is also within the scope of the present invention.
In the method, it is preferred that two or more polynucleotide markers or protein markers for detecting human Th17 cells are detected in order to improve the detection sensitivity.
In the present method, the sample containing cells derived from human includes a biological sample obtained from human or a sample containing cultured human cells. The biological sample includes blood, tissue, synovial fluid, cerebrospinal fluid, pleural fluid, ascitic fluid and the like.
An embodiment of the method for detecting the presence of the polynucleotide marker for detecting human Th17 cells is described.
Nucleic acid (DNA or RNA) is extracted from a sample containing cells derived from human by a well-known method in the art such as the one using a phenolic extraction and ethanol precipitation or a commercial DNA extraction kit.
Then, the presence of the polynucleotide marker in the obtained nucleic acid sample is detected, preferably using the nucleic acid probe for detecting human Th17 cells. When the presence of the polynucleotide marker is detected by nucleic acid amplification method such as PCR, RT-PCR, real-time PCR, LAMP (Loop-mediated isothermal amplification) and the like, the nucleic acid probe for detecting human Th17 cells is preferably a primer set for amplifying the polynucleotide marker by a nucleic acid amplification method.
The presence of the polynucleotide marker for detecting human Th17 cells may also be detected by well-known methods in the art, for example hybridization methods such as Southern hybridization, Northern hybridization, fluorescence in situ hybridization (FISH), or DNA chip or microarray. Such methods are carried out under the stringent condition, and the hybridization of the nucleic acid probe for detecting human Th17 cells is detected by detecting the labeling substance and the like to detect the presence of the polynucleotide marker.
An embodiment of the method for detecting the presence of the protein marker for detecting human Th17 cells is described.
When the target protein marker is an intracellular protein, proteins are extracted from a sample containing cells derived from human by using well-known methods in the art. The extraction of proteins from a sample can be accomplished by known methods such as disruption of the cells by ultrasonic, lysis of the cells with a cell lysis solution. The protein marker in the obtained protein extract can be detected by using the molecule which specifically binds to the protein marker. Specifically, the protein marker for detecting human Th17 cells can be detected by well-known methods in the art such as ELISA or Western blotting. The molecule which specifically binds to the protein marker in the detection is preferably the above nucleic acid aptamer, antibody, ligand or receptor, and more preferably the antibody for detecting human Th17 cells.
When the target protein marker is a secretory protein, the protein marker secreted in the sample containing the cells can be detected by using the molecule which specifically binds to the protein marker.
Alternatively, the cells (lymphocytes) are recovered from the sample containing the cells from human and the obtained cells are stimulated with anti-CD3 antibody, anti-CD28 antibody, concanavalin A, phytohemagglutinin (PHA), phorbol myristate acetate (PMA), ionomycin or the like. Then, the secreted protein marker can be detected by using the molecule which specifically binds to the protein marker.
Specifically, the protein marker can be detected by well-known methods in the art such as ELISA or Western blotting. The molecule which specifically binds to the protein marker in the detection is preferably the above nucleic acid aptamer, antibody, ligand or receptor, and more preferably the antibody for detecting human Th17 cells.
When the target protein marker is a protein located on the cell surface, the protein marker located on the cell surface in the sample containing the cells derived from human can be detected by using the molecule which specifically binds to the protein marker.
Alternatively, a membrane fraction of the cells is obtained from the sample containing the cells derived from human and the protein marker in the membrane fraction can be detected by using the molecule which specifically binds to the protein marker. Specifically, the protein marker can be detected by well-known methods in the art such as ELISA, Western blotting or a method based on flow cytometry (FCM). The molecule which specifically binds to the protein marker in the detection is preferably the above nucleic acid aptamer, antibody, ligand or receptor, and more preferably the antibody for detecting human Th17 cells.
For example, the protein marker for detecting human Th17 cells can be detected by FCM as follows.
First, the sample containing the cells derived from human is brought into contact with the antibody for detecting human Th17 cells labeled with an appropriate labeling substance. Human Th17 cells, when exist, bind to the labeled antibody on their surfaces. Then, the sample containing the cells bound to the labeling substance can be applied to a flow cytometer to detect human Th17 cells. Human Th17 cells that have bound to the labeling substance can optionally be classified and fractionated by using a cell sorter.
Such method of FCM is well-known to a person skilled in the art and he can appropriately select the reaction conditions.
The present invention also provides a reagent for detecting human Th17 cells which can be used in the present method for detecting human Th17 cells
The reagent comprises at least one substance selected from a nucleic acid probe which specifically hybridizes to the polynucleotide marker for detecting human Th17 cells, and a nucleic acid aptamer, antibody, ligand and receptor which specifically binds to the protein marker for detecting human Th17 cells.
The present invention is now described in detail by way of Examples, which do not limit the present invention.
1. Isolation of Th1, Th2, Treg and Th17 Cells from Human Peripheral Blood
(1) Isolation of Th1, Th2 and Th17 Cells from Human Peripheral Blood
Buffy coat obtained from peripheral blood of a healthy adult was overlaid on Ficoll-paque plus solution (GE Healthcare Bioscience) and centrifuged to obtain a monocyte fraction. Crude CD4 positive cells were purified from the fraction by using magnetic beads bound to anti-CD4 antibody (Miltenyi Biotec).
The obtained CD4 positive cells were stained with the fluorescence labeled antibodies shown in Table 1 and then Th1, Th2 and Th17 cells were separated by a cell sorter (FACS Aria: Becton Dickinson). The separation was carried out with the gating shown in Table 2.
TABLE 1 | |||
Fluorescence | |||
Antigen | labeling substance | Clone | Manufacturer |
CD4 | APC-Cy7 | RPA-T4 | BD Biosciences |
CD25 | PE-Cy7 | BC96 | eBioscience |
CXCR3 | Alexa Fluor ™ 488 | 1C6/CXCR3 | BD Biosciences |
CCR4 | APC | FAB1567A | R&D systems |
CCR6 | PE | 11A9 | BD Biosciences |
TABLE 2 | |||
Cell | Gating | ||
Th1 | CD4high CD25low-negative CXCR3+ CCR6− CCR4− | ||
Th2 | CD4high CD25low-negative CXCR3− CCR6− CCR4+ | ||
Th17 | CD4high CD25low-negative CXCR3− CCR6+ CCR4+ | ||
The above gating is described in detail in the reference by Acosta-Rodriguez E V et al. (Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells, Nat Immunol., 2007, vol. 8, p. 639-646).
(2) Isolation of Treg Cells from Human Peripheral Blood
CD4 positive cells obtained in the same manner as the above (1) were stained with the fluorescence labeled antibodies shown in Table 3, and CD4high CD25high CD127internal-negative cells were purified as Treg cells by using the above cell sorter.
TABLE 3 | |||
Fluorescence | |||
Antigen | Labeling substance | Clone | Manufacturer |
CD4 | FITC | OKT4 | eBioscience |
CD25 | PE-Cy7 | BC96 | eBioscience |
GD45RO | PE | UCHL1 | BioLegend |
CD127 | Alexa Fluor ™ 647 | HIL-7R-M21 | BD Biosciences |
The above gating is described in detail in the reference by Weihong Liu et al. (CD 127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells, J Exp Med. 2006, vol. 203, p. 1701-1711).
2. Cell Culture
(1) Th1, Th2 and Th17 Cell Cultures
Th1, Th2 and Th17 cells derived from adult peripheral blood obtained in the above step 1. (1) were respectively plated in a 96-well plate at the density of 1.5×105 cells/0.3 ml/well. The medium used was Yssel medium (IMDM, 1% human serum of AB-type, 0.25% BSA, 1.8 mg/l 2-aminomethanol, 40 mg/l transferrin, 5 mg/l insulin, 2 mg/l linoleic acid, 2 mg/l oleic acid, 2 mg/l palmitic acid, 1% penicillin/streptomycin).
For activation and proliferation of the above cells, magnetic beads coated with anti-CD2/3/28 antibody (Miltenyi Biotec) (hereinafter also referred to as “antibody beads”) were added at 0.75×105 per well. After addition of cytokines and neutralizing antibody(s) suitable for differentiation culture of respective Th1, Th2 and Th17 cells, cells were incubated in an incubator at 37° C. with 5% CO2. Cytokines and neutralizing antibodies used are shown in Table 4.
TABLE 4 | ||
Cell | Cytokine | Neutralizing antibody (Clone) |
Th1 | IL-12, IL-2 | Anti-IL-4 antibody (MP4-25D2) |
Th2 | IL-4, IL-2 | Anti-IFN-γ antibody (R4-6A2) |
Th17 | TGF-β1, IL-6, IL-23, | Anti-IL-4 antlbody (MP4-25D2), |
IL-21, IL-1β, TNFα, IL-2 | Anti-IFN-γ antibody (R4-6A2) | |
The concentrations of the above cytokines were 50 ng/ml for IL-6 and 10 ng/ml for other than IL-6.
The concentrations of antibodies were 10 μg/ml for anti-IFN-γ antibody and 2.5 μg/ml for anti-IL-4 antibody. The cytokines and neutralizing antibodies were obtained from R&D systems and eBioscience, respectively.
After three days from the start of culture, cells were diluted three-fold with the medium containing the above cytokines and antibody(s) and cultured for further seven days (10 days in total).
After ten days from the start of culture, the obtained Th1, Th2 and Th17 cells were respectively divided into two equal parts, and one was washed with Yssel medium and PBS before centrifugation to collect cells, which were stored at −80° C. until the subsequent RNA extraction step. These cells were designated as Th1, Th2 and Th17 cells “without activation stimulation”. The other half was added with the antibody beads and cultured for three more hours to re-activate the cells. The cells were collected by centrifugation and similarly stored at −80° C. These cells were designated as Th1, Th2 and Th17 cells “with activation stimulation”.
(2) Treg Cell Culture
Treg cells obtained in the above step 1. (2) were cultured in the same manner in Yssel medium as the above step 2. (1) and activated with the antibody beads. To the medium were added cytokines IL-2 and TGF-β1 (R&D systems), and neutralizing antibodies anti-IFN-γ antibody, anti-IL-4 antibody (eBioscience) and anti-IL-6 antibody (BD Bioscience).
These cytokines and neutralizing antibodies were used at the concentrations of 10 ng/ml and 5 μg/ml, respectively.
After three days from the start of culture, cells were added with the cytokines and neutralizing antibodies at the same amounts as those at the start of the culture. After culturing for three more days, cells were divided into two equal parts, one half was not added with the antibody beads used for activation and the other half was added with the antibody beads before culturing further three hours, thereby obtaining Treg cells “without activation stimulation” and Treg cells “with activation stimulation”, respectively. The cells were then collected by centrifugation and stored at −80° C. until the subsequent RNA extraction step.
3. Extraction of Total RNA
The cells obtained as the above step 2. were subjected to extraction of total RNAs using RNeasy Plus Mini kit and RNeasy micro kit (QIAGEN).
The specific procedures were according to the attached instructions of the kits.
4. Expression Analysis by Microarray
Total RNAs (10 to 100 ng) extracted from the cells as the above step 3. were reverse-transcribed to cDNAs with Two-Cycle Target Labeling and Control Reagents (Affymetrix), and further transcribed to biotinylated-cRNAs. The amplified biotinylated-cRNAs (20 μg) were fragmented. The specific procedures were according to the attached instruction of the kit.
The biotinylated-cRNAs derived from the cells as obtained above (15 μg) were applied to GeneChip Human Genome U-133 Plus 2.0 Array (Affymetrix) as samples, transferred to GeneChip Hybridization Oven 640 (Affymetrix) and hybridized under the conditions of 45° C. and 60 rpm for 16 hours.
After completion of the hybridization, the microarray was washed and fluorescence-labeled in GeneChip Fluidic Station 450 (Affymetrix), and scanned in GeneChip Scanner 3000 7G (Affymetrix) to obtain fluorescent intensity data.
5. Selection of Genes Specifically Expressed in Human Th17 Cells
The fluorescent data obtained in the above step 4. was standardized with the expression analysis software GeneSpring Ver. 10 (Agilent Technologies) based on MAS5 algorithm. Relative fluorescent intensities of the genes from Th17 cells were compared with those from Th1, Th2 and Treg cells.
The genes whose relative fluorescent intensities in Th17 cells were three or more times higher than any of those of Th1, Th2 and Treg cells and which were significantly expressed (which showed “p value <0.05” after ANOVA test between four groups of relative fluorescent intensities in Th1, Th2, Treg and Th17 cells) were identified as the genes which were specifically expressed in Th17 cells.
The number of samples used in the above selection step is shown in Table 5.
TABLE 5 | ||||
Th1 | Th2 | Th17 | Treg | |
w/ activation stimulation | 5 | 5 | 5 | 4 |
w/o activation stimulation | 5 | 5 | 5 | 3 |
The genes specifically expressed in Th17 cells “without activation stimulation” and “with activation stimulation” are shown in Tables 6 and 7, respectively.
TABLE 6 |
Without activation stimulation |
Expression ratio |
Location of | Entrez | Protein | Transcript | UniGene | Probe Set | Th17/ | |||
encoded protein | Gene symbol | Gene ID | ID | ID | ID | ID | Th1 | Th17/Th2 | Th17/Treg |
Membrane | ADAM12 | 8038 | NP_003465, | NM_003474, | Hs.594537 | 202952_s_at | 21.8 | 80.1 | 3.2 |
NP_067673 | NM_021641 | ||||||||
ANKS1B | 56899 | NP_064525, | NM_020140, | Hs.506458 | 227439_at | 6.9 | 11.7 | 4.3 | |
NP_690001, | NM_152788, | 240292_x_at | 7.8 | 10.3 | 4.6 | ||||
NP_858056 | NM_181670 | ||||||||
ATP6V0A4 | 50617 | NP_065683, | NM_020632, | Hs.98967 | 220197_at | 22.8 | 244.1 | 153.8 | |
NP_570855, | NM_130840, | ||||||||
NP_570856 | NM_130841 | ||||||||
ATP9A | 10079 | NP_006036 | NM_006045 | Hs.714307 | 212062_at | 5.7 | 53.5 | 44.3 | |
BVES | 11149 | NP_009004, | NM_007073, | Hs.221660 | 228783_at | 3.0 | 6.5 | 16.2 | |
NP_671488 | NM_147147 | ||||||||
C5orf40 | 408263 | NP_001001343 | NM_001001343 | Hs.437066 | 1554801_at | 9.4 | 12.8 | 3.1 | |
CDH4 | 1002 | NP_001785 | NM_001794 | Hs.473231 | 206866_at | 19.2 | 16.0 | 7.6 | |
DIO2 | 1734 | NP_000784, | NM_000793, | Hs.202354 | 203700_s_at | 9.2 | 3.4 | 17.1 | |
NP_001007024, | NM_001007023, | ||||||||
NP_054644 | NM_013989 | ||||||||
DMD | 1756 | NP_000100, | NM_000109, | Hs.495912 | 203881_s_at | 10.3 | 3.2 | 10.0 | |
NP_003997, | NM_004006, | ||||||||
NP_003998, | NM_004007, | ||||||||
NP_004000, | NM_004009, | ||||||||
NP_004001, | NM_004010, | ||||||||
NP_004002, | NM_004011, | ||||||||
NP_004003, | NM_004012, | ||||||||
NP_004004, | NM_004013, | ||||||||
NP_004005, | NM_004014, | ||||||||
NP_004006, | NM_004015, | ||||||||
NP_004007, | NM_004016, | ||||||||
NP_004008, | NM_004017, | ||||||||
NP_004009, | NM_004018, | ||||||||
NP_004010, | NM_004019, | ||||||||
NP_004011, | NM_004020, | ||||||||
NP_004012, | NM_004021, | ||||||||
NP_004013, | NM_004022, | ||||||||
NP_004014 | NM_004023 | ||||||||
DRD2 | 1813 | NP_000786, | NM_000795, | Hs.73893 | 216938_x_at | 5.3 | 5.6 | 5.4 | |
NP_057658 | NM_016574 | ||||||||
GJC1 | 10052 | NP_001073852, | NM_001080383, | Hs.532593 | 228776_at | 7.0 | 10.7 | 4.9 | |
NP_005488 | NM_005497 | 243502_at | 3.8 | 10.5 | 8.3 | ||||
GPR34 | 2857 | NP_001091048, | NM_001097579, | Hs.495989 | 223620_at | 4.2 | 7.9 | 7.0 | |
NP_005291 | NM_005300 | ||||||||
IL23R | 149233 | NP_653302 | NM_144701 | Hs.677426 | 1552912_a_at | 8.2 | 15.3 | 4.1 | |
IRS2 | 8660 | NP_003740 | NM_003749 | Hs.442344 | 209184_s_at | 3.5 | 4.0 | 3.3 | |
209185_s_at | 6.0 | 5.9 | 4.3 | ||||||
KCNE3 | 10008 | NP_005463 | NM_005472 | Hs.523899 | 227647_at | 9.8 | 8.3 | 5.9 | |
L1CAM | 3897 | NP_000416, | NM_000425, | Hs.522818 | 204584_at | 8.5 | 9.4 | 5.1 | |
NP_076493 | NM_024003 | ||||||||
PGBD5, | 79605, | NP_078830, | NM_024554, | Hs.520463 | 219225_at | 9.9 | 17.3 | 11.3 | |
LOC100134440 | 100134440 | XP_001716155 | XM_001716103 | ||||||
MCAM | 4162 | NP_006491 | NM_006500 | Hs.599039 | 210869_s_at | 9.5 | 18.0 | 5.6 | |
MFAP3L | 9848 | NP_001009554, | NM_001009554, | Hs.593942 | 205442_at | 11.5 | 29.9 | 7.1 | |
NP_067679 | NM_021647 | ||||||||
MS4A7 | 58475 | NP_067024, | NM_021201, | Hs.530735 | 223343_at | 16.6 | 11.7 | 3.2 | |
NP_996821, | NM_206938, | ||||||||
NP_996822, | NM_206939, | ||||||||
NP_996823 | NM_206940 | ||||||||
MYO7A | 4647 | NP_000251, | NM_000260, | Hs.370421 | 208189_s_at | 19.4 | 22.9 | 6.5 | |
NP_001120651, | NM_001127179, | ||||||||
NP_001120652 | NM_001127180 | ||||||||
ODZ4 | 26011 | NP_001092286 | NM_001098816 | Hs.213087 | 213273_at | 9.8 | 13.1 | 7.0 | |
PHKA1 | 5255 | NP_001116142, | NM_001122670, | Hs.201379 | 229876_at | 4.2 | 3.7 | 15.8 | |
NP_002628 | NM_002637 | ||||||||
PTPRM | 5797 | NP_001098714, | NM_001105244, | Hs.49774 | 1555579_s_at | 3.6 | 76.0 | 3.7 | |
NP_002836 | NM_002845 | ||||||||
RGS1 | 5996 | NP_002913 | NM_002922 | Hs.75256 | 202988_s_at | 3.3 | 3.6 | 3.9 | |
SHB | 6461 | NP_003019 | NM_003028 | Hs.521482 | 1557458_s_at | 14.9 | 27.8 | 7.4 | |
SHROOM2 | 357 | NP_001640 | NM_001649 | Hs.567236 | 204967_at | 3.4 | 3.4 | 3.4 | |
SLC16A4 | 9122 | NP_004687 | NM_004696 | Hs.351306 | 205234_at | 66.3 | 20.4 | 3.4 | |
SLC44A3 | 126969 | NP_001107578, | NM_001114106, | Hs.483423 | 228221_at | 3.1 | 9.3 | 3.5 | |
NP_689582 | NM_152369 | ||||||||
SLC6A15 | 55117 | NP_060527, | NM_018057, | Hs.44424 | 206376_at | 10.7 | 11.9 | 15.2 | |
NP_877499 | NM_182767 | ||||||||
SLCO2B1 | 11309 | NP_009187 | NM_007256 | Hs.7884 | 203473_at | 9.7 | 6.0 | 6.8 | |
SYNGR3 | 9143 | NP_004200 | NM_004209 | Hs.435277 | 205691_at | 4.7 | 7.9 | 5.5 | |
TANC2 | 26115 | NP_079461 | NM_025185 | Hs.410889 | 208425_s_at | 4.7 | 9.0 | 7.3 | |
224952_at | 6.1 | 5.8 | 7.5 | ||||||
TJP1 | 7082 | NP_003248, | NM_003257, | Hs.716406 | 202011_at | 15.3 | 19.2 | 4.3 | |
NP_783297 | NM_175610 | ||||||||
TMEM163 | 81615 | NP_112185 | NM_030923 | Hs.369471 | 1552626_a_at | 16.1 | 32.5 | 16.4 | |
223503_at | 28.8 | 47.9 | 29.7 | ||||||
TNS3 | 64759 | NP_073585 | NM_022748 | Hs.520814 | 217853_at | 7.6 | 158.8 | 4.5 | |
UPK1B | 7348 | NP_008883 | NM_006952 | Hs.271580 | 210065_s_at | 5.8 | 7.5 | 4.6 | |
WDFY3 | 23001 | NP_055806, | NM_014991, | Hs.480116 | 212598_at | 14.2 | 18.4 | 45.6 | |
NP_848698, | NM_178583, | 212602_at | 18.7 | 56.1 | 29.3 | ||||
NP_848700 | NM_178585 | 212606_at | 23.0 | 82.7 | 71.7 | ||||
Extracellular/ | C17orf99 | 100141515 | NP_001156547 | NM_001163075 | Hs.633034 | 236981_at | 29.1 | 10.9 | 4.1 |
secreted | CXCL13 | 10563 | NP_006410 | NM_006419 | Hs.100431 | 205242_at | 57.7 | 20.1 | 4.6 |
EBI3 | 10148 | NP_005746 | NM_005755 | Hs.501452 | 219424_at | 3.6 | 43.8 | 3.7 | |
IL17A | 3605 | NP_002181 | NM_002190 | Hs.41724 | 216876_s_at | 340.3 | 618.9 | 21.8 | |
IL17F | 112744 | NP_443104 | NM_052872 | Hs.272295 | 234408_at | 559.0 | 778.4 | 525.7 | |
IL1A | 3552 | NP_000566 | NM_000575 | Hs.1722 | 210118_s_at | 38.1 | 13.8 | 6.5 | |
IL22 | 50616 | NP_065386 | NM_020525 | Hs.287369 | 222974_at | 7.5 | 26.0 | 13.6 | |
IL26 | 55801 | NP_060872 | NM_018402 | Hs.272350 | 221111_at | 11.6 | 13.5 | 53.7 | |
IL9 | 3578 | NP_000581 | NM_000590 | Hs.960 | 208193_at | 103.8 | 193.5 | 24.1 | |
PCOLCE2 | 26577 | NP_037495 | NM_013363 | Hs.8944 | 219295_s_at | 10.6 | 16.8 | 25.3 | |
PNOC | 5368 | NP_006219 | NM_006228 | Hs.88218 | 205901_at | 36.8 | 27.3 | 69.3 | |
SMPDL3A | 10924 | NP_006705 | NM_006714 | Hs.486357 | 213624_at | 4.0 | 3.8 | 7.9 | |
TGFBI | 7045 | NP_000349 | NM_000358 | Hs.369397 | 201506_at | 54.7 | 476.7 | 33.8 | |
WNT3 | 7473 | NP_110380 | NM_030753 | Hs.445884 | 229103_at | 6.6 | 5.9 | 6.2 | |
Intracellular | BCAT1 | 586 | NP_005495 | NM_005504 | Hs.438993 | 214390_s_at | 3.1 | 4.1 | 18.9 |
214452_at | 3.5 | 6.4 | 24.8 | ||||||
225285_at | 3.0 | 3.5 | 31.5 | ||||||
226517_at | 3.1 | 3.5 | 38.3 | ||||||
BHLHE22 | 27319 | NP_689627 | NM_152414 | Hs.591870 | 228636_at | 18.9 | 24.7 | 40.5 | |
C13orf18, | 80183, | NP_079389, | NM_025113, | Hs.98117 | 44790_s_at | 3.2 | 11.2 | 32.0 | |
LOC728970 | 728970 | XP_001132115, | XM_001132115, | ||||||
XP_001133896, | XM_001133896, | ||||||||
XP_001720207 | XM_001720155 | ||||||||
CA2 | 760 | NP_000058 | NM_000067 | Hs.155097 | 209301_at | 6.3 | 452.7 | 103.6 | |
CCDC3 | 83643 | NP_113643 | NM_031455 | Hs.498720 | 223316_at | 16.3 | 106.1 | 42.1 | |
CDS1 | 1040 | NP_001254 | NM_001263 | Hs.654899 | 205709_s_at | 13.9 | 26.7 | 3.8 | |
CHN1 | 1123 | NP_001020372, | NM_001025201, | Hs.654534 | 212624_s_at | 6.9 | 12.3 | 6.4 | |
NP_001813 | NM_001822 | ||||||||
CLIC5, | 53405, | NP_001107558, | NM_001114086, | Hs.485489 | 213317_at | 6.7 | 53.5 | 13.3 | |
LOC100131610 | 100131610 | NP_058625, | NM_016929, | 217628_at | 3.1 | 9.1 | 4.2 | ||
XP_001723610 | XM_001723558 | 243917_at | 13.9 | 56.8 | 16.7 | ||||
219866_at | 7.1 | 28.2 | 17.8 | ||||||
CTSH | 1512 | NP_004381, | NM_004390, | Hs.148641 | 202295_s_at | 4.7 | 10.4 | 5.6 | |
NP_683880 | NM_148979 | ||||||||
CYP7B1 | 9420 | NP_004811 | NM_004820 | Hs.667720 | 207386_at | 12.3 | 10.2 | 4.1 | |
DAPK2 | 23604 | NP_055141 | NM_014326 | Hs.237886 | 206324_s_at | 7.3 | 9.9 | 8.3 | |
215184_at | 6.3 | 11.0 | 7.1 | ||||||
DDIT4L | 115265 | NP_660287 | NM_145244 | Hs.480378 | 228057_at | 3.1 | 5.2 | 106.8 | |
DHRS9 | 10170 | NP_001135742, | NM_001142270, | Hs.179608 | 219799_s_at | 8.3 | 14.6 | 11.9 | |
NP_001135743, | NM_001142271, | 223952_x_at | 5.3 | 7.8 | 7.7 | ||||
NP_005762, | NM_005771, | 224009_x_at | 6.3 | 7.9 | 7.0 | ||||
NP_954674 | NM_199204 | ||||||||
DMRT1 | 1761 | NP_068770 | NM_021951 | Hs.98586 | 220493_at | 3.6 | 16.6 | 6.4 | |
DSE | 29940 | NP_001074445, | NM_001080976, | Hs.486292 | 218854_at | 13.9 | 41.8 | 26.2 | |
NP_037484 | NM_013352 | ||||||||
ERC2 | 26059 | NP_056391 | NM_015576 | Hs.476389 | 213938_at | 3.5 | 6.1 | 6.1 | |
FBXL17 | 64839 | NP_073735 | NM_022824 | Hs.657225 | 227203_at | 8.9 | 7.7 | 4.7 | |
FBXL21 | 26223 | NP_036291 | NM_012159 | Hs.591275 | 1555412_at | 22.9 | 29.2 | 13.0 | |
FERMT2 | 10979 | NP_001128471, | NM_001134999, | Hs.509343 | 209210_s_at | 3.1 | 9.5 | 5.8 | |
NP_001128472, | NM_001135000, | ||||||||
NP_006823 | NM_006832 | ||||||||
FHOD3 | 80206 | NP_079411 | NM_025135 | Hs.436636 | 218980_at | 7.2 | 10.3 | 7.8 | |
H2AFY2 | 55506 | NP_061119 | NM_018649 | Hs.499953 | 218445_at | 5.2 | 6.5 | 6.4 | |
HHEX | 3087 | NP_002720 | NM_002729 | Hs.118651 | 204689_at | 3.6 | 5.9 | 6.4 | |
HLX | 3142 | NP_068777 | NM_021958 | Hs.74870 | 214438_at | 4.1 | 8.4 | 26.3 | |
HS3ST1 | 9957 | NP_005105 | NM_005114 | Hs.507348 | 205466_s_at | 21.2 | 6.0 | 3.2 | |
IRAK3 | 11213 | NP_001135995, | NM_001142523, | Hs.369265 | 213817_at | 14.5 | 16.5 | 6.0 | |
NP_009130 | NM_007199 | 220034_at | 5.5 | 10.3 | 3.4 | ||||
MACC1 | 346389 | NP_877439 | NM_182762 | Hs.598388 | 1566766_a_at | 5.9 | 15.7 | 3.5 | |
MAML3 | 55534 | NP_061187 | NM_018717 | Hs.586165 | 242794_at | 5.4 | 5.7 | 4.1 | |
MYO10 | 4651 | NP_036466 | NM_012334 | Hs.481720 | 201976_s_at | 39.5 | 17.2 | 7.1 | |
NR5A2 | 2494 | NP_003813, | NM_003822, | Hs.33446 | 208343_s_at | 5.5 | 17.9 | 39.5 | |
NP_995582 | NM_205860 | ||||||||
OTUB2 | 78990 | NP_075601 | NM_023112 | Hs.278815 | 219369_s_at | 3.4 | 3.7 | 6.3 | |
222878_s_at | 3.2 | 3.2 | 6.6 | ||||||
PAPSS2 | 9060 | NP_001015880, | NM_001015880, | Hs.524491 | 203058_s_at | 4.4 | 5.1 | 19.5 | |
NP_004661 | NM_004670 | 203060_s_at | 6.6 | 17.0 | 14.3 | ||||
PCBP3 | 54039 | NP_001123613, | NM_001130141, | Hs.474049 | 230486_at | 4.1 | 3.6 | 4.8 | |
NP_065389 | NM_020528 | ||||||||
PDE4DIP | 9659 | NP_001002810, | NM_001002810, | Hs.654651 | 205872_x_at | 4.3 | 33.4 | 3.3 | |
NP_001002811, | NM_001002811, | Hs.613082 | 209700_x_at | 4.1 | 10.9 | 9.5 | |||
NP_001002812, | NM_001002812, | ||||||||
NP_055459, | NM_014644, | ||||||||
NP_071754 | NM_022359 | ||||||||
PHLDA1 | 22822 | NP_031376 | NM_007350 | Hs.602085 | 217999_s_at | 3.6 | 5.0 | 10.3 | |
225842_at | 3.3 | 3.2 | 8.0 | ||||||
PLD1 | 5337 | NP_001123553, | NM_001130081, | Hs.382865 | 177_at | 3.5 | 3.4 | 10.3 | |
NP_002653 | NM_002662 | 215723_s_at | 3.9 | 3.4 | 11.4 | ||||
226636_at | 5.7 | 3.6 | 13.1 | ||||||
PPARG | 5468 | NP_005028, | NM_005037, | Hs.162646 | 208510_s_at | 7.9 | 134.5 | 16.5 | |
NP_056953, | NM_015869, | ||||||||
NP_619725, | NM_138711, | ||||||||
NP_619726 | NM_138712 | ||||||||
PTPN13 | 5783 | NP_006255, | NM_006264, | Hs.436142 | 243792_x_at | 3.5 | 4.2 | 7.9 | |
NP_542414, | NM_080683, | ||||||||
NP_542415, | NM_080684, | ||||||||
NP_542416 | NM_080685 | ||||||||
RBM20 | 282996 | NP_001127835, | NM_001134363, | Hs.715766 | 238763_at | 8.0 | 3.5 | 3.0 | |
XP_001716171, | XM_001716119, | ||||||||
XP_291671, | XM_291671, | ||||||||
XP_944430 | XM_939337 | ||||||||
RGS18 | 64407 | NP_570138 | NM_130782 | Hs.440890 | 223809_at | 3.3 | 6.9 | 8.8 | |
RORC | 6097 | NP_001001523, | NM_001001523, | Hs.256022 | 228806_at | 14.0 | 170.6 | 7.7 | |
NP_005051 | NM_005060 | ||||||||
NINL | 22981 | NP_079452 | NM_025176 | Hs.696157 | 207705_s_at | 4.7 | 4.7 | 3.1 | |
RTN2 | 6253 | NP_005610, | NM_005619, | Hs.47517 | 34408_at | 3.7 | 4.6 | 4.5 | |
NP_996783, | NM_206900, | ||||||||
NP_996784 | NM_206901 | ||||||||
SH3RF2 | 153769 | NP_689763 | NM_152550 | Hs.443728 | 243582_at | 5.8 | 4.1 | 18.5 | |
SIM1 | 6492 | NP_005059 | NM_005068 | Hs.520293 | 1556300_s_at | 8.8 | 4.8 | 69.0 | |
206876_at | 8.7 | 4.8 | 37.5 | ||||||
SNAI2 | 6591 | NP_003059 | NM_003068 | Hs.360174 | 213139_at | 24.6 | 22.5 | 13.8 | |
SOX2 | 6657 | NP_003097 | NM_003106 | Hs.518438 | 228038_at | 9.6 | 8.3 | 3.4 | |
SPIRE1 | 56907 | NP_001122098, | NM_001128626, | Hs.515283 | 1554807_a_at | 4.7 | 6.1 | 3.8 | |
NP_001122099, | NM_001128627, | 224995_at | 8.0 | 9.0 | 4.7 | ||||
NP_064533 | NM_020148 | 225018_at | 6.6 | 9.2 | 6.3 | ||||
TBC1D12 | 23232 | NP_056003 | NM_015188 | Hs.500598 | 221858_at | 7.7 | 5.8 | 5.5 | |
TGM5 | 9333 | NP_004236, | NM_004245, | Hs.129719 | 207911_s_at | 3.6 | 6.6 | 5.1 | |
NP_963925 | NM_201631 | ||||||||
TMOD1 | 7111 | NP_003266 | NM_003275 | Hs.494595 | 203661_s_at | 7.0 | 14.7 | 5.1 | |
203662_s_at | 7.8 | 14.5 | 4.5 | ||||||
TSHZ2 | 128553 | NP_775756 | NM_173485 | Hs.649877 | 220213_at | 3.6 | 12.4 | 3.8 | |
Hs.271605 | 243940_at | 3.1 | 10.6 | 4.1 | |||||
TUBB6 | 84617 | NP_115914 | NM_032525 | Hs.193491 | 209191_at | 4.1 | 12.7 | 4.7 | |
Unknown | C1orf106 | 55765 | NP_001136041, | NM_001142569, | Hs.518997 | 219010_at | 78.5 | 111.8 | 3.3 |
NP_060735 | NM_018265 | ||||||||
C6orf145 | 221749 | NP_899229 | NM_183373 | Hs.484500 | 212923_s_at | 10.4 | 3.8 | 5.2 | |
LOC401097 | 401097 | XP_001717155, | XM_001717103, | Hs.710781 | 236738_at | 6.8 | 3.3 | 24.9 | |
XP_001718614, | XM_001718562, | ||||||||
XP_001718795 | XM_001718743 | ||||||||
MAMLD1 | 10046 | NP_005482 | NM_005491 | Hs.20136 | 205088_at | 6.6 | 8.3 | 34.1 | |
ZC3H12C | 85463 | NP_203748 | NM_033390 | Hs.376289 | 231899_at | 3.0 | 4.1 | 18.7 | |
— | — | — | AA579799, | Hs.663788 | 215768_at | 4.1 | 6.1 | 6.7 | |
AA947186, | |||||||||
AL049337, | |||||||||
AW665328 | |||||||||
— | — | — | AK093229 | Hs.586723 | 222900_at | 5.9 | 3.0 | 4.5 | |
— | — | — | AK055628, | Hs.594351 | 226777_at | 21.6 | 39.7 | 3.6 | |
uc001ljj.1 | |||||||||
— | — | — | AK129763, | Hs.157726 | 227452_at | 4.6 | 4.2 | 4.5 | |
CR595588, | |||||||||
uc002jiy.1, | |||||||||
uc002jiz.1 | |||||||||
— | — | — | AA416573, | Hs.654918 | 229951_x_at | 4.7 | 15.0 | 7.1 | |
AA628762, | |||||||||
D53835, | |||||||||
D53836, | |||||||||
H24473, | |||||||||
R37871, | |||||||||
R40232, | |||||||||
T10348, | |||||||||
T23451, | |||||||||
W56351, | |||||||||
W57867, | |||||||||
Z28733 | |||||||||
— | — | — | AI766299 | — | 236338_at | 4.3 | 4.4 | 3.3 | |
— | — | — | AI262017, | Hs.666775 | 237923_at | 6.9 | 5.3 | 4.0 | |
AI280978, | |||||||||
AI284950, | |||||||||
AI733224, | |||||||||
AI733801 | |||||||||
TABLE 7 | |
Location of | Expression ratio |
encoded | Entrez | Protein | Transcript | UniGene | Probe Set | Th17/ | Th17/ | ||
protein | Gene symbol | Gene ID | ID | ID | ID | ID | Th1 | Th2 | Th17/Treg |
Without activation stimulation |
Unknown | — | — | — | AA687415, | Hs.434948 | 238009_at | 4.0 | 19.0 | 27.6 |
AA96901, | |||||||||
AI291640, | |||||||||
AI446064, | |||||||||
AI634557, | |||||||||
AI694948, | |||||||||
AI701854, | |||||||||
AI983938, | |||||||||
AV745212, | |||||||||
AV745909, | |||||||||
AV746001, | |||||||||
AW008696, | |||||||||
AW511701, | |||||||||
AW974416, | |||||||||
BG149302, | |||||||||
BG150103, | |||||||||
N66771, | |||||||||
R66991 | |||||||||
— | — | — | AI148241, | Hs.659083 | 238151_at | 50.6 | 21.1 | 24.4 | |
AI735444, | |||||||||
BE645654, | |||||||||
BF510855, | |||||||||
BF511636 | |||||||||
— | — | — | AK094629 | Hs.594896 | 238623_at | 4.9 | 4.8 | 3.4 | |
— | — | — | AI682088, | Hs.606172 | 241726_at | 5.4 | 5.7 | 9.5 | |
AI951058, | |||||||||
F06296, | |||||||||
F13164, | |||||||||
T77624, | |||||||||
Z44722 |
With activation stimulation |
Membrane | ADAM12 | 8038 | NP_003465, | NM_003474, | Hs.594537 | 202952_s_at | 19.5 | 71.0 | 3.5 |
NP_067673 | NM_021641 | ||||||||
AKAP12 | 9590 | NP_005091, | NM_005100, | Hs.371240 | 210517_s_at | 9.8 | 4.5 | 12.8 | |
NP_653080 | NM_144497 | 227529_s_at | 8.9 | 5.7 | 45.5 | ||||
ANKS1B | 56899 | NP_064525, | NM_020140, | Hs.506458 | 227439_at | 5.7 | 10.5 | 15.1 | |
NP_690001, | NM_152788, | 227440_at | 3.6 | 12.0 | 6.3 | ||||
NP_858056 | NM_181670 | 240292_x_at | 5.1 | 9.9 | 8.5 | ||||
ATP6V0A4 | 50617 | NP_065683, | NM_020632, | Hs.98967 | 220197_at | 9.0 | 96.4 | 64.8 | |
NP_570855, | NM_130840, | ||||||||
NP_570856 | NM_130841 | ||||||||
ATP9A | 10079 | NP_006036 | NM_006045 | Hs.714307 | 212062_at | 7.5 | 55.4 | 46.4 | |
BVES | 11149 | NP_009004, | NM_007073, | Hs.221660 | 228783_at | 3.4 | 5.9 | 9.8 | |
NP_671488 | NM_147147 | ||||||||
C5orf40 | 408263 | NP_001001343 | NM_001001343 | Hs.437066 | 1554801_at | 17.2 | 21.0 | 5.4 | |
C9orf125 | 84302 | NP_115718 | NM_032342 | Hs.655738 | 224458_at | 7.5 | 5.2 | 8.2 | |
CDH4 | 1002 | NP_001785 | NM_001794 | Hs.473231 | 206866_at | 7.4 | 13.7 | 11.6 | |
DIO2 | 1734 | NP_000784, | NM_000793, | Hs.202354 | 203699_s_at | 5.7 | 8.0 | 15.4 | |
NP_001007024, | NM_001007023, | 203700_s_at | 12.2 | 13.6 | 14.1 | ||||
NP_054644 | NM_013989 | 231240_at | 9.6 | 5.3 | 6.3 | ||||
DMD | 1756 | NP_000100, | NM_000109, | Hs.495912 | 203881_s_at | 9.7 | 3.1 | 10.4 | |
NP_003997, | NM_004006, | ||||||||
NP_003998, | NM_004007, | ||||||||
NP_004000, | NM_004009, | ||||||||
NP_004001, | NM_004010, | ||||||||
NP_004002, | NM_004011, | ||||||||
NP_004003, | NM_004012, | ||||||||
NP_004004, | NM_004013, | ||||||||
NP_004005, | NM_004014, | ||||||||
NP_004006, | NM_004015, | ||||||||
NP_004007, | NM_004016, | ||||||||
NP_004008, | NM_004017, | ||||||||
NP_004009, | NM_004018, | ||||||||
NP_004010, | NM_004019, | ||||||||
NP_004011, | NM_004020, | ||||||||
NP_004012, | NM_004021, | ||||||||
NP_004013, | NM_004022, | ||||||||
NP_004014 | NM_004023 | ||||||||
DPY19L2 | 283417 | NP_776173 | NM_173812 | Hs.533644 | 230158_at | 12.5 | 13.0 | 3.4 | |
GPR34 | 2857 | NP_001091048, | NM_001097579 | Hs.495989 | 223620_at | 7.2 | 12.6 | 22.1 | |
HRH4 | 59340 | NP_001137300, | NM_001143828, | Hs.287388 | 221170_at | 45.8 | 3.0 | 45.6 | |
NP_067637 | NM_021624 | ||||||||
IL23R | 149233 | NP_653302 | NM_144701 | Hs.677426 | 1561853_a_at | 15.1 | 7.8 | 6.2 | |
IRS2 | 8660 | NP_003740 | NM_003749 | Hs.442344 | 209185_s_at | 3.3 | 6.4 | 5.1 | |
KCNE3 | 10008 | NP_005463 | NM_005472 | Hs.523899 | 227647_at | 14.9 | 5.0 | 3.7 | |
L1CAM | 3897 | NP_000416, | NM_000425, | Hs.522818 | 204584_at | 10.3 | 6.6 | 5.9 | |
NP_076493 | NM_024003 | ||||||||
MCAM | 4162 | NP_006491 | NM_006500 | Hs.599039 | 210869_s_at | 12.8 | 24.4 | 4.3 | |
MFAP3L | 9848 | NP_001009554, | NM_001009554, | Hs.593942 | 205442_at | 25.8 | 22.6 | 10.5 | |
NP_067679 | NM_021647 | 210492_at | 3.5 | 4.7 | 6.7 | ||||
MUC20 | 200958 | NP_001091986, | NM_001098516, | Hs.308992 | 231941_s_at | 8.3 | 3.4 | 7.2 | |
NP_689886, | NM_152673, | ||||||||
XP_001726746 | XM_001726694 | ||||||||
MYO7A | 4647 | NP_000251, | NM_000260, | Hs.370421 | 208189_s_at | 13.7 | 13.0 | 6.8 | |
NP_001120651, | NM_001127179, | 211103_at | 7.5 | 15.1 | 5.1 | ||||
NP_001120652 | NM_001127180 | ||||||||
POPDC3 | 64208 | NP_071756 | NM_022361, | Hs.458336 | 219926_at | 4.5 | 12.9 | 12.8 | |
NR_024539 | |||||||||
PTPRM | 5797 | NP_001098714, | NM_001105244, | Hs.49774 | 1555579_s_at | 4.1 | 66.0 | 4.1 | |
NP_002836 | NM_002845 | ||||||||
SHROOM2 | 357 | NP_001640 | NM_001649 | Hs.567236 | 204967_at | 11.5 | 3.5 | 5.9 | |
SLC16A4 | 9122 | NP_004687 | NM_004696 | Hs.351306 | 205234_at | 29.8 | 16.6 | 6.8 | |
SLCO2B1 | 11309 | NP_009187 | NM_007256 | Hs.7884 | 203473_at | 11.0 | 5.9 | 5.9 | |
SORBS1 | 10580 | NP_001030126, | NM_001034954, | Hs.713556 | 218087_s_at | 37.9 | 4.7 | 12.8 | |
NP_001030127, | NM_001034955, | 222513_s_at | 14.4 | 3.6 | 8.2 | ||||
NP_001030128, | NM_001034956, | ||||||||
NP_001030129, | NM_001034957, | ||||||||
NP_006425, | NM_006434, | ||||||||
NP_056200, | NM_015385, | ||||||||
NP_079267 | NM_024991 | ||||||||
TANC1 | 85461 | NP_203752 | NM_033394 | Hs.61590 | 225308_s_at | 8.1 | 17.7 | 4.9 | |
TANC2 | 26115 | NP_079461 | NM_025185 | Hs.410889 | 224952_at | 5.3 | 4.9 | 6.4 | |
TJP1 | 7082 | NP_003248, | NM_003257, | Hs.716406 | 202011_at | 11.5 | 11.7 | 5.6 | |
NP_783297 | NM_175610 | ||||||||
TMEM163 | 81615 | NP_112185 | NM_030923 | Hs.369471 | 1552626_a_at | 10.8 | 12.6 | 13.9 | |
223503_at | 18.5 | 23.9 | 21.7 | ||||||
TMEM44 | 93109 | NP_001011655, | NM_001011655, | Hs.478729 | 228054_at | 7.4 | 5.2 | 3.3 | |
NP_612408 | NM_138399 | ||||||||
TNS3 | 64759 | NP_073585 | NM_022748 | Hs.520814 | 217853_at | 7.8 | 27.1 | 6.4 | |
UNC13C | 440279 | NP_001074003 | NM_001080534 | Hs.657273 | 1556095_at | 7.3 | 6.1 | 3.8 | |
UPK1B | 7348 | NP_008883 | NM_006952 | Hs.271580 | 210065_s_at | 5.3 | 9.6 | 10.3 | |
WDFY3 | 23001 | NP_055806, | NM_014991, | Hs.480116 | 212598_at | 10.7 | 16.1 | 19.6 | |
NP_848698, | NM_178583, | 212602_at | 8.5 | 19.4 | 9.8 | ||||
NP_848700 | NM_178585 | 212606_at | 22.6 | 62.2 | 20.5 | ||||
Extracellular/ | CXCL13 | 10563 | NP_006410 | NM_006419 | Hs.100431 | 205242_at | 47.5 | 40.4 | 4.8 |
secreted | IL17A | 3605 | NP_002181 | NM_002190 | Hs.41724 | 208402_at | 16.5 | 11.1 | 3.2 |
216876_s_at | 404.7 | 50.0 | 7.6 | ||||||
IL17F | 112744 | NP_443104 | NM_052872 | Hs.272295 | 234408_at | 464.4 | 421.4 | 77.1 | |
IL22 | 50616 | NP_065386 | NM_020525 | Hs.287369 | 221165_s_at | 4.7 | 4.6 | 4.3 | |
222974_at | 4.3 | 5.5 | 9.8 | ||||||
IL26 | 55801 | NP_060872 | NM_018402 | Hs.272350 | 221111_at | 10.2 | 22.5 | 67.8 | |
IL9 | 3578 | NP_000581 | NM_000590 | Hs.960 | 208193_at | 729.7 | 174.0 | 35.8 | |
PCOLCE2 | 26577 | NP_037495 | NM_013363 | Hs.8944 | 219295_s_at | 10.8 | 19.3 | 6.2 | |
PNOC | 5368 | NP_006219 | NM_006228 | Hs.88218 | 205901_at | 39.4 | 11.4 | 24.3 | |
SMPDL3A | 10924 | NP_006705 | NM_006714 | Hs.486357 | 213624_at | 3.4 | 3.3 | 3.5 | |
TGFBI | 7045 | NP_000349 | NM_000358 | Hs.369397 | 201506_at | 55.9 | 318.3 | 32.0 | |
Intracellular | BCAT1 | 586 | NP_005495 | NM_005504 | Hs.438993 | 214452_at | 3.1 | 5.8 | 28.9 |
BHLHE22 | 27319 | NP_689627 | NM_152414 | Hs.591870 | 228636_at | 11.6 | 14.2 | 18.7 | |
C13orf18, | 80183, | NP_079389, | NM_025113, | Hs.98117 | 44790_s_at | 3.2 | 18.8 | 12.4 | |
LOC728970 | 728970 | XP_001132115, | XM_001132115, | ||||||
XP_001133896, | XM_001133896, | ||||||||
XP_001720207 | XM_001720155 | ||||||||
CA2 | 760 | NP_000058 | NM_000067 | Hs.155097 | 209301_at | 5.2 | 61.3 | 167.6 | |
CCDC3 | 83643 | NP_113643 | NM_031455 | Hs.498720 | 223316_at | 11.2 | 52.3 | 43.4 | |
CDS1 | 1040 | NP_001254 | NM_001263 | Hs.654899 | 205709_s_at | 7.3 | 9.5 | 4.2 | |
226185_at | 4.2 | 7.8 | 3.3 | ||||||
CHN1 | 1123 | NP_001020372, | NM_001025201, | Hs.654534 | 212624_s_at | 11.5 | 21.3 | 9.1 | |
NP_001813 | NM_001822 | ||||||||
CLIC5, | 53405, | NP_001107558, | NM_001114086, | Hs.485489 | 213317_at | 7.1 | 22.1 | 9.6 | |
LOC100131610 | 100131610 | NP_058625, | NM_016929, | 217628_at | 3.1 | 4.2 | 4.6 | ||
XP_001723610 | XM_001723558 | 243917_at | 10.8 | 17.2 | 11.7 | ||||
219866_at | 6.2 | 10.6 | 12.2 | ||||||
CTSH | 1512 | NP_004381, | NM_004390, | Hs.148641 | 202295_s_at | 4.6 | 12.1 | 6.9 | |
NP_683880 | NM_148979 | ||||||||
CYP7B1 | 9420 | NP_004811 | NM_004820 | Hs.667720 | 207386_at | 16.4 | 11.8 | 5.3 | |
DAPK2 | 23604 | NP_055141 | NM_014326 | Hs.237886 | 206324_s_at | 4.4 | 4.7 | 3.9 | |
DMRT1 | 1761 | NP_068770 | NM_021951 | Hs.98586 | 220493_at | 5.2 | 18.4 | 3.9 | |
DSE | 29940 | NP_001074445, | NM_001080976, | Hs.486292 | 218854_at | 15.0 | 51.2 | 22.3 | |
NP_037484 | NM_013352 | ||||||||
EML1 | 2009 | NP_001008707, | NM_001008707, | Hs.12451 | 204796_at | 10.1 | 8.9 | 5.8 | |
NP_004425 | NM_004434 | 204797_s_at | 3.1 | 3.1 | 3.2 | ||||
FBXL17 | 64839 | NP_073735 | NM_022824 | Hs.657225 | 227203_at | 12.6 | 11.8 | 4.5 | |
FBXL21 | 26223 | NP_036291 | NM_012159 | Hs.591275 | 1555412_at | 26.5 | 35.3 | 22.3 | |
FHOD3 | 80206 | NP_079411 | NM_025135 | Hs.436636 | 218980_at | 7.0 | 9.9 | 6.7 | |
H2AFY2 | 55506 | NP_061119 | NM_018649 | Hs.499953 | 218445_at | 3.9 | 8.2 | 4.7 | |
HIST1H2BC | 8347 | NP_003517 | NM_003526 | Hs.658713 | 236193_at | 3.8 | 4.4 | 3.3 | |
HLX | 3142 | NP_068777 | NM_021958 | Hs.74870 | 214438_at | 3.3 | 5.2 | 39.3 | |
IRAK3 | 11213 | NP_001135995, | NM_001142523, | Hs.369265 | 213817_at | 9.4 | 18.8 | 6.5 | |
NP_009130 | NM_007199 | ||||||||
MACC1 | 346389 | NP_877439 | NM_182762 | Hs.598388 | 1566764_at | 5.6 | 12.8 | 3.5 | |
1566766_a_at | 9.2 | 17.3 | 4.7 | ||||||
MAML3 | 55534 | NP_061187 | NM_018717 | Hs.586165 | 242794_at | 6.4 | 5.7 | 4.6 | |
MAP3K4 | 4216 | NP_005913, | NM_005922, | Hs.390428 | 204089_x_at | 3.3 | 3.3 | 3.4 | |
NP_006715 | NM_006724 | 216199_s_at | 3.2 | 3.6 | 3.4 | ||||
MYO10 | 4651 | NP_036466 | NM_012334 | Hs.481720 | 1554026_a_at | 9.1 | 11.7 | 7.1 | |
201976_s_at | 45.4 | 19.1 | 15.0 | ||||||
216222_s_at | 3.0 | 6.2 | 6.7 | ||||||
OTUB2 | 78990 | NP_075601 | NM_023112 | Hs.278815 | 219369_s_at | 3.1 | 3.4 | 3.8 | |
222878_s_at | 4.2 | 7.2 | 4.8 | ||||||
PAPSS2 | 9060 | NP_001015880, | NM_001015880, | Hs.524491 | 203058_s_at | 5.5 | 11.0 | 11.1 | |
NP_004661 | NM_004670 | 203060_s_at | 6.3 | 47.2 | 17.3 | ||||
PCBP3 | 54039 | NP_001123613, | NM_001130141, | Hs.474049 | 230486_at | 4.5 | 3.1 | 5.0 | |
NP_065389 | NM_020528 | ||||||||
PDE4DIP | 9659 | NP_001002810, | NM_001002810, | Hs.654651 | 205872_x_at | 5.2 | 33.6 | 4.3 | |
NP_001002811, | NM_001002811, | Hs.613082 | 209700_x_at | 4.9 | 29.1 | 8.3 | |||
NP_001002812, | NM_001002812, | ||||||||
NP_055459, | NM_014644, | ||||||||
NP_071754 | NM_022359 | ||||||||
PDK4 | 5166 | NP_002603 | NM_002612 | Hs.8364 | 225207_at | 5.3 | 3.0 | 4.1 | |
PLD1 | 5337 | NP_001123553, | NM_001130081, | Hs.382865 | 226636_at | 3.7 | 3.2 | 8.2 | |
NP_002653 | NM_002662 | ||||||||
PPARG | 5468 | NP_005028, | NM_005037, | Hs.162646 | 208510_s_at | 8.0 | 22.8 | 14.1 | |
NP_056953, | NM_015869, | ||||||||
NP_619725, | NM_138711, | ||||||||
NP_619726 | NM_138712 | ||||||||
PTPN13 | 5783 | NP_006255, | NM_006264, | Hs.436142 | 204201_s_at | 3.1 | 4.5 | 19.7 | |
NP_542414, | NM_080683, | 243792_x_at | 7.9 | 5.5 | 11.7 | ||||
NP_542415, | NM_080684, | ||||||||
NP_542416 | NM_080685 | ||||||||
RGS18 | 64407 | NP_570138 | NM_130782 | Hs.440890 | 223809_at | 4.1 | 4.9 | 3.4 | |
RGS2 | 5997 | NP_002914 | NM_002923 | Hs.78944 | 202388_at | 3.3 | 3.5 | 8.1 | |
RGS20 | 8601 | NP_003693, | NM_003702, | Hs.368733 | 210138_at | 6.4 | 4.9 | 9.7 | |
NP_733466 | NM_170587 | ||||||||
RORC | 6097 | NP_001001523, | NM_001001523, | Hs.256022 | 228806_at | 150.1 | 51.2 | 5.7 | |
NP_005051 | NM_005060 | ||||||||
SIM1 | 6492 | NP_005059 | NM_005068 | Hs.520293 | 1556300_s_at | 14.5 | 5.8 | 99.6 | |
206876_at | 10.9 | 5.2 | 26.9 | ||||||
SNAI2 | 6591 | NP_003059 | NM_003068 | Hs.360174 | 213139_at | 8.2 | 15.0 | 6.8 | |
SOX2 | 6657 | NP_003097 | NM_003106 | Hs.518438 | 228038_at | 14.4 | 14.4 | 16.4 | |
SPIRE1 | 56907 | NP_001122098, | NM_001128626, | Hs.515283 | 1554807_a_at | 6.0 | 3.3 | 4.4 | |
NP_001122099, | NM_001128627, | 224995_at | 7.2 | 5.2 | 5.9 | ||||
NP_064533 | NM_020148 | 225018_at | 5.5 | 5.4 | 7.8 | ||||
TBC1D12 | 23232 | NP_056003 | NM_015188 | Hs.500598 | 221858_at | 4.2 | 3.2 | 3.1 | |
TGM5 | 9333 | NP_004236, | NM_004245, | Hs.129719 | 207911_s_at | 5.1 | 7.7 | 6.5 | |
NP_963925 | NM_201631 | ||||||||
TMOD1 | 7111 | NP_003266 | NM_003275 | Hs.494595 | 203661_s_at | 6.2 | 10.7 | 4.0 | |
203662_s_at | 6.2 | 9.5 | 3.7 | ||||||
TUBB6 | 84617 | NP_115914 | NM_032525 | Hs.193491 | 209191_at | 3.5 | 11.2 | 6.4 | |
Unknown | C12orf64 | 283310 | NP_775862 | NM_173591 | Hs.355145 | 1553746_a_at | 4.2 | 5.3 | 10.8 |
C6orf168 | 84553 | NP_115900 | NM_032511 | Hs.573245 | 232067_at | 3.3 | 5.8 | 37.1 | |
CAMSAP1L1 | 23271 | NP_982284 | NM_203459 | Hs.23585 | 217196_s_at | 22.5 | 10.1 | 3.7 | |
MAGED4, | 728239, | NP_001092270, | NM_001098800, | Hs.571729 | 223313_s_at | 16.3 | 8.6 | 3.5 | |
MAGED4B | 81557 | NP_110428, | NM_030801, | ||||||
NP_803879, | NM_177535, | ||||||||
NP_803881 | NM_177537 | ||||||||
— | — | — | AK093612 | Hs.663643 | 1556602_at | 4.1 | 5.9 | 6.3 | |
— | — | — | BC010059 | Hs.637648 | 1562957_at | 6.6 | 3.6 | 4.6 | |
— | — | — | AK055628, | Hs.594351 | 226777_at | 30.4 | 42.8 | 3.4 | |
uc001ljj.1 | |||||||||
— | — | — | GENSCAN00000030683 | — | 227985_at | 13.4 | 19.2 | 3.6 | |
— | — | — | AA416573, | Hs.654918 | 229951_x_at | 4.2 | 13.5 | 4.9 | |
AA628762, | |||||||||
D53835, | |||||||||
D53836, | |||||||||
H24473, | |||||||||
R37871, | |||||||||
R40232, | |||||||||
T10348, | |||||||||
T23451, | |||||||||
W56351, | |||||||||
W57867, | |||||||||
Z28733 | |||||||||
— | — | — | AK027107 | Hs.655798 | 232331_at | 3.5 | 3.5 | 9.0 | |
— | — | — | AI269134, | Hs.657330 | 235438_at | 73.9 | 22.0 | 3.3 | |
AI312873, | |||||||||
AI671475, | |||||||||
AV656012, | |||||||||
AW162011, | |||||||||
BG151392, | |||||||||
H69527, | |||||||||
N43169, | |||||||||
Z36958 | |||||||||
— | — | — | AA687415, | Hs.434948 | 238009_at | 4.6 | 15.9 | 15.0 | |
AA96901, | |||||||||
AI291640, | |||||||||
AI446064, | |||||||||
AI634557, | |||||||||
AI694948, | |||||||||
AI701854, | |||||||||
AI983938, | |||||||||
AV745212, | |||||||||
AV745909, | |||||||||
AV746001, | |||||||||
AW008696, | |||||||||
AW511701, | |||||||||
AW974416, | |||||||||
BG149302, | |||||||||
BG150103, | |||||||||
N66771, | |||||||||
R66991 | |||||||||
— | — | — | AI148241, | Hs.659083 | 238151_at | 37.6 | 48.1 | 29.9 | |
AI735444, | |||||||||
BE645654, | |||||||||
BF510855, | |||||||||
BF511636 | |||||||||
— | — | — | AK094629 | Hs.594896 | 238623_at | 7.0 | 5.6 | 6.8 | |
— | — | — | AI435469, | Hs.656932 | 241022_at | 6.1 | 10.7 | 12.4 | |
BF111679, | |||||||||
BF112253, | |||||||||
R37814 | |||||||||
— | — | — | AA846423, | Hs.665895 | 243922_at | 16.7 | 12.8 | 6.0 | |
AI022103, | |||||||||
BF061333 | |||||||||
— | — | — | AA648972, | Hs.602350 | 244247_at | 3.9 | 3.4 | 5.3 | |
AA879467, | |||||||||
AI802768, | |||||||||
AW974600 | |||||||||
Among the above genes, those shown in Table 8 have been known for their specific expression in Th17 cells.
TABLE 8 | ||
SEQ | Expression ratio |
ID | Gene symbol | Entrez | Protein | Transcript | UniGene | Probe Set | Th17/ | ||
NO: | (Gene title) | Gene ID | ID | ID | ID | ID | Th1 | Th17/Th2 | Th17/Treg |
175 | IL23R(interleukin 23 receptor) | 149233 | NP_653302 | NM_144701 | Hs.677426 | 1552912_a_at | 7.6 | 11.7 | 4.5 |
176 | IL17A( |
3605 | NP_002181 | NM_002190 | Hs.41724 | 216876_s_at | 397.5 | 473.0 | 29.3 |
177 | IL17F(interleukin 17F) | 112744 | NP_443104 | NM_052872 | Hs.272295 | 234408_at | 611.6 | 951.0 | 383.6 |
178 | IL22(interleukin 22) | 50616 | NP_065386 | NM_020525 | Hs.287369 | 222974_at | 6.4 | 29.9 | 10.6 |
179 | IL26(interleukin 26) | 55801 | NP_060872 | NM_018402 | Hs.272350 | 221111_at | 10.1 | 13.0 | 39.4 |
180 | RORC(RAR-related | 6097 | NP_001001523, | NM_001001523, | Hs.256022 | 228806_at | 13.8 | 174.9 | 7.6 |
orphan receptor C) | NP_005051 | NM_005060 | |||||||
Expression levels of those known genes in Th1, Th2, Treg and Th17 cells obtained in the above step 2. were analyzed with microarray as described above. It was found that those genes were expressed 4 to 950 times higher in Th17 cells than in Th1, Th2 and Treg cells. These results are shown in FIG. 1 . These results indicated that the above cells are suitable for investigation of markers for detecting Th17 cells.
The present inventors have identified novel polynucleotide markers for detecting Th17 cells by excluding the genes shown in Table 8 from those obtained as above. These novel polynucleotide markers are shown in Table 9.
In this table, “Condition” means with or without activation stimulation of cells. The genes designated as “Common” in the column of “Condition” are the genes specifically expressed in both Th17 cells with stimulation and without stimulation. The genes designated as “With stimulation” and “Without stimulation” are the genes specifically expressed either in Th17 cells with stimulation or without stimulation, respectively.
TABLE 9 | |||||||||
Location of | SEQ | ||||||||
encoded | Entrez | Protein | Transcript | UniGene | Probe Set | ID | |||
protein | Condition | No. | Gene symbol | Gene ID | ID | ID | ID | ID | NO: |
Membrane | Common | 1 | ADAM12 | 8038 | NP_003465, | NM_003474, | Hs.594537 | 202952_s_at | 1 |
NP_067673 | NM_021641 | ||||||||
2 | ANKS1B | 56899 | NP_064525, | NM_020140, | Hs.506458 | 227439_at | 2 | ||
NP_690001, | NM_152788, | 240292_x_at | 3 | ||||||
NP_858056 | NM_181670 | ||||||||
3 | ATP6V0A4 | 50617 | NP_065683, | NM_020632, | Hs.98967 | 220197_at | 4 | ||
NP_570855, | NM_130840, | ||||||||
NP_570856 | NM_130841 | ||||||||
4 | ATP9A | 10079 | NP_006036 | NM_006045 | Hs.714307 | 212062_at | 5 | ||
5 | BVES | 11149 | NP_009004, | NM_007073, | Hs.221660 | 228783_at | 6 | ||
NP_671488 | NM_147147 | ||||||||
6 | C5orf40 | 408263 | NP_001001343 | NM_001001343 | Hs.437066 | 1554801_at | 7 | ||
7 | CDH4 | 1002 | NP_001785 | NM_001794 | Hs.473231 | 206866_at | 8 | ||
8 | DIO2 | 1734 | NP_000784, | NM_000793, | Hs.202354 | 203700_s_at | 9 | ||
NP_001007024, | NM_001007023, | ||||||||
NP_054644 | NM_013989 | ||||||||
9 | DMD | 1756 | NP_000100, | NM_000109, | Hs.495912 | 203881_s_at | 10 | ||
NP_003997, | NM_004006, | ||||||||
NP_003998, | NM_004007, | ||||||||
NP_004000, | NM_004009, | ||||||||
NP_004001, | NM_004010, | ||||||||
NP_004002, | NM_004011, | ||||||||
NP_004003, | NM_004012, | ||||||||
NP_004004, | NM_004013, | ||||||||
NP_004005, | NM_004014, | ||||||||
NP_004006, | NM_004015, | ||||||||
NP_004007, | NM_004016, | ||||||||
NP_004008, | NM_004017, | ||||||||
NP_004009, | NM_004018, | ||||||||
NP_004010, | NM_004019, | ||||||||
NP_004011, | NM_004020, | ||||||||
NP_004012, | NM_004021, | ||||||||
NP_004013, | NM_004022, | ||||||||
NP_004014 | NM_004023 | ||||||||
10 | GPR34 | 2857 | NP_001091048, | NM_001097579, | Hs.495989 | 223620_at | 11 | ||
NP_005291 | NM_005300 | ||||||||
11 | IRS2 | 8660 | NP_003740 | NM_003749 | Hs.442344 | 209184_s_at | 12 | ||
209185_s_at | 13 | ||||||||
12 | KCNE3 | 10008 | NP_005463 | NM_005472 | Hs.523899 | 227647_at | 14 | ||
13 | L1CAM | 3897 | NP_000416, | NM_000425, | Hs.522818 | 204584_at | 15 | ||
NP_076493 | NM_024003 | ||||||||
14 | MCAM | 4162 | NP_006491 | NM_006500 | Hs.599039 | 210869_s_at | 16 | ||
15 | MFAP3L | 9848 | NP_001009554, | NM_001009554, | Hs.593942 | 205442_at | 17 | ||
NP_067679 | NM_021647 | ||||||||
16 | MYO7A | 4647 | NP_000251, | NM_00260, | Hs.370421 | 208189_s_at | 18 | ||
NP_001120651, | NM_001127179, | ||||||||
NP_001120652 | NM_001127180 | ||||||||
17 | PTPRM | 5797 | NP_001098714, | NM_001105244, | Hs.49774 | 1555579_s_at | 19 | ||
NP_002836 | NM_002845 | ||||||||
18 | SHROOM2 | 357 | NP_001640 | NM_001649 | Hs.567236 | 204967_at | 20 | ||
19 | SLC16A4 | 9122 | NP_004687 | NM_004696 | Hs.351306 | 205234_at | 21 | ||
20 | SLCO2B1 | 11309 | NP_009187 | NM_007256 | Hs.7884 | 203473_at | 22 | ||
21 | TANC2 | 26115 | NP_079461 | NM_025185 | Hs.410889 | 208425_s_at | 23 | ||
224952_at | 24 | ||||||||
22 | TJP1 | 7082 | NP_003248, | NM_003257, | Hs.716406 | 202011_at | 25 | ||
NP_783297 | NM_175610 | ||||||||
23 | TMEM163 | 81615 | NP_112185 | NM_030923 | Hs.369471 | 1552626_a_at | 26 | ||
223503_at | 27 | ||||||||
24 | TNS3 | 64759 | NP_073585 | NM_022748 | Hs.520814 | 217853_at | 28 | ||
25 | UPK1B | 7348 | NP_008883 | NM_006952 | Hs.271580 | 210065_s_at | 29 | ||
26 | WDFY3 | 23001 | NP_055806, | NM_014991, | Hs.480116 | 212598_at | 30 | ||
NP_848698, | NM_178583, | 212602_at | 31 | ||||||
NP_848700 | NM_178585 | 212606_at | 32 | ||||||
w/o | 27 | DRD2 | 1813 | NP_000786, | NM_000795, | Hs.73893 | 216938_x_at | 33 | |
stimulation | NP_057658 | NM_016574 | |||||||
28 | GJC1 | 10052 | NP_001073852, | NM_001080383, | Hs.532593 | 228776_at | 34 | ||
NP_005488 | NM_005497 | 243502_at | 35 | ||||||
Without | 29 | PGBD5, | 79605, | NP_078830, | NM_024554, | Hs.520463 | 219225_at | 36 | |
stimulation | LOC100134440 | 100134440 | XP_001716155 | XM_001716103 | |||||
30 | MS4A7 | 58475 | NP_067024, | NM_021201, | Hs.530735 | 223343_at | 37 | ||
NP_996821, | NM_206938, | ||||||||
NP_996822, | NM_206939, | ||||||||
NP_996823 | NM_206940 | ||||||||
31 | ODZ4 | 26011 | NP_001092286 | NM_001098816 | Hs.213087 | 213273_at | 38 | ||
32 | PHKA1 | 5255 | NP_001116142, | NM_001122670, | Hs.201379 | 229876_at | 39 | ||
NP_002628 | NM_002637 | ||||||||
33 | RGS1 | 5996 | NP_002913 | NM_002922 | Hs.75256 | 202988_s_at | 40 | ||
34 | SHB | 6461 | NP_003019 | NM_003028 | Hs.521482 | 1557458_s_at | 41 | ||
35 | SLC44A3 | 126969 | NP_001107578, | NM_001114106, | Hs.483423 | 228221_at | 42 | ||
NP_689582 | NM_152369 | ||||||||
36 | SLC6A15 | 55117 | NP_060527, | NM_018057, | Hs.44424 | 206376_at | 43 | ||
NP_877499 | NM_182767 | ||||||||
37 | SYNGR3 | 9143 | NP_004200 | NM_004209 | Hs.435277 | 205691_at | 44 | ||
With | 38 | AKAP12 | 9590 | NP_005091, | NM_005100, | Hs.371240 | 210517_s_at | 45 | |
stimulation | NP_653080 | NM_144497 | 227529_s_at | 46 | |||||
39 | C9orf125 | 84302 | NP_115718 | NM_032342 | Hs.655738 | 224458_at | 47 | ||
40 | DPY19L2 | 283417 | NP_776173 | NM_173812 | Hs.533644 | 230158_at | 48 | ||
41 | HRH4 | 59340 | NP_001137300, | NM_001143828, | Hs.287388 | 221170_at | 49 | ||
NP_067637 | NM_021624 | ||||||||
42 | MUC20 | 200958 | NP_001091986, | NM_001098516, | Hs.308992 | 231941_s_at | 50 | ||
NP_689886, | NM_152673, | ||||||||
XP_001726746 | XM_001726694 | ||||||||
43 | POPDC3 | 64208 | NP_071756 | NM_022361, | Hs.458336 | 219926_at | 51 | ||
NR_024539 | |||||||||
44 | SORBS1 | 10580 | NP_001030126, | NM_001034954, | Hs.713556 | 218087_s_at | 52 | ||
NP_001030127, | NM_001034955, | 222513_s_at | 53 | ||||||
NP_001030128, | NM_001034956, | ||||||||
NP_001030129, | NM_001034957, | ||||||||
NP_006425, | NM_006434, | ||||||||
NP_056200, | NM_015385, | ||||||||
NP_079267 | NM_024991 | ||||||||
45 | TANC1 | 85461 | NP_203752 | NM_033394 | Hs.61590 | 225308_s_at | 54 | ||
46 | TMEM44 | 93109 | NP_001011655, | NM_001011655, | Hs.478729 | 228054_at | 55 | ||
NP_612408 | NM_138399 | ||||||||
47 | UNC13C | 440279 | NP_001074003 | NM_001080534 | Hs.657273 | 1556095_at | 56 | ||
Extra- | Common | 48 | CXCL13 | 10563 | NP_006410 | NM_006419 | Hs.100431 | 205242_at | 57 |
cellular/ | 49 | IL9 | 3578 | NP_000581 | NM_000590 | Hs.960 | 208193_at | 58 | |
secreted | 50 | PCOLCE2 | 26577 | NP_037495 | NM_013363 | Hs.8944 | 219295_s_at | 59 | |
51 | PNOC | 5368 | NP_006219 | NM_006228 | Hs.88218 | 205901_at | 60 | ||
52 | SMPDL3A | 10924 | NP_006705 | NM_006714 | Hs.486357 | 213624_at | 61 | ||
53 | TGFBI | 7045 | NP_000349 | NM_000358 | Hs.369397 | 201506_at | 62 | ||
w/o | 54 | C17orf99 | 100141515 | NP_001156547 | NM_001163075 | Hs.633034 | 236981_at | 63 | |
stimulation | 55 | EBI3 | 10148 | NP_005746 | NM_005755 | Hs.501452 | 219424_at | 64 | |
56 | IL1A | 3552 | NP_000566 | NM_000575 | Hs.1722 | 210118_s_at | 65 | ||
57 | WNT3 | 7473 | NP_110380 | NM_030753 | Hs.445884 | 229103_at | 66 | ||
Intracellular | Common | 58 | BCAT1 | 586 | NP_005495 | NM_005504 | Hs.438993 | 214390_s_at | 67 |
214452_at | 68 | ||||||||
225285_at | 69 | ||||||||
226517_at | 70 | ||||||||
59 | BHLHE22 | 27319 | NP_689627 | NM_152414 | Hs.591870 | 228636_at | 71 | ||
60 | C13orf18, | 80183, | NP_079389, | NM_025113, | Hs.98117 | 44790_s_at | 72 | ||
LOC728970 | 728970 | XP_001132115, | XM_001132115, | ||||||
XP_001133896, | XM_001133896, | ||||||||
XP_001720207 | XM_001720155 | ||||||||
61 | CA2 | 760 | NP_000058 | NM_000067 | Hs.155097 | 209301_at | 73 | ||
62 | CCDC3 | 83643 | NP_113643 | NM_031455 | Hs.498720 | 223316_at | 74 | ||
63 | CDS1 | 1040 | NP_001254 | NM_001263 | Hs.654899 | 205709_s_at | 75 | ||
64 | CHN1 | 1123 | NP_001020372, | NM_001025201, | Hs.654534 | 212624_s_at | 76 | ||
NP_001813 | NM_001822 | ||||||||
65 | CLIC5, | 53405, | NP_001107558, | NM_001114086, | Hs.485489 | 213317_at | 77 | ||
LOC100131610 | 100131610 | NP_058625, | NM_016929, | 217628_at | 78 | ||||
XP_001723610 | XM_001723558 | 243917_at | 79 | ||||||
219866_at | 80 | ||||||||
66 | CTSH | 1512 | NP_004381, | NM_004390, | Hs.148641 | 202295_s_at | 81 | ||
NP_683880 | NM_148979 | ||||||||
67 | CYP7B1 | 9420 | NP_004811 | NM_004820 | Hs.667720 | 207386_at | 82 | ||
68 | DAPK2 | 23604 | NP_055141 | NM_014326 | Hs.237886 | 206324_s_at | 83 | ||
215184_at | 84 | ||||||||
69 | DMRT1 | 1761 | NP_068770 | NM_021951 | Hs.98586 | 220493_at | 85 | ||
70 | DSE | 29940 | NP_001074445, | NM_001080976, | Hs.486292 | 218854_at | 86 | ||
NP_037484 | NM_013352 | ||||||||
71 | FBXL17 | 64839 | NP_073735 | NM_022824 | Hs.657225 | 227203_at | 87 | ||
72 | FBXL21 | 26223 | NP_036291 | NM_012159 | Hs.591275 | 1555412_at | 88 | ||
73 | FHOD3 | 80206 | NP_079411 | NM_025135 | Hs.436636 | 218980_at | 89 | ||
74 | H2AFY2 | 55506 | NP_061119 | NM_018649 | Hs.499953 | 218445_at | 90 | ||
75 | HLX | 3142 | NP_068777 | NM_021958 | Hs.74870 | 214438_at | 91 | ||
76 | IRAK3 | 11213 | NP_001135995, | NM_001142523, | Hs.369265 | 213817_at | 92 | ||
NP_009130 | NM_007199 | 220034_at | 93 | ||||||
77 | MACC1 | 346389 | NP_877439 | NM_182762 | Hs.598388 | 1566766_a_at | 94 | ||
78 | MAML3 | 55534 | NP_061187 | NM_018717 | Hs.586165 | 242794_at | 95 | ||
79 | MYO10 | 4651 | NP_036466 | NM_012334 | Hs.481720 | 201976_s_at | 96 | ||
80 | OTUB2 | 78990 | NP_075601 | NM_023112 | Hs.278815 | 219369_s_at | 97 | ||
222878_s_at | 98 | ||||||||
81 | PAPSS2 | 9060 | NP_001015880, | NM_001015880, | Hs.524491 | 203058_s_at | 99 | ||
NP_004661 | NM_004670 | 203060_s_at | 100 | ||||||
82 | PCBP3 | 54039 | NP_001123613, | NM_001130141, | Hs.474049 | 230486_at | 101 | ||
NP_065389 | NM_020528 | ||||||||
83 | PDE4DIP | 9659 | NP_001002810, | NM_001002810, | Hs.654651 | 205872_x_at | 102 | ||
NP_001002811, | NM_001002811, | Hs.613082 | 209700_x_at | 103 | |||||
NP_001002812, | NM_001002812, | ||||||||
NP_055459, | NM_014644, | ||||||||
NP_071754 | NM_022359 | ||||||||
84 | PLD1 | 5337 | NP_001123553, | NM_001130081, | Hs.382865 | 177_at | 104 | ||
NP_002653 | NM_002662 | 215723_s_at | 105 | ||||||
226636_at | 106 | ||||||||
85 | PPARG | 5468 | NP_005028, | NM_005037, | Hs.162646 | 208510_s_at | 107 | ||
NP_056953, | NM_015869, | ||||||||
NP_619725, | NM_138711, | ||||||||
NP_619726 | NM_138712 | ||||||||
86 | PTPN13 | 5783 | NP_006255, | NM_006264, | Hs.436142 | 243792_x_at | 108 | ||
NP_542414, | NM_080683, | ||||||||
NP_542415, | NM_080684, | ||||||||
NP_542416 | NM_080685 | ||||||||
87 | RGS18 | 64407 | NP_570138 | NM_130782 | Hs.440890 | 223809_at | 109 | ||
88 | SIM1 | 6492 | NP_005059 | NM_005068 | Hs.520293 | 1556300_s_at | 110 | ||
206876_at | 111 | ||||||||
89 | SNAI2 | 6591 | NP_003059 | NM_003068 | Hs.360174 | 213139_at | 112 | ||
90 | SOX2 | 6657 | NP_003097 | NM_003106 | Hs.518438 | 228038_at | 113 | ||
91 | SPIRE1 | 56907 | NP_001122098, | NM_001128626, | Hs.515283 | 1554807_a_at | 114 | ||
NP_001122099, | NM_001128627, | 224995_at | 115 | ||||||
NP_064533 | NM_020148 | 225018_at | 116 | ||||||
92 | TBC1D12 | 23232 | NP_056003 | NM_015188 | Hs.500598 | 221858_at | 117 | ||
93 | TGM5 | 9333 | NP_004236, | NM_004245, | Hs.129719 | 207911_s_at | 118 | ||
NP_963925 | NM_201631 | ||||||||
94 | TMOD1 | 7111 | NP_003266 | NM_003275 | Hs.494595 | 203661_s_at | 119 | ||
203662_s_at | 120 | ||||||||
95 | TUBB6 | 84617 | NP_115914 | NM_032525 | Hs.193491 | 209191_at | 121 | ||
Without | 96 | DDIT4L | 115265 | NP_660287 | NM_145244 | Hs.480378 | 228057_at | 122 | |
stimulation | 97 | DHRS9 | 10170 | NP_001135742, | NM_001142270, | Hs.179608 | 219799_s_at | 123 | |
NP_001135743, | NM_001142271, | 223952_x_at | 124 | ||||||
NP_005762, | NM_005771, | 224009_x_at | 125 | ||||||
NP_954674 | NM_199204 | ||||||||
98 | ERC2 | 26059 | NP_056391 | NM_015576 | Hs.476389 | 213938_at | 126 | ||
99 | FERMT2 | 10979 | NP_001128471, | NM_001134999, | Hs.509343 | 209210_s_at | 127 | ||
NP_001128472, | NM_001135000, | ||||||||
NP_006823 | NM_006832 | ||||||||
100 | HHEX | 3087 | NP_002720 | NM_002729 | Hs.118651 | 204689_at | 128 | ||
101 | HS3ST1 | 9957 | NP_005105 | NM_005114 | Hs.507348 | 205466_s_at | 129 | ||
102 | NR5A2 | 2494 | NP_003813, | NM_003822, | Hs.33446 | 208343_s_at | 130 | ||
NP_995582 | NM_205860 | ||||||||
103 | PHLDA1 | 22822 | NP_031376 | NM_007350 | Hs.602085 | 217999_s_at | 131 | ||
225842_at | 132 | ||||||||
104 | RBM20 | 282996 | NP_001127835, | NM_001134363, | Hs.715766 | 238763_at | 133 | ||
XP_001716171, | XM_001716119, | ||||||||
XP_291671, | XM_291671, | ||||||||
XP_944430 | XM_939337 | ||||||||
105 | NINL | 22981 | NP_079452 | NM_025176 | Hs.696157 | 207705_s_at | 134 | ||
106 | RTN2 | 6253 | NP_005610, | NM_005619, | Hs.47517 | 34408_at | 135 | ||
NP_996783, | NM_206900, | ||||||||
NP_996784 | NM_206901 | ||||||||
107 | SH3RF2 | 153769 | NP_689763 | NM_152550 | Hs.443728 | 243582_at | 136 | ||
108 | TSHZ2 | 128553 | NP_775756 | NM_173485 | Hs.649877 | 220213_at | 137 | ||
Hs.271605 | 243940_at | 138 | |||||||
With | 109 | EML1 | 2009 | NP_001008707, | NM_001008707, | Hs.12451 | 204796_at | 139 | |
stimulation | NP_004425 | NM_004434 | 204797_s_at | 140 | |||||
110 | HIST1H2BC | 8347 | NP_003517 | NM_003526 | Hs.658713 | 236193_at | 141 | ||
111 | MAP3K4 | 4216 | NP_005913, | NM_005922, | Hs.390428 | 204089_x_at | 142 | ||
NP_006715 | NM_006724 | 216199_s_at | 143 | ||||||
112 | PDK4 | 5166 | NP_002603 | NM_002612 | Hs.8364 | 225207_at | 144 | ||
113 | RGS2 | 5997 | NP_002914 | NM_002923 | Hs.78944 | 202388_at | 145 | ||
114 | RGS20 | 8601 | NP_003693, | NM_003702, | Hs.368733 | 210138_at | 146 | ||
NP_733466 | NM_170587 | ||||||||
Unknown | Common | 115 | — | — | — | AK055628, | Hs.594351 | 226777_at | 147 |
uc001ljj.1 | |||||||||
116 | — | — | — | AA416573, | Hs.654918 | 229951_x_at | 148 | ||
AA628762, | |||||||||
D53835, | |||||||||
D53836, | |||||||||
H24473, | |||||||||
R37871, | |||||||||
R40232, | |||||||||
T10348, | |||||||||
T23451, | |||||||||
W56351, | |||||||||
W57867, | |||||||||
Z28733 | |||||||||
117 | — | — | — | AA687415, | Hs.434948 | 238009_at | 149 | ||
AA96901, | |||||||||
AI291640, | |||||||||
AI446064, | |||||||||
AI634557, | |||||||||
AI694948, | |||||||||
AI701854, | |||||||||
AI983938, | |||||||||
AV745212, | |||||||||
AV745909, | |||||||||
AV746001, | |||||||||
AW008696, | |||||||||
AW511701, | |||||||||
AW974416, | |||||||||
BG149302, | |||||||||
BG150103, | |||||||||
N66771, | |||||||||
R66991 | |||||||||
118 | — | — | — | AI148241, | Hs.659083 | 238151_at | 150 | ||
AI735444, | |||||||||
BE645654, | |||||||||
BF510855, | |||||||||
BF511636 | |||||||||
119 | — | — | — | AK094629 | Hs.594896 | 238623_at | 151 | ||
Without | 120 | C1orf106 | 55765 | NP_001136041, | NM_001142569, | Hs.518997 | 219010_at | 152 | |
stimulation | NP_060735 | NM_018265 | |||||||
121 | C6orf145 | 221749 | NP_899229 | NM_183373 | Hs.484500 | 212923_s_at | 153 | ||
122 | LOC401097 | 401097 | XP_001717155, | XM_001717103, | Hs.710781 | 236738_at | 154 | ||
XP_001718614, | XM_001718562, | ||||||||
XP_001718795 | XM_001718743 | ||||||||
123 | MAMLD1 | 10046 | NP_005482 | NM_005491 | Hs.20136 | 205088_at | 155 | ||
124 | ZC3H12C | 85463 | NP_203748 | NM_033390 | Hs.376289 | 231899_at | 156 | ||
125 | — | — | — | AA579799, | Hs.663788 | 215768_at | 157 | ||
AA947186, | |||||||||
AL049337, | |||||||||
AW665328 | |||||||||
126 | — | — | — | AK093229 | Hs.586723 | 222900_at | 158 | ||
127 | — | — | — | AK129763, | Hs.157726 | 227452_at | 159 | ||
CR595588, | |||||||||
uc002jiy.1, | |||||||||
uc002jiz.1 | |||||||||
128 | — | — | — | AI766299 | — | 236338_at | 160 | ||
129 | — | — | — | AI262017, | Hs.666775 | 237923_at | 161 | ||
AI280978, | |||||||||
AI284950, | |||||||||
AI733224, | |||||||||
AI733801 | |||||||||
130 | — | — | — | AI682088, | Hs.606172 | 241726_at | 162 | ||
AI951058, | |||||||||
F06296, | |||||||||
F13164, | |||||||||
T77624, | |||||||||
Z44722 | |||||||||
With | 131 | C12orf64 | 283310 | NP_775862 | NM_173591 | Hs.355145 | 1553746_a_at | 163 | |
stimulation | 132 | C6orf168 | 84553 | NP_115900 | NM_032511 | Hs.573245 | 232067_at | 164 | |
133 | CAMSAP1L1 | 23271 | NP_982284 | NM_203459 | Hs.23585 | 217196_s_at | 165 | ||
134 | MAGED4, | 728239, | NP_001092270, | NM_001098800, | Hs.571729 | 223313_s_at | 166 | ||
MAGED4B | 81557 | NP_110428, | NM_030801, | ||||||
NP_803879, | NM_177535, | ||||||||
NP_803881 | NM_177537 | ||||||||
135 | — | — | — | AK093612 | Hs.663643 | 1556602_at | 167 | ||
136 | — | — | — | BC010059 | Hs.637648 | 1562957_at | 168 | ||
137 | — | — | — | GENSCAN00000030683 | — | 227985_at | 169 | ||
138 | — | — | — | AK027107 | Hs.655798 | 232331_at | 170 | ||
139 | — | — | — | AI269134, | Hs.657330 | 235438_at | 171 | ||
AI312873, | |||||||||
AI671475, | |||||||||
AV656012, | |||||||||
AW162011, | |||||||||
BG151392, | |||||||||
H69527, | |||||||||
N43169, | |||||||||
Z36958 | |||||||||
140 | — | — | — | AI435469, | Hs.656932 | 241022_at | 172 | ||
BF111679, | |||||||||
BF112253, | |||||||||
R37814 | |||||||||
141 | — | — | — | AA846423, | Hs.665895 | 243922_at | 173 | ||
AI022103, | |||||||||
BF061333 | |||||||||
142 | — | — | — | AA648972, | Hs.602350 | 244247_at | 174 | ||
AA879467, | |||||||||
AI802768, | |||||||||
AW974600 | |||||||||
It is believed that detection of the polynucleotide markers shown in Table 9 by well-known methods in the art such as PCR or detection of proteins encoded by these polynucleotide markers by well-known methods in the art such as ELISA or flow cytometry allows specific detection of human Th17 cells.
1. Preparation of Measurement Samples
(1) Preparation of MCAM Measurement Samples
To Th17 cells “without activation stimulation” (5×106 cells/ml) prepared in Example 1 under the paragraph “2. Cell culture” was added a phycoerythrin (PE)-labeled anti-MCAM antibody (BioLegend) to a final concentration of 1.25 μg/ml and reaction was carried out at 4° C. for 20 minutes.
After the reaction, Th17 cells were washed by adding phosphate buffered saline (PBS) containing 0.5% BSA and centrifuging to collect the cells. The washed Th17 cells were suspended in PBS containing 0.5 μg/ml 7-amino-actinomycin D (7-AAD) and 0.5% BSA to prepare a MCAM measurement sample of Th17 cells (5×106 cells/ml).
MCAM measurement samples of Th1 cells (5×106 cells/ml), of Th2 cells (5×106 cells/ml) and of Treg cells (5×106 cells/ml) were prepared in the similar manner as above except that Th1, Th2 and Treg cells “without activation stimulation”, respectively, were used instead of Th17 cells “without activation stimulation”.
A negative control sample (5×106 cells/ml) was prepared by adding a PE-labeled mouse IgG2a isotype control (BioLegend) to a final concentration of 1.0 μg/ml instead of the PE-labeled MCAM antibody and reacting at 4° C. for 20 minutes.
(2) Preparation of PTPRM Measurement Samples
To Th17 cells “without activation stimulation” (5×106 cells/ml) prepared in Example 1 under the paragraph “2. Cell culture” was added an anti-PTPRM antibody (Abcam) to a final concentration of 2.0 μg/ml and reaction was carried out at 4° C. for 20 minutes.
After the reaction, Th17 cells were added with PBS containing 0.5% BSA and centrifuged to collect the cells. The collected Th17 cells were suspended in PBS containing 0.5% BSA. The suspension was added with a PE-labeled anti-mouse IgG antibody (BioLegend) to a final concentration of 1.0 μg/ml and reaction was carried out at 4° C. for 20 minutes.
After reaction with the PE-labeled anti-mouse IgG antibody, Th17 cells were washed by adding PBS containing 0.5% BSA and centrifuging to collect the cells. The washed Th17 cells were suspended in PBS containing 0.5 μg/ml 7-amino-actinomycin D (7-AAD) and 0.5% BSA to prepare a PTPRM measurement sample of Th17 cells (5×106 cells/ml).
PTPRM measurement samples of Th1 cells (5×106 cells/ml), of Th2 cells (5×106 cells/ml) and of Treg cells (5×106 cells/ml) were prepared in the similar manner as above except that Th1, Th2 and Treg cells “without activation stimulation”, respectively, were used instead of Th17 cells “without activation stimulation”.
A negative control sample (5×106 cells/ml) was prepared by adding a mouse IgG2a isotype control (BioLegend) to a final concentration of 1.0 μg/ml instead of the anti-PTPRM antibody and reacting at 4° C. for 20 minutes.
(3) Preparation of CCR6 Measurement Samples
CCR6 measurement samples of Th17 cells (5×106 cells/ml), of Th1 cells (5×106 cells/ml), of Th2 cells (5×106 cells/ml) and of Treg cells (5×106 cells/ml) were prepared in the similar manner as the above paragraph “(1) Preparation of MCAM measurement samples” except that a PE-labeled anti-CCR6 antibody (BD Bioscience) was used at a final concentration of 1.0 μg/ml instead of the PE-labeled anti-MCAM antibody.
A negative control sample (5×106 cells/ml) was prepared by adding a PE-labeled mouse IgG1 isotype control (BioLegend) to a final concentration of 1.0 μg/ml instead of the PE-labeled anti-CCR6 antibody and reacting at 4° C. for 20 minutes.
(4) Preparation of FOXP3 Measurement Samples
Th17 cells “without activation stimulation” (5×106 cells/ml) prepared in Example 1 under the paragraph “2. Cell culture” were fixed and permeability of the cell membranes was increased using FOXP3 staining buffer set (eBioscience) before addition of a PE-labeled anti-FOXP3 antibody (BioLegend) to a final concentration of 3.125 μg/ml and reaction at 4° C. for 20 minutes.
After the reaction, Th17 cells were washed by adding phosphate buffered saline (PBS) containing 0.5% BSA and centrifuging to collect the cells. The washed Th17 cells were suspended in PBS containing 0.5% BSA to prepare a FOXP3 measurement sample of Th17 cells (5×106 cells/ml).
FOXP3 measurement samples of Th1 cells (5×106 cells/ml), of Th2 cells (5×106 cells/ml) and of Treg cells (5×106 cells/ml) were prepared in the similar manner as above except that Th1, Th2 and Treg cells “without activation stimulation”, respectively, were used instead of Th17 cells “without activation stimulation”.
A negative control sample (5×106 cells/ml) was prepared by adding a PE-labeled mouse IgG1 isotype control (BioLegend) to a final concentration of 1.0 μg/ml instead of the PE-labeled FOXP3 antibody and reacting at 4° C. for 20 minutes.
(5) Preparation of GRP34 Measurement Samples
Th17 cells “without activation stimulation” prepared in Example 1 under the paragraph “2. Cell culture” were prepared in 5% FBS/RPMI at 2.5×105 cells/ml. Phorbol myristate acetate at a final concentration of 50 ng/ml and ionomycin at a final concentration of 1 μM were added and incubated at 37° C. for 4 hours to stimulate Th17 cells. Then, brefeldin A was added to a final concentration of 10 μg/ml and incubated at 37° C. for 2 hours.
After cultivation, Th17 cells were washed twice by adding phosphate buffered saline (PBS) containing 0.5% BSA and centrifuging to collect the cells. The washed Th17 cells were added with 2% paraformaldehyde to fix the cells. After fixing the cells, a saponin buffer (0.5% saponin, 0.5% bovine serum albumin (BSA), 1 mM sodium azide (in PBS)) was added to accelerate cell membrane permeability of Th17 cells.
The sample after saponin treatment was added with an anti-GPR34 antibody (Lifespan Biosciences) to a final concentration of 25.0 μg/ml and reaction was carried out at 4° C. for 20 minutes. After the reaction, the saponin buffer was added and Th17 cells were collected by centrifugation. The collected Th17 cells were suspended in the saponin buffer. The suspension was added with a PE-labeled anti-mouse IgG antibody (BioLegend) to a final concentration of 1.0 μg/ml and reaction was carried out at 4° C. for 20 minutes.
After the reaction with the PE-labeled anti-mouse IgG antibody, Th17 cells were washed twice by adding the saponin buffer and centrifuging to collect the cells. The washed Th17 cells were suspended in PBS containing 0.5% BSA to prepare a GRP34 measurement sample of Th17 cells (2.5×105 cells/ml).
GRP34 measurement samples of Th1 cells, of Th2 cells and of Treg cells were prepared in the similar manner as above except that Th1, Th2 and Treg cells “without activation stimulation”, respectively, were used instead of Th17 cells “without activation stimulation”.
A negative control sample (2.5×106 cells/ml) was prepared by adding a mouse IgG2a isotype control (BioLegend) to a final concentration of 1.0 μg/ml instead of the anti-GPR34 antibody and reacting at 4° C. for 20 minutes.
(6) Preparation of IL-17a Measurement Samples
Th17 cells “without activation stimulation” prepared in Example 1 under the paragraph “2. Cell culture” were prepared in 5% FBS/RPMI at 2.5×105 cells/ml. Phorbol myristate acetate at a final concentration of 50 ng/ml and ionomycin at a final concentration of 1 μM were added and incubated at 37° C. for 4 hours to stimulate Th17 cells. Then, brefeldin A was added to a final concentration of 10 μg/ml and incubated at 37° C. for 2 hours.
After cultivation, Th17 cells were washed by adding phosphate buffered saline (PBS) containing 0.5% BSA and centrifuging to collect the cells. The washed Th17 cells were added with 2% paraformaldehyde to fix the cells. After fixing the cells, a saponin buffer (0.5% saponin, 0.5% bovine serum albumin (BSA), 1 mM sodium azide (in PBS)) was added to accelerate cell membrane permeability of Th17 cells.
The sample after saponin treatment was added with a PerCP-Cy5.5-labeled anti-IL-17A antibody (eBioscience) to a final concentration of 0.15 μg/ml and reaction was carried out at 4° C. for 20 minutes.
After the reaction, Th17 cells were washed by adding the saponin buffer and centrifuging to collect cells. The washed Th17 cells were suspended in PBS containing 0.5% BSA to prepare a IL-17A measurement sample of Th17 cells (2.5×105 cells/ml).
A negative control sample (2.5×106 cells/ml) was prepared by adding a PerCP-Cy5.5-labeled mouse IgG1 isotype control (eBioscience) to a final concentration of 1.0 μg/ml instead of the PerCP-Cy5.5-labeled anti-IL-17A antibody.
(7) Preparation of IFN-γ Measurement Samples
IFN-γ measurement samples of Th17 cells (2.5×105 cells/ml), of Th1 cells (2.5×105 cells/ml), of Th2 cells (2.5×105 cells/ml) and of Treg cells (2.5×105 cells/ml) were prepared in the similar manner as the above paragraph “(6) Preparation of IL-17A measurement samples” except that an Alexa488-labeled anti-IFN-γ antibody (BioLegend) was used at a final concentration of 1.0 μg/ml instead of the PerCP-Cy5.5-labeled anti-IL-17A antibody.
A negative control sample (2.5×106 cells/ml) was prepared by adding an Alex488-labeled mouse IgG 1 isotype control (BioLegend) to a final concentration of 1.0 μg/ml instead of the Alexa488-labeled anti-IFN-γ antibody and reacting at 4° C. for 20 minutes.
(8) Preparation of IL-4 Measurement Samples
IL-4 measurement samples of Th17 cells (2.5×105 cells/ml), of Th1 cells (2.5×105 cells/ml), of Th2 cells (2.5×105 cells/ml) and of Treg cells (2.5×105 cells/ml) were prepared in the similar manner as the above paragraph “(6) Preparation of IL-17A measurement samples” except that an APC-labeled anti-IL-4 antibody (eBioscience) was used at a final concentration of 0.2 μg/ml instead of the PerCP-Cy5.5-labeled anti-IL-17A antibody.
A negative control sample (2.5×106 cells/ml) was prepared by adding an APC-labeled rat IgG1 isotype control (BioLegend) to a final concentration of 1.0 μg/ml instead of the APC-labeled anti-IL-4 antibody and reacting at 4° C. for 20 minutes.
2. Expression Analysis of Protein Markers in Measurement Samples Using Flow Cytometer
The prepared measurement samples were analyzed by FACSCanto II (BD Bioscienct) and FACS DIVA software (BD Bioscience). Histograms (particle size distribution) of fluorescent intensities obtained by the analysis are shown in FIGS. 2 to 9 , which correspond respectively to the histograms obtained from MCAM measurement samples, PTPRM measurement samples, GPR34 measurement samples, CCR6 measurement samples, IL-17A measurement samples, IFN-γ measurement samples, IL-4 measurement samples, and FOXP3 measurement samples. In FIGS. 2 to 9 , the vertical axis of the histograms shows the number of cells and the horizontal axis shows the fluorescent intensity. The numbers at the upper right of the histograms correspond to the ratio (%) of positive cells for the marker gene relative to the number of total cells in the respective measurement samples. The cells were determined as positive or negative based on the maximal fluorescent intensity in the negative control. Namely, the cells having higher fluorescent intensity than the maximal fluorescent intensity of the negative control were determined as positive, while the cells having a fluorescent intensity equal to or lower than the maximal fluorescent intensity of the negative control were determined as negative. The ratio of positive cells was calculated as the ratio of the number of positive cells relative to the number of total cells.
CCR6 and IL-17A are known markers for Th17 cells. FIGS. 5 and 6 show that the expression levels of CCR6 and IL-17A proteins are high in Th17 cells. IFN-γ is a known marker for Th1 cells. FIG. 7 shows that the expression level of IFN-γ protein is high in Th1 cells. IL-4 is a known marker for Th2 cells. FIG. 8 shows that the expression level of IL-4 protein is high in Th2 cells. FOXP3 is a known marker for Treg cells. FIG. 9 shows that the expression level of FOXP3 protein is high in Treg cells. Thus, it is indicated that these measurement samples are suitable for expression analysis of protein markers.
1. Preparation of cDNA
(1) Preparation of cDNA from Cells “without Activation Stimulation”
Total RNA (0.1 μg) of Th17 cells “without activation stimulation” extracted in Example 1 under the paragraph “3. Extraction of total RNA” was reverse-transcribed with a poly dT primer (Hokkaido System Science Co., Ltd.), random primers (Hokkaido System Science Co., Ltd.) and Superscript III reverse transcriptase (Invitrogen Corporation) to obtain cDNA of Th17 cells “without activation stimulation”. Reverse transcription was carried out according to the attached instructions.
cDNAs of Th1 cells “without activation stimulation”, of Th2 cells “without activation stimulation” and of Treg cells “without activation stimulation” were prepared in the similar manner as above except that total RNAs (0.1 μg) of Th1 cells, Th2 cells and Treg cells “without activation stimulation” were used instead of total RNA (0.1 μg) of Th17 cells “without stimulation”.
The number of samples of the cells “without activation stimulation” used for preparation of cDNA is shown in Table 10.
TABLE 10 | ||||
Th1 | ||||
cells | Th2 cells | Th17 cells | Treg cells | |
w/o activation stimulation | 5 | 5 | 5 | 4 |
(2) Preparation of cDNA from Cells “with Activation Stimulation”
Th17 cells “without activation stimulation” prepared in Example 1 under the paragraph “2. Cell culture” were prepared in 5% FBS/RPMI at 2.5×105 cells/ml. Th17 cells were stimulated by incubating the cells at 37° C. for 3 hours with T cell activation/expansion kit (Miltenyi Biotec). These Th17 cells “with activation stimulation” were subjected to extraction of total RNA in the same manner as Example 1, “3. Extraction of total RNA”. The extracted total RNA (0.1 μg) of Th17 cells “with activation stimulation” was reverse-transcribed with a poly dT primer (Hokkaido System Science Co., Ltd.), random primers (Hokkaido System Science Co., Ltd.) and Superscript III reverse transcriptase (Invitrogen Corporation) to obtain cDNA of Th17 cells “with activation stimulation”. Reverse transcription was carried out according to the attached instructions.
cDNAs of Th1 cells “with activation stimulation”, of Th2 cells “with activation stimulation” and of Treg cells “with activation stimulation” were prepared in the similar manner as above except that total RNAs (0.1 μg) of Th1 cells, Th2 cells and Treg cells “with activation stimulation” were used instead of total RNA (0.1 μg) of Th17 cells “with activation stimulation”.
The number of samples of the cells “with activation stimulation” used for preparation of cDNA is shown in Table 11.
TABLE 11 | ||||
Th1 cells | Th2 cells | Th17 cells | Treg cells | |
w/ activation stimulation | 5 | 5 | 5 | 3 |
2. Design of Primer Sets
The following primer sets were designed with Primer3 software.
(1) Primer Sets for Detecting Th17 Cells
Primer sets were designed for the genes ADAM12, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, L1CAM, MCAM, SHROOM2, TMEM163, UPK1B, DRD2, PGBD5 (LOC100134440), ODZ4, SLC6A15, AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC, TGFBI, IL1A, BHLHE22, PPARG, SIM1 and SNAI2, which were detected in Example 1 as the polynucleotide markers for detecting Th17 cells.
(2) Primer Sets for Known Markers for Th17 Cells
Primer sets were designed for known gene markers for Th17 cells, CCR6, RORC and IL-17A.
(3) Primer Sets for Known Markers for Th1 Cells
Primer sets were designed for known gene markers for Th1 cells, TBX21 and IFN-γ.
(4) Primer Sets for Known Markers for Th2 Cells
Primer sets were designed for known gene markers for Th2 cells, GATA3 and IL-4.
(5) Primer Sets for Known Markers for Treg Cells
Primer sets were designed for a known gene marker for Treg cells, FOXP3.
(6) Primer Sets for Internal Controls
Primer sets were designed for internal control genes, Gapdh, ACTB, B2M and UBC.
Designed primer sets are shown in Table 12.
TABLE 12 | ||||
SEQ | SEQ | |||
Gene | ID | ID | ||
symbol | Forward primer | NO: | Reverse primer | NO: |
ADAM12 | TCTCCCTCGCTCGAAATTACA | 181 | CAGAATATCCCCGTACATGTCCAT | 182 |
ATP6V0A4 | TCCTTGAACATCTTTGGCTCTTC | 183 | TCCATGTGCCGTTTCTGAAC | 184 |
ATP9A | AGAGGAGCAGTATCAGGACTTTGAA | 185 | AGCGGTCGTGCACACTCA | 186 |
BVES | CGGCTTGCACCAGTTTCTTC | 187 | GCTCCTTCTTCTATCGGTTTCATC | 188 |
C5orf40 | TCGGAGGGCAGAGCTCTAAC | 189 | CCTCGATGTTCATCCCGATT | 190 |
CDH4 | GATCAGCCCCACTCTCCAAA | 191 | GATGGATCCCCACTGATGATG | 192 |
DIO2 | CATGATGCTAAGAGTCCTGGGTAA | 193 | TTCTGCAACTGAGAAGCACATATG | 194 |
L1CAM | CAAGGAGGGCCAGTGCAA | 195 | GAAGCCCCACCCTTCTCTTC | 196 |
MCAM | GGGCATCCCTGTGAACAGTAA | 197 | GGTACCCGTTCCTCCCTACAC | 198 |
SHROOM2 | TGCATGTTAATGGTGAGTGAATCC | 199 | |
200 |
TMEM163 | GGTCAAACTCCTCATCGACATG | 201 | CCCCTTCACTCAAACATCTCGTA | 202 |
UPK1B | CCAGTGGAAAAACAATGGAGTCA | 203 | ACAGCAATTGTCCTGGAGCAT | 204 |
DRD2 | CTGCTCATCGCTGTCATCGT | 205 | CGGGACACAGCCATGCA | 206 |
PGBD5 | AGAGTTTGAGAAGCAAGGGATTTACT | 207 | GGCCGGTGCAGTCACTCTT | 208 |
ODZ4 | GCCCACAGACTTAGCCATCA | 209 | TCCCGGCGACAATGC | 210 |
SLC6A15 | TGCCACCACCTATTACTGGTACA | 211 | AGTTTAAGCCCCCACTTTCAGAA | 212 |
AKAP12 | TCCATAGCTGGGTCTGGTGTAGA | 213 | TTCTTGATTGAGACCCAGGATTC | 214 |
C9orf125 | GAGAGGCTCCAGCACTACATCA | 215 | CTACACCAACCCATTCCAGGAT | 216 |
POPDC3 | TTCAGTTCCTGGATTCTCCTGAGT | 217 | CAGTGAGGGTTACCTGAAAAATGC | 218 |
UNC13C | TCAGGGACCAACCACCAAGA | 219 | CAGGACAGGTGTGTAGGCAGTTT | 220 |
PCOLCE2 | CCACCACATTCCCTGTAACCA | 221 | TCCGTCTACACTTTTGTTGACACA | 222 |
PNOC | CTCAGTCTCTTCTCCAGTGTGTTCA | 223 | GGAGCTTCTCCTGGCATGTG | 224 |
TGFBI | GGGCGGCAAAAAACTGAGA | 225 | CCGCGATGCAGGTGTTCT | 226 |
IL1A | CAATTGTATGTGACTGCCCAAGA | 227 | TGGGTATCTCAGGCATCTCCTT | 228 |
BHLHE22 | TGCTCCCCACCCCCTTTA | 229 | CTGCTTTGTTTGCTCTGCAAGT | 230 |
PPARG | CCTGAGCCACTGCCAACATT | 231 | AGGTGTCAGATTTTCCCTCAGAAT | 232 |
SIM1 | CATGCCTCACATCGCTTCAG | 233 | CCACACTATCTTCATCCCAATGAC | 234 |
SNAI2 | CTTGCCCTCACTGCAACAGA | 235 | TCTGCAGATGAGCCCTCAGA | 236 |
TBX21 | GATGCGCCAGGAAGTTTCA | 237 | GACGCCCCCTTGTTGTTTG | 238 |
GATA3 | GCGGGCTCTATCACAAAATGA | 239 | GCCTTCGCTTGGGCTTAAT | 240 |
FOXP3 | CACCTGGCTGGGAAAATGG | 241 | GGAGCCCTTGTCGGATGAT | 242 |
CCR6 | GGCAGTTCTCCAGGCTATTTGT | 243 | GGAGGCCAAAGACACAGATCA | 244 |
RORC | CCAAGGCTCAGTCATGAGAACA | 245 | GCGGAAGAAGCCCTTGCA | 246 |
IFNG | CCAACGCAAAGCAATACATGA | 247 | CGAAACAGCATCTGACTCCTTTT | 248 |
IL4 | TGGGTCTCACCTCCCAACTG | 249 | GCCGGCACATGCTAGCA | 250 |
IL17A | CCCAAAAGGTCCTCAGATTACTACA | 251 | CATTGCGGTGGAGATTCCA | 252 |
GAPDH | ACCCACTCCTCCACCTTTGA | 253 | TTGCTGTAGCCAAATTCGTTGT | 254 |
ACTB | CAGCAGATGTGGATCAGCAAG | 255 | GCATTTGCGGTGGACGAT | 256 |
B2M | TGCTGTCTCCATGTTTGATGTATCT | 257 | TCTCTGCTCCCCACCTCTAAGT | 258 |
UBC | GTCGCAGCCGGGATTTG | 259 | GCATTGTCAAGTGACGATCACA | 260 |
3. Expression Analysis of Gene Markers by Real-Time PCR
(1) Real-Time PCR Using cDNAs of Cells “Without Activation Stimulation” as Templates
cDNAs of Th17 cells “without activation stimulation” obtained from samples in the above “1. Preparation of cDNA” were respectively used as a template. The primer sets used were the primer sets for ADAM12, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, L1CAM, MCAM, SHROOM2, TMEM163, UPK1B, DRD2, PGBD5, ODZ4, SLC6A15, AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC, TGFBI, IL1A, BHLHE22, PPARG, SIM1, SNAI2, TBX21, GATA3, FOXP3, CCR6, RORC, GAPDH, ACTB, B2M and UBC, which were designed as described in “2. Design of primer sets”. Real-time PCR was carried out with the template, primer sets and Power SYBR Green PCR Master Mix (Applied Biosystems) in 7300 Real Time PCR System (Applied Biosystems) and Ct value of each gene was measured. PCR was carried out at 50° C. for 2 minutes, 95° C. for 10 minutes followed by 45 cycles of 95° C. for 15 seconds and 60° C. for 1 minute and two cycles of 95° C. for 15 seconds and 60° C. for 1 minute. Ct value was measured by automatic calculation on 7300 Fast SDS software (Applied Biosystems).
Real-time PCR was also carried out in the similar manner as above except that cDNAs of Th1 cells “without activation stimulation” obtained from 5 samples, cDNAs of Th2 cells “without activation stimulation” obtained from 5 samples and cDNAs of Treg cells “without activation stimulation” obtained from 4 samples were used as a template instead of cDNAs of Th17 cells “without activation stimulation”, and Ct values for the genes were measured.
(2) Real-Time PCR Using cDNAs of Cells “with Activation Stimulation” as Templates
cDNAs of Th17 cells “with activation stimulation” obtained from 5 samples in the above “1. Preparation of cDNA” were used as a template. The primer sets used were the primer sets for AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC, TGFBI, IFNG, IL4, IL17A, GAPDH, ACTB, B2M and UBC, which were designed as described in “2. Design of primer sets”. Real-time PCR was carried out with the template, primer sets and Power SYBR Green PCR Master Mix (Applied Biosystems) in 7300 Real Time PCR System (Applied Biosystems) and Ct value of each gene was measured. PCR was carried out at 50° C. for 2 minutes, 95° C. for 10 minutes followed by 45 cycles of 95° C. for 15 seconds and 60° C. for 1 minute and two cycles of 95° C. for 15 seconds and 60° C. for 1 minute. Ct value was measured by automatic calculation on 7300 Fast SDS software (Applied Biosystems).
Real-time PCR was also carried out in the similar manner as above except that cDNAs of Th1 cells “with activation stimulation” obtained from 5 samples, cDNAs of Th2 cells “with activation stimulation” obtained from 5 samples and cDNAs of Treg cells “with activation stimulation” obtained from 3 samples were used as a template instead of cDNAs of Th17 cells “with activation stimulation”, and Ct values for the genes were measured.
(3) Analysis of Expression Level
Based on the Ct values obtained from real-time PCR, expression levels of the gene markers were calculated according to the formula (I):
(Expression level of a gene)=100000×2−y (I)
wherein: y=(Ct value of a gene)−(((Ct value of Gapdh gene)+(Ct value of ACTB gene)+(Ct value of B2M gene)+(Ct value of UBC gene))/4)
(Expression level of a gene)=100000×2−y (I)
wherein: y=(Ct value of a gene)−(((Ct value of Gapdh gene)+(Ct value of ACTB gene)+(Ct value of B2M gene)+(Ct value of UBC gene))/4)
The expression level of each gene marker in Th17 cells “without activation stimulation” was obtained as an average of the expression levels of the gene marker in question obtained from five cDNAs used as templates. The expression level of each gene marker in Th17 cells “with activation stimulation” was also obtained as an average of the expression levels of the gene marker in question obtained from five cDNAs used as templates.
Similarly, the expression level of each gene marker in Th1 cells or Th2 cells “without activation stimulation” or “with activation stimulation” was obtained as an average of the expression levels of the gene marker in question obtained from five cDNAs used as templates. The expression level of each gene marker in Treg cells “without activation expression” was obtained as an average of the expression levels of the gene marker in question obtained from four cDNAs used as templates. The expression level of each gene marker in Treg cells “with activation stimulation” was obtained as an average of the expression levels of the gene marker in question obtained from three cDNAs used as templates.
Expression levels of the gene markers are shown in Tables 13 and 14. Table 13 shows expression levels of gene markers in Th1, Th2, Treg and Th17 cells “without activation stimulation” and Table 14 shows expression levels of gene markers in Th1, Th2, Treg and Th17 cells “with activation stimulation”
Expression levels of gene markers in the cells “without activation stimulation”
TABLE 13 | |
Location of | Expression level |
encoded protein | Gene symbol | Th1 | Th2 | Treg | Th17 |
Membrane | ADAM12 | 9.95 | 0.55 | 22.08 | 193.83 |
ATP6V0A4 | 35.21 | 2.55 | 7.17 | 625.03 | |
ATP9A | 125.11 | 9.08 | 41.42 | 407.43 | |
BVES | 23.85 | 3.58 | 6.84 | 77.99 | |
C5orf40 | 0.74 | 0.00 | 33.36 | 107.84 | |
CDH4 | 4.93 | 7.47 | 29.44 | 143.90 | |
DIO2 | 0.46 | 1.25 | 0.91 | 10.40 | |
L1CAM | 41.95 | 45.03 | 72.77 | 220.54 | |
MCAM | 62.69 | 18.93 | 159.46 | 500.64 | |
SHROOM2 | 0.22 | 0.46 | 0.90 | 11.44 | |
TMEM163 | 13.77 | 8.78 | 24.25 | 249.56 | |
UPK1B | 2.94 | 0.12 | 0.55 | 22.59 | |
DRD2 | 51.14 | 49.86 | 58.21 | 884.06 | |
PGBD5 | 10.30 | 11.96 | 19.04 | 157.52 | |
ODZ4 | 1.14 | 0.44 | 0.39 | 41.82 | |
SLC6A15 | 0.50 | 3.46 | 2.65 | 27.71 | |
AKAP12 | 29.57 | 30.67 | 46.71 | 110.16 | |
C9orf125 | 1.31 | 0.50 | 3.43 | 39.73 | |
POPDC3 | 0.23 | 0.00 | 0.52 | 10.19 | |
UNC13C | 0.08 | 0.08 | 0.27 | 12.10 | |
Extracellular/ | PCOLCE2 | 0.60 | 0.00 | 2.59 | 15.64 |
secreted | PNOC | 8.01 | 25.75 | 5.43 | 335.81 |
TGFBI | 58.45 | 31.18 | 253.89 | 1427.38 | |
IL1A | 13.47 | 47.92 | 128.89 | 502.06 | |
Intracellular | BHLHE22 | 32.48 | 13.80 | 29.69 | 247.81 |
PPARG | 120.16 | 16.40 | 92.84 | 456.67 | |
SIM1 | 143.63 | 229.39 | 40.78 | 837.78 | |
SNAI2 | 0.15 | 0.03 | 4.20 | 69.35 | |
Known markers | TBX21 | 4851.97 | 21.94 | 513.23 | 26.92 |
GATA3 | 1820.22 | 5684.93 | 4811.71 | 1353.37 | |
FOXP3 | 471.34 | 250.11 | 21799.93 | 334.68 | |
CCR6 | 102.73 | 42.69 | 939.98 | 401.01 | |
RORC | 96.77 | 3.75 | 328.99 | 788.05 | |
Expression levels of gene markers in the cells “with activation stimulation
TABLE 14 | ||
Location of | Gene | Expression level |
encoded protein | symbol | Th1 | Th2 | Treg | Th17 |
Membrane | AKAP12 | 34.55 | 59.13 | 40.36 | 201.43 |
C9orf125 | 0.51 | 0.00 | 1.92 | 35.77 | |
POPDC3 | 7.28 | 2.60 | 3.42 | 28.09 | |
UNC13C | 0.04 | 0.36 | 1.76 | 11.11 | |
Extracellular/ | PCOLCE2 | 1.01 | 0.36 | 2.04 | 20.82 |
secreted | PNOC | 10.33 | 28.87 | 0.63 | 289.07 |
TGFBI | 39.99 | 6.24 | 86.85 | 861.02 | |
Known markers | IFNG | 191944.46 | 393.70 | 1593.07 | 1118.25 |
IL4 | 4011.14 | 8401.51 | 329.94 | 108.98 | |
IL17A | 84.43 | 458.57 | 1600.38 | 34052.24 | |
Expression levels of gene markers in Th17 cells and ratios thereof relative to the expression levels of the gene markers in Th1, Th2 and Treg cells are shown in Tables 15 and 16. Table 15 shows expression levels of gene markers in Th17 cells “without activation stimulation” and ratios thereof relative to the expression levels of the gene markers in Th1, Th2 and Treg cells “without activation stimulation”. Table 16 shows expression levels of gene markers in Th17 cells “with activation stimulation” and ratios thereof relative to the expression levels of the gene markers in Th1, Th2 and Treg cells “with activation stimulation”. The values shown in the columns of Th17/Th1, Th17/Th2 and Th17/Treg in Tables 15 and 16 were calculated as follows:
Th17/Th1=(Expression level in Th17 cells)/(Expression level in Th1 cells)
Th17/Th2=(Expression level in Th17 cells)/(Expression level in Th2 cells)
Th17/Treg=(Expression level in Th17 cells)/(Expression level in Treg cells)
Th17/Th1=(Expression level in Th17 cells)/(Expression level in Th1 cells)
Th17/Th2=(Expression level in Th17 cells)/(Expression level in Th2 cells)
Th17/Treg=(Expression level in Th17 cells)/(Expression level in Treg cells)
TABLE 15 | |
Location of encoded | Expression ratio |
protein | Gene symbol | Th17/Th1 | Th17/Th2 | Th17/Treg |
Membrane | ADAM12 | 19.49 | 352.65 | 8.78 |
ATP6V0A4 | 17.75 | 245.31 | 87.13 | |
ATP9A | 3.26 | 44.86 | 9.84 | |
BVES | 3.27 | 21.80 | 11.41 | |
C5orf40 | 144.92 | ∞ | 3.23 | |
CDH4 | 29.17 | 19.26 | 4.89 | |
DIO2 | 22.83 | 8.34 | 11.42 | |
L1CAM | 5.26 | 4.90 | 3.03 | |
MCAM | 7.99 | 26.44 | 3.14 | |
SHROOM2 | 53.13 | 24.85 | 12.71 | |
TMEM163 | 18.13 | 28.42 | 10.29 | |
UPK1B | 7.69 | 191.37 | 41.23 | |
DRD2 | 17.29 | 17.73 | 15.19 | |
PGBD5 | 15.30 | 13.17 | 8.27 | |
ODZ4 | 36.59 | 94.68 | 106.41 | |
SLC6A15 | 55.24 | 8.01 | 10.47 | |
AKAP12 | 3.72 | 3.59 | 2.36 | |
C9orf125 | 30.34 | 79.90 | 11.59 | |
POPDC3 | 44.01 | ∞ | 19.75 | |
UNC13C | 152.73 | 157.50 | 44.10 | |
Extracellular/ | PCOLCE2 | 25.86 | 4097.03 | 6.04 |
secreted | PNOC | 41.93 | 13.04 | 61.86 |
TGFBI | 24.42 | 45.77 | 5.62 | |
IL1A | 37.28 | 10.48 | 3.90 | |
Intracellular | BHLHE22 | 7.63 | 17.96 | 8.35 |
PPARG | 3.80 | 27.85 | 4.92 | |
SIM1 | 5.83 | 3.65 | 20.54 | |
SNAI2 | 466.76 | 2536.05 | 16.52 | |
Known markers | TBX21 | 0.01 | 1.23 | 0.05 |
GATA3 | 0.74 | 0.24 | 0.28 | |
FOXP3 | 0.71 | 1.34 | 0.02 | |
CCR6 | 3.90 | 9.39 | 0.43 | |
RORC | 8.14 | 210.37 | 2.40 | |
TABLE 16 | |
Location of | Expression ratio |
encoded protein | Gene symbol | Th17/Th1 | Th17/Th2 | Th17/Treg |
Membrane | AKAP12 | 5.83 | 3.41 | 4.99 |
C9orf125 | 69.61 | ∞ | 18.59 | |
POPDC3 | 3.86 | 10.79 | 8.20 | |
UNC13C | 266.35 | 31.25 | 6.30 | |
Extracellular/ | PCOLCE2 | 20.54 | 58.21 | 10.22 |
secreted | PNOC | 27.99 | 10.01 | 456.13 |
TGFBI | 21.53 | 138.01 | 9.91 | |
Known markers | IFN-γ | 0.01 | 2.84 | 0.70 |
IL-4 | 0.03 | 0.01 | 0.33 | |
IL-17A | 403.31 | 74.26 | 21.28 | |
Table 15 shows that the expression levels of ADAM12, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, L1CAM, MCAM, SHROOM2, TMEM163, UPK1B, DRD2, PGBD5, ODZ4, SLC6A15, AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC, TGFBI, IL1A, BHLHE22, PPARG, SIM1 and SNAI2 in Th17 cells “without activation stimulation” are two or more times higher than that in Th1, Th2 and Treg cells “without activation stimulation”.
Table 16 shows that the expression levels of AKAP12, C9orf125, POPDC3, UNC13C, PCOLCE2, PNOC and TGFBI in Th17 cells “with activation stimulation” are two or more times higher than that in Th1, Th2 and Treg cells “with activation stimulation”.
Thus, it is demonstrated that these genes are useful as polynucleotide markers for detecting Th17 cells.
1. Isolation of CD4 Positive Cells from Peripheral Blood of Healthy Subjects and Patients with Rheumatoid Arthritis
Peripheral blood from healthy adults (healthy subjects) and patients with rheumatoid arthritis was collected in blood collecting tubes NP-HE0557 (NIPRO) and peripheral blood CD4 positive cells were isolated with magnetic beads bound to anti-CD4 antibody (Miltenyi Biotec). Isolation of CD4 positive cells using anti-CD4 antibody beads was carried out according to the attached instruction.
2. Preparation of cDNA from Peripheral Blood CD4 Positive Cells
Total RNA was extracted from the isolated peripheral blood CD4 positive cells in the same manner as Example 1, “3. Extraction of total RNA”. The extracted total RNA (0.1 μg) of peripheral blood CD4 positive cells were reverse-transcribed with a poly dT primer (Hokkaido System Science Co., Ltd.), random primers (Hokkaido System Science Co., Ltd.) and Superscript III reverse transcriptase (Invitrogen Corporation) to obtain cDNA of peripheral blood CD4 positive cells. Reverse transcription was carried out according to the attached instructions.
The number of samples of peripheral blood CD4 positive cells used for preparation of cDNA is shown in Table 17.
TABLE 17 | ||
Healthy subject | Patient with rheumatoid arthritis | |
w/o activation | 9 | 9 |
stimulation | ||
3. Expression Analysis of Gene Markers by Real-Time PCR
(1) Real-Time PCR Using cDNAs of Peripheral Blood CD4 Positive Cells as Templates
cDNAs of peripheral blood CD4 positive cells obtained from nine healthy subjects and nine patients with rheumatoid arthritis as prepared in the above “2. Preparation of cDNA from peripheral blood CD4 positive cells” were used as templates. The primer sets used were the primer sets for ATP6V0A4, BVES, C5orf40, UPK1B, DRD2, PCOLCE2, PNOC, TGFBI, BHLHE22, SIM1, CCR6, RORC, GAPDH, ACTB, B2M, and UBC, which were designed as described in “2. Design of primer sets”. Real-time PCR was carried out with the template, primer sets and Power SYBR Green PCR Master Mix (Applied Biosystems) in 7300 Real Time PCR System (Applied Biosystems) and Ct value of each gene was measured. PCR was carried out at 50° C. for 2 minutes, 95° C. for 10 minutes followed by 45 cycles of 95° C. for 15 seconds and 60° C. for 1 minute and two cycles of 95° C. for 15 seconds and 60° C. for 1 minute. Ct value was measured by automatic calculation on 7300 Fast SDS software (Applied Biosystems).
(2) Analysis of Expression Level
Expression levels of the gene markers were calculated according to the above formula (I). The expression level of each gene marker in peripheral blood CD4 positive cells of the patients with rheumatoid arthritis was obtained as an average of the expression levels of the gene marker in question obtained from nine cDNAs used as templates. Similarly, the expression level of each gene marker in peripheral blood CD4 positive cells of the healthy subjects was obtained as an average of the expression levels of the gene marker in question obtained from nine cDNAs used as templates.
Expression levels of the gene markers in peripheral blood CD4 positive cells from healthy subjects and patients with rheumatoid arthritis and expression ratios of the gene markers between peripheral blood CD4 positive cells of healthy subjects and patients with rheumatoid arthritis are shown in Table 18. In Table 18, “RA” denotes patients with rheumatoid arthritis and “HC” denotes healthy subjects. The values shown in the column RA group/HC group were calculated as follows:
RA group/HC group=(Expression level in peripheral blood CD4 positive cells of patients with rheumatoid arthritis)/(Expression level in peripheral blood CD4 positive cells of healthy subjects)
RA group/HC group=(Expression level in peripheral blood CD4 positive cells of patients with rheumatoid arthritis)/(Expression level in peripheral blood CD4 positive cells of healthy subjects)
TABLE 18 | ||
Expression | ||
ratio | ||
Location of encoded | Expression level | RA group/ |
protein | Gene symbol | HC group | RA group | HC group |
Membrane | ATP6V0A4 | 6.44 | 52.16 | 8.10 |
BVES | 0.08 | 32.79 | 403.57 | |
C5orf40 | 0.04 | 21.60 | 496.29 | |
UPK1B | 0.31 | 39.65 | 126.98 | |
DRD2 | 59.42 | 243.55 | 4.10 | |
Extracellular/ | PCOLCE2 | 0.07 | 4.94 | 70.29 |
secreted | PNOC | 18.89 | 73.38 | 3.88 |
TGFBI | 1651.40 | 5413.26 | 3.28 | |
Intracellular | BHLHE22 | 3.15 | 27.75 | 8.81 |
SIM1 | 4.75 | 20.73 | 4.36 | |
Known markers | CCR6 | 3136.22 | 4316.17 | 1.38 |
RORC | 528.64 | 421.20 | 0.80 | |
Table 18 shows that the expression levels of ATP6V0A4, BVES, C5orf40, UPK1B, DRD2, PCOLCE2, PNOC, TGFBI, BHLHE22 and SIM1 in the RA group were three or more times higher than that in the HC group. This indicates that these genes are useful as polynucleotide markers for screening of patients with rheumatoid arthritis.
1. Isolation of Th17 and Th22 Cells from Human Peripheral Blood
Buffy coat obtained from peripheral blood of a healthy adult was overlaid on Ficoll-paque plus solution (GE Healthcare Bioscience) and centrifuged to obtain a monocyte fraction. Crude CD4 positive cells were purified from the fraction by using magnetic beads bound to anti-CD4 antibody (Miltenyi Biotec).
The obtained CD4 positive cells were stained with the fluorescence labeled antibodies shown in Table 19 and then Th17 and Th22 cells were separated by a cell sorter (FACS Aria: Becton Dickinson). The separation was carried out with the gating shown in Table 20.
TABLE 19 | |||
Fluorescent | |||
Antigen | labeling substance | Clone | Manufacturer |
CD4 | APC-Cy7 | RPA-T4 | BD Biosciences |
CD25 | PE-Cy7 | BC96 | eBioscience |
CXCR3 | Alexa Fluor ™ 488 | 1C6/CXCR3 | BD Biosciences |
CCR4 | APC | FAB1567A | R&D systems |
CCR6 | PE | 11A9 | BD Biosciences |
CD45RA | APC | HI100 | BioLegend |
CCR10 | PE | 6588-5 | BioLegend |
TABLE 20 | ||
Cell | Gating | |
Th17 | CD4high CD25low-negative CXCR3− CCR6+ CCR4+ | |
Th22 | CD4high CD25low-negative CD45RA− CXCR3− CCR10+ | |
The above gating is described in detail in the reference by Acosta-Rodriguez E V et al. (Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells, Nat Immunol., vol. 8, p. 639-646 (2007)).
2. Th17 and Th22 Cell Cultures
Th17 and Th22 cells derived from adult peripheral blood obtained in the above step 1. were respectively plated in a 96-well plate at the density of 1.5×105 cells/0.3 ml/well. The medium used was Yssel medium (IMDM, 1% human serum of AB-type, 0.25% BSA, 1.8 mg/l 2-aminomethanol, 40 mg/l transferrin, 5 mg/l insulin, 2 mg/l linoleic acid, 2 mg/l oleic acid, 2 mg/l palmitic acid, 1% penicillin/streptomycin).
For activation and proliferation of the above cells, magnetic beads coated with anti-CD2/3/28 antibody (Miltenyi Biotec) (hereinafter also referred to as “antibody beads”) were added at 0.75×105 per well. After addition of cytokines and neutralizing antibodies suitable for differentiation culture of respective Th17 and Th22 cells, cells were incubated in an incubator at 37° C. with 5% CO2. Cytokines and neutralizing antibodies used are shown in Table 21.
TABLE 21 | ||
Cell | Cytokine | Neutralizing antibody (clone) |
Th17 | TGF-β1, IL-6, IL-23, | Anti-IL-4 antibody (MP4-25D2), |
IL-21, IL-1β, TNFα, IL-2 | Anti-IFN-γ antibody (R4-6A2), | |
Th22 | IL-6, TNFα, IL-2 | Anti-IL-4 antibody (MP4-25D2), |
Anti-IFN-γ antibody (R4-6A2), | ||
Anti-TGFβ antibody (9016) | ||
The concentrations of the above cytokines were 50 ng/ml for IL-6 and 10 ng/ml for other than IL-6. The concentrations of antibodies were 10 μg/ml for anti-IFN-γ antibody, 2.5 μg/ml for anti-IL-4 antibody and 2.5 μg/ml for anti-TGF-β antibody.
The cytokines and neutralizing antibodies were obtained from R&D systems and eBioscience, respectively.
After three days from the start of culture, cells were diluted three-fold with the medium containing the above cytokines and antibodies and cultured for further seven days (10 days in total).
After ten days from the start of culture, the obtained Th17 and Th22 cells were respectively divided into two equal parts, and one was washed with Yssel medium and PBS before centrifugation to collect cells, which were stored at −80° C. until the subsequent RNA extraction step. These cells were designated as Th17 and Th22 cells “without activation stimulation”. The other half was added with the antibody beads and cultured for three more hours to re-activate the cells. The cells were collected by centrifugation and similarly stored at −80° C. These cells were designated as Th17 and Th22 cells “with activation stimulation”.
3. Extraction of Total RNA
The cells obtained as the above step 2. were subjected to extraction of total RNAs using RNeasy Plus Mini kit and RNeasy micro kit (QIAGEN). The specific procedures were according to the attached instructions of the kits.
4. Expression Analysis by Microarray
Total RNAs (10 to 100 ng) extracted from the cells as the above step 3. were reverse-transcribed to cDNAs with Two-Cycle Target Labeling and Control Reagents (Affymetrix), and further transcribed to biotinylated-cRNAs. The amplified biotinylated-cRNAs (20 μg) were fragmented. The specific procedures were according to the attached instructions of the kit.
The biotinylated-cRNAs derived from the cells as obtained above (15 μg) were applied to GeneChip Human Genome U-133 Plus 2.0 Array (Affymetrix) as samples, transferred to GeneChip Hybridization Oven 640 (Affymetrix) and hybridized under the conditions of 45° C. and 60 rpm for 16 hours.
After completion of the hybridization, the microarray was washed and fluorescence-labeled in GeneChip Fluidic Station 450 (Affymetrix), and scanned in GeneChip Scanner 3000 7G (Affymetrix) to obtain fluorescent intensity data.
The fluorescent data obtained were standardized with the expression analysis software GeneSpring Ver.11 (Agilent Technologies) based on MAS5 algorithm to obtain relative fluorescent intensities of the genes in the cells. The relative fluorescent intensities correspond to the expression levels of the genes in these cells.
Tables 22 and 23 show the results of the relative fluorescent intensities of the genes corresponding to the polynucleotide markers in Th17 cells obtained in Example 1 compared to those in Th22 cells. Table 22 shows expression ratios of the polynucleotide markers in Th17 and Th22 cells “without activation stimulation” and Table 23 shows expression ratios of the polynucleotide markers in Th17 and Th22 cells “with activation stimulation”. In the tables, values in the column “Th17/Th22” correspond to the values obtained by dividing the relative fluorescent intensity of a gene corresponding to a polynucleotide marker in Th17 cells by that in Th22 cells.
TABLE 22 | ||
Location of encoded | Expression ratio | |
protein | Gene symbol | Th22/Th17 |
Membrane | ADAM12 | 11.1 |
ATP6V0A4 | 521.3 | |
ATP9A | 33.9 | |
BVES | 3.5 | |
C5orf40 | 7.7 | |
CDH4 | 12.5 | |
DIO2 | 10.6 | |
MCAM | 10.5 | |
SHROOM2 | 5.2 | |
TMEM163 | 5.6 | |
3.8 | ||
UPK1B | 9.2 | |
DRD2 | 5.8 | |
LOC100134440, PGBD5 | 14.5 | |
ODZ4 | 8.2 | |
SLC6A15 | 12.2 | |
AKAP12 | 17.2 | |
36.1 | ||
C9orf125 | 3.3 | |
Extracellular/ | PCOLCE2 | 9.0 |
secreted | PNOC | 38.5 |
TGFBI | 182.0 | |
IL1A | 17.7 | |
Intracellular | BHLHE22 | 108.3 |
PPARG | 13.6 | |
SIM1 | 4.6 | |
5.0 | ||
SNAI2 | 8.2 | |
Membrane | PTPRM | 36.3 |
TABLE 23 | |||
Location of encoded | Expression ratio | ||
protein | Gene symbol | Th17/Th22 | |
Membrane | AKAP12 | 12.8 | |
22.9 | |||
C9orf125 | 6.8 | ||
POPDC3 | 5.4 | ||
Extracellular/ | PCOLCE2 | 11.9 | |
secreted | PNOC | 8.5 | |
TGFBI | 367.4 | ||
Membrane | GPR34 | 28.2 | |
Tables 22 and 23 clearly indicate that the polynucleotide markers in Th17 cells obtained in Example 1 are expressed three or more times higher in Th17 cells than in Th22 cells. Thus, it is demonstrated that the polynucleotide markers shown in Tables 22 and 23 are useful for detection of Th17 cells.
Claims (6)
1. A method for detecting human IL-17-producing helper T-cells comprising:
isolating CD4-positive cells from a blood sample with an anti-CD4 antibody;
mixing at least some of said CD4-positive cells with a labeling substance and with an antibody that specifically binds to a protein encoded by a PTPRM gene, wherein one or more of the CD4-positive cells, the antibody that specifically binds to a protein encoded by a PTPRM gene, and the labeling substance, form a complex;
applying said complex to a flow cytometer; and
detecting the presence of an IL-17-producing helper T-cell by detecting the label of the complex using the flow cytometer, wherein said sample is determined to contain a human IL-17-producing helper T-cell when the label is detected with the flow cytometer in the detecting step.
2. The method according to claim 1 , further comprising detecting a protein encoded by a MCAM gene.
3. The method according to claim 1 , further comprising detecting a protein encoded by a L1CAM gene.
4. The method according to claim 1 , further comprising detecting a protein encoded by a GPR34 gene.
5. The method according to claim 1 , further comprising detecting a protein encoded by a gene,
wherein the gene is selected from the group consisting of:
genes encoding membrane proteins consisting of: ADAM12, ANKS1B, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, DMD, IRS2, KCNE3, MFAP3L, MYO7A, SHROOM2, SLC16A4, SLCO2B1, TANC2, TJP1, TMEM163, TNS3, UPK1B, WDFY3, DRD2, GJC1, PGBD5 (LOC100134440), MS4A7, ODZ4, PHKA1, RGS1, SHB, SLC44A3, SLC6A15, SYNGR3, AKAP12, C9orf125, DPY19L2, HRH4, MUC20, POPDC3, SORBS1, TANC1, TMEM44 and UNC13C;
genes encoding secretory proteins consisting of: CXCL13, PCOLCE2, PNOC, SMPDL3A, TGFBI, C17orf99, EBI3, IL1A and WNT3;
genes encoding intracellular proteins consisting of: BCAT1, BHLHE22, C13orf18 (LOC728970), CA2, CCDC3, CDS1, CHN1, CLIC5 (LOC100131610), CTSH, CYP7B1, DAPK2, DMRT1, DSE, FBXL17, FBXL21, FHOD3, H2AFY2, HLX, IRAK3, MACC1, MAML3, MYO10, OTUB2, PAPSS2, PCBP3, PDE4DIP, PLD1, PPARG, PTPN13, RGS18, SIM1, SNAI2, SOX2, SPIRE1, TBC1D12, TGM5, TMOD1, TUBB6, DDIT4L, DHRS9, ERC2, FERMT2, HHEX, HS3ST1, NR5A2, PHLDA1, RBM20, NINL, RTN2, SH3RF2, TSHZ2, EML1, HIST1H2BC, MAP3K4, PDK4, RGS2 and RGS20;
genes consisting of: C1orf106, C6orf145, LOC401097, MAMLD1, ZC3H12C, C12orf64, C6orf168, CAMSAP1L1 and MAGED4 (MAGED4B); and
genes comprising at least one nucleic acid sequence selected from SEQ ID NO: 147 to 151, 157 to 162 and 167 to 174.
6. The method according to claim 5 , wherein the gene is selected from the group consisting of:
genes encoding membrane proteins consisting of: ADAM12, ATP6V0A4, ATP9A, BVES, C5orf40, CDH4, DIO2, SHROOM2, TMEM163, UPK1B, DRD2, PGBD5 (LOC100134440), ODZ4, SLC6A15, AKAP12, C9orf125, POPDC3 and UNC13C;
genes encoding secretory proteins consisting of: PCOLCE2, PNOC, TGFBI and IL1A; and
genes encoding intracellular proteins consisting of BHLHE22, PPARG, SIM1 and SNAI2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/868,638 US9410208B2 (en) | 2009-07-29 | 2013-04-23 | Marker and reagent for detection of human IL-17-producing helper T cells, and method for detection of human IL-17-producing helper T cells |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-176755 | 2009-07-29 | ||
JP2009176755 | 2009-07-29 | ||
PCT/JP2010/062807 WO2011013753A1 (en) | 2009-07-29 | 2010-07-29 | Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells |
US13/360,324 US20120129724A1 (en) | 2009-07-29 | 2012-01-27 | Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells |
US13/868,638 US9410208B2 (en) | 2009-07-29 | 2013-04-23 | Marker and reagent for detection of human IL-17-producing helper T cells, and method for detection of human IL-17-producing helper T cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/360,324 Division US20120129724A1 (en) | 2009-07-29 | 2012-01-27 | Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells |
Publications (2)
Publication Number | Publication Date |
---|---|
US20130267435A1 US20130267435A1 (en) | 2013-10-10 |
US9410208B2 true US9410208B2 (en) | 2016-08-09 |
Family
ID=43529405
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/360,324 Abandoned US20120129724A1 (en) | 2009-07-29 | 2012-01-27 | Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells |
US13/868,638 Active US9410208B2 (en) | 2009-07-29 | 2013-04-23 | Marker and reagent for detection of human IL-17-producing helper T cells, and method for detection of human IL-17-producing helper T cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/360,324 Abandoned US20120129724A1 (en) | 2009-07-29 | 2012-01-27 | Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells |
Country Status (5)
Country | Link |
---|---|
US (2) | US20120129724A1 (en) |
EP (1) | EP2460880B1 (en) |
JP (1) | JP5858785B2 (en) |
CN (1) | CN102482667B (en) |
WO (1) | WO2011013753A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160297860A1 (en) * | 2013-11-20 | 2016-10-13 | The Regents Of The University Of California | Identification of a novel b cell cytokine |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5946605B2 (en) * | 2011-01-28 | 2016-07-06 | シスメックス株式会社 | Method for detecting human IL-17-producing helper T cells |
JP5885926B2 (en) * | 2011-01-28 | 2016-03-16 | シスメックス株式会社 | Method for evaluating the presence of rheumatoid arthritis and biomarker set used in the method |
AU2012262961A1 (en) * | 2011-06-02 | 2013-11-28 | Novartis Ag | Biomarkers for hedgehog inhibitor therapy |
CN103451273B (en) * | 2012-05-31 | 2015-03-04 | 益善生物技术股份有限公司 | TGM5 gene mutation detection specific primer and liquid phase chip |
TWI595007B (en) * | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | Anti-mcam antibodies and associated methods of use |
EP2708898A1 (en) * | 2012-09-14 | 2014-03-19 | Sterna Biologicals GmbH & Co. Kg | Method for diagnosing a molecular phenotype of a patient suffering from an illness related to chronic inflammation |
CN103060327B (en) * | 2012-12-20 | 2015-02-18 | 深圳先进技术研究院 | Recognition probe, detection method and application of cancer cells |
CN109439626B (en) * | 2018-11-09 | 2022-10-14 | 复旦大学附属中山医院 | Composition for obtaining Th22 cells in vitro and application thereof |
US20230061456A1 (en) * | 2020-01-24 | 2023-03-02 | Decibel Therapeutics, Inc. | Methods and compositions for generating type 1 vestibular hair cells |
CN112143797A (en) * | 2020-09-30 | 2020-12-29 | 中国医学科学院病原生物学研究所 | HIST1H2BC applied to differential diagnosis of active tuberculosis |
CN113881707B (en) * | 2021-10-25 | 2023-07-14 | 中国人民解放军军事科学院军事医学研究院 | Product, method and application for regulating and controlling immune suppression effect of umbilical cord mesenchymal stem cells |
WO2023206347A1 (en) * | 2022-04-29 | 2023-11-02 | 苏州瀛创生物科技有限公司 | Ddit4l spliced product as diagnostic marker for alzheimer's disease |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000186046A (en) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | Therapeutic agent for and diagnosis of chronic rheumatism and |
WO2005029091A2 (en) | 2003-09-15 | 2005-03-31 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
WO2008104608A1 (en) | 2007-03-01 | 2008-09-04 | Universite Catholique De Louvain | Method for the determination and the classification of rheumatic conditions |
WO2009002515A1 (en) | 2007-06-25 | 2008-12-31 | Vertex Pharmaceuticals Incorporated | Th-17 cells |
WO2009092087A2 (en) | 2008-01-18 | 2009-07-23 | The Brigham And Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human th17 cells |
WO2009107785A1 (en) | 2008-02-28 | 2009-09-03 | シスメックス株式会社 | Marker for detection of il-17-producing helper t-cell, and method for detection of il-17-producing helper t-cell |
WO2010024289A1 (en) | 2008-08-27 | 2010-03-04 | シスメックス株式会社 | Marker for detecting il-17-producing helper t cell, and method for detecting il-17-producing helter t cell |
-
2010
- 2010-07-29 JP JP2011524831A patent/JP5858785B2/en active Active
- 2010-07-29 WO PCT/JP2010/062807 patent/WO2011013753A1/en active Application Filing
- 2010-07-29 EP EP10804499.1A patent/EP2460880B1/en active Active
- 2010-07-29 CN CN201080039872.9A patent/CN102482667B/en active Active
-
2012
- 2012-01-27 US US13/360,324 patent/US20120129724A1/en not_active Abandoned
-
2013
- 2013-04-23 US US13/868,638 patent/US9410208B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000186046A (en) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | Therapeutic agent for and diagnosis of chronic rheumatism and |
WO2005029091A2 (en) | 2003-09-15 | 2005-03-31 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
JP2007506100A (en) | 2003-09-15 | 2007-03-15 | オクラホマ メディカル リサーチ ファウンデーション | Methods using cytokine assays to diagnose, treat and evaluate inflammatory and autoimmune diseases |
WO2008104608A1 (en) | 2007-03-01 | 2008-09-04 | Universite Catholique De Louvain | Method for the determination and the classification of rheumatic conditions |
WO2009002515A1 (en) | 2007-06-25 | 2008-12-31 | Vertex Pharmaceuticals Incorporated | Th-17 cells |
WO2009092087A2 (en) | 2008-01-18 | 2009-07-23 | The Brigham And Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human th17 cells |
WO2009107785A1 (en) | 2008-02-28 | 2009-09-03 | シスメックス株式会社 | Marker for detection of il-17-producing helper t-cell, and method for detection of il-17-producing helper t-cell |
WO2010024289A1 (en) | 2008-08-27 | 2010-03-04 | シスメックス株式会社 | Marker for detecting il-17-producing helper t cell, and method for detecting il-17-producing helter t cell |
Non-Patent Citations (32)
Title |
---|
Affimetrix GeneChip Human Genome U133 Arrays Data Sheet, 2003-2007, downloaded from http://media.affymetrix.com/support/technical/datasheets/hgu133arrays-datasheet.pdf on Oct. 5, 2012. |
Affimetrix GeneChip Human Genome U133 Plus 2.0 Array Probe Sheet, FASTA format, Aug. 20, 2008, downloaded from http://www.affymetrix.com/Auth/analysis/downloads/data/HG-U133-Plus-2.probe-fasta.zip on Oct. 5, 2012, Only pp. 7813-7814. |
Affimetrix GeneChip Human Genome U133 Plus 2.0 Array Target Sheet, FASTA format, Aug. 20, 2008, downloaded from http://www.affymetrix.com/Auth/analysis/downloads/data/HG-U133-Plus-2.targetzip on Oct. 5, 2012. Only p. 2953. |
Appay et al., Journal of Immunology, 2007; 179:7406-7414. * |
Aricescu et al., "Homo sapiens protein tyrosine phosphatase, receptor type, M (PTPRM), transcript variant 1, mRNA", GenBank Accession No. NM-001105244, The National Center for Biotechnology, Sep. 21, 2007, retrieved from http://www.ncbi.nlm.nih.gov/nuccore/NM-001105244 on Jul. 4, 2013, pp. 1-9. |
Aricescu et al., "Structure of a Tyrosine Phosphatase Adhesive Interaction Reveals a Spacer-Clamp Mechanism", Science, 2007, 317:1217-1220. |
Aricescu et al., The EMBO Journal, 2006, vol. 25, pp. 701-712. * |
Bianchi et al., Experimental Cell Research, 1999, vol. 248, pp. 329-338. * |
Engemaier et al., Genomics, 2006, vol. 87, pp. 254-264. * |
Eva V. Acosta-Rodriguez et al., "Surface phenotype and antigenic specificity of human interleukin 17-Producing T helper memory cells", Nature Immunology, 2007, 8(6): 639-646. |
Francesco Annunziato et al., "Phenotypic and functional features of human Th17 cells", The Journal of Experimental Medicine, 2007, 204(8): 1849-1861. |
Gebbink et al., "Cloning, Expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase", Febs Letters, 1991: 290(1 & 2):123-130. |
Harrington et al., Nature Immunology, 2005, vol. 6, pp. 1123-1132. * |
Hendrik Streeck et al., "Rapid ex vivo isolation and long-term culture of human Th17 cells", Journal of Immunological Methods, 2008, pp. 115-125, vol. 333. |
Ivaylo I. Ivanov et al., "The Orphan Nuclear Receptor RORgammaT Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells", Cell, 2006, 126: 1121-1133. |
Ivaylo I. Ivanov et al., "The Orphan Nuclear Receptor RORγT Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells", Cell, 2006, 126: 1121-1133. |
Jason S. Stumhofer et al., "Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system", Nature Immunology, 2006, 7(9): 937-945. |
Korn et al., Annu. Rev. Immunol., 2009, vol. 27, pp. 485-517. * |
Kristiansen et al., Analytical Cellular Pathology, 203, vol. 25, pp. 77-81. * |
Lorenzo Cosmi et al., "Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor", The Journal of Experimental Medicine, Jul. 28, 2008, pp. 1903-1918, vol. 205, No. 8. |
Maddaluno et al., JEM, 2009, vol. 206 pp. 623-635. * |
Marchese et al., GEnomics, 1999, vol. 56, pp. 12-21. * |
Miyagawa et al., Immunology, 2009, vol. 128, pp. 405-419. * |
Miyahara et al., Journal of Surgical Oncology, 2001, vol. 77, pp. 49-54. * |
Mochizuki et al., Cancer Science, 2007, vol. 98, pp. 621-628. * |
Nicholas J. Wilson et al., "Development, cytokine profile and function of human interleukin 17-producing helper T cells", Nature Immunology, 2007, 7: 1-8. |
Ormerod, Cell Separation a Practical Approach, 1998, pp. 169-189. * |
S. Homs et al., "Predominant TH1 and Cytotoxic Phenotype in Biopsies from Renal Transplant Recipients with Transplant Glomerulopathy", American Journal of Transplantation, 2009, 9: 1230-1236. |
Sui et al., American Jounral of PAthology, 2005, vol. 166, pp. 1247-1258. * |
Wagner et al., "Physical Mapping of Receptor Type Protein Tyrosine Phosphatase Sigma (PTPRS) to Human Chromosome 19p13.3", Genomics, 1996, 38:76-78. |
Weihong Liu et al., CD127 expression inversely correlates with foxP3 and suppressive function of human CD4+ T reg cells, Journal of Experimental Medicine, 2006, 203(7): 1701-1711. |
Weizmann Institute, "Query results for probes for PTPRM gene", retrieved from URL/http://genecards.weizmann.ac.il.cgi-bin/geneannot/GA-search.pl on Jan. 18, 2013. |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160297860A1 (en) * | 2013-11-20 | 2016-10-13 | The Regents Of The University Of California | Identification of a novel b cell cytokine |
Also Published As
Publication number | Publication date |
---|---|
JP5858785B2 (en) | 2016-02-10 |
JPWO2011013753A1 (en) | 2013-01-10 |
US20120129724A1 (en) | 2012-05-24 |
EP2460880A9 (en) | 2012-12-19 |
CN102482667A (en) | 2012-05-30 |
WO2011013753A1 (en) | 2011-02-03 |
EP2460880B1 (en) | 2014-11-19 |
EP2460880A4 (en) | 2013-03-20 |
US20130267435A1 (en) | 2013-10-10 |
EP2460880A1 (en) | 2012-06-06 |
CN102482667B (en) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9410208B2 (en) | Marker and reagent for detection of human IL-17-producing helper T cells, and method for detection of human IL-17-producing helper T cells | |
EP2639305A1 (en) | Markers for detecting human follicular helper t cells and method for detecting human follicular helper t cells | |
WO2010024289A1 (en) | Marker for detecting il-17-producing helper t cell, and method for detecting il-17-producing helter t cell | |
US8889361B2 (en) | Gene expression signatures in enriched tumor cell samples | |
Lee et al. | Gene expression profiles during human CD4+ T cell differentiation | |
US20110008795A1 (en) | Marker for detection of il-17-producing helper t-cell, and method for detection of il-17-producing helper t-cell | |
JPWO2012002011A1 (en) | Method for predicting therapeutic effect of immunotherapy for cancer patient, and gene set and kit used in the method | |
WO2007021004A1 (en) | Msx1/2, MARKERS OF GROWING PROGENITOR CELL OF DOPAMINE-PRODUCING NEURON | |
WO2007021003A1 (en) | Nato3, MARKER OF GROWING PROGENITOR CELL OF DOPAMINE-PRODUCING NEURON | |
US20140038839A1 (en) | Human il-17 producing helper t cell detection method | |
US20100248251A1 (en) | Tissue Rejection | |
US11860168B2 (en) | Biomarkers for early diagnosis and differentiation of mycobacterial infection | |
KR101547307B1 (en) | Biomaker for diagnosing epilepsy | |
US7867712B2 (en) | Nucleic acid sequences associated with cell states | |
JP2007312683A (en) | Method for producing matured dendritic cell | |
JP2023064788A (en) | Evaluation method of t-cell, and composition for evaluating t-cell | |
JP2023064789A (en) | Evaluation method of t-cell, and composition for evaluating t-cell | |
Htun | Downregulation in IFNGR1 Increases Suspectiblity to Mycobacterium Avium Subspecies Paratuberculosis Infection in Crohn's Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |